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Abstract
Thrombospondin: An emerging keystone in skeletal muscle structure and
function
Gerald N. Audet
Our objective was to elucidate the effects of TSP-1 on skeletal muscle structure and
function, and its potential role in the progression of skeletal muscle dysfunction. The central
hypothesis was that TSP-1 is a critical negative regulator of skeletal muscle angiogenesis. In
chapter 3, we used a TSP-1 mimetic delivered by mini osmotic pumps to show that TSP-1 can
reduce capillarity across three distinct muscle types. We found that those given the mimetic had
a 35% decrease in soleus capillarity, a 20% decrease in the gastrocnemius, and an 11% decrease
in the plantaris. This confirmed the critical role that TSP-1 plays in physiological skeletal
muscle angiogenesis. Despite previous evidence showing that TSP-1 is an important regulator of
apoptosis in tumorigenesis, we found no apoptosis in the skeletal muscle of those animals treated
with the TSP-1 mimetic, as measured by TUNEL staining or cell death ELISA. Further, again
using this same mimetic, in chapters 3 and 4 we failed to find any change in whole body
exercise, as measured by maximal running speed, or direct muscle function as measured by ex
vivo muscle simulation, in relation to the TSP-1 induced capillary rarefaction. This may further
support the notion that it is not simply one factor that controls exercise capacity, but a
combination of many different components and systems. Further, previous evidence suggested
that a TSP-1/TNFα axis could be controlling skeletal muscle capillarity rarefaction in chronic
systemic inflammation. In chapter 5 we examined the role overexpression of TNFα has on
skeletal muscle capillary regression in a mouse model of chronic lung disease. Despite showing
a 16% decrease in capillarity of the soleus, we found no change in TSP-1 expression. What

factors are at play in this specific disease model remains unknown; however our data suggests
that TSP-2 could be central to pathological capillary regression seen with this model. Finally, in
chapter 4 we also suggest that TSP-1 may be playing a role in the regulation of mitochondrial
electron transport enzyme activity, and hence perhaps mitochondrial function. This could
provide a new and exciting role for TSP-1. This will require further investigation. Together, the
studies in this document build upon data showing that skeletal muscle angiogenesis is a dynamic
process controlled by positive and negative angiogenic proteins. It provides new and exciting
evidence for the importance of negative angiogenic proteins, specifically that of TSP-1 and TSP2, and lays the groundwork for investigation into potential medical therapies targeting aberrant
angiogenesis in skeletal muscle.
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Chapter 1: Purpose, Specific Aims,
Introduction, and Significance
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Introduction
Purpose:
Meeting the metabolic demands of skeletal muscle during exercise is critical for optimal
muscle function. Dysregulation of the delivery of oxygen and nutrients to muscle can contribute
to chronic disease morbidity and mortality. Because of this, skeletal muscle capillarity and
angiogenesis play essential roles in both health and disease. Angiogenesis is a dynamic process
thought to be controlled by the balance between positive and negative angiogenic proteins.
While there is an established body of literature pertaining to the positive regulators in angiogenic
responses to exercise and disease, the identification and precise role of negative regulators
remains poorly understood but may prove to be important in treating the aberrant angiogenesis
found in some disease states.
One potentially critical anti-angiogenic protein is thrombospondin-1 (TSP-1). TSP-1 has
a wide range of functions, which include the regulation of wound healing, apoptosis, and
angiogenesis. As an anti-angiogenic factor, TSP-1 suppresses the essential processes of vascular
growth by inhibiting endothelial cell proliferation, survival, and migration. Through these
pathways, and others, it is possible that TSP-1 plays a role in skeletal muscle capillary
rarefaction and contributes to the skeletal muscle comorbity seen in chronic diseases like cancer,
diabetes mellitus, cardiovascular disease (CVD) and chronic obstructive pulmonary disease
(COPD).
Our objective is to elucidate the effects of TSP-1 on skeletal muscle structure and
function, and its potential role in the progression of skeletal muscle dysfunction. The central
hypothesis is that TSP-1 is a critical negative regulator of skeletal muscle angiogenesis. To test
our hypothesis, we will examine gain and loss in the function of TSP-1 and explore a potential
2

connection between TNFα induced systemic inflammation and TSP-1-induced
pathological/physiological changes in skeletal muscle.
Specific Aims:
Specific Aim 1: Examine the role of TSP-1 in exercise training-induced skeletal muscle
angiogenesis using 1) a TSP-1 mimetic and 2) TSP-1 knock-out mouse model.
In wild-type (WT) mice administered a TSP-1 mimetic, we hypothesize that exercise
training induced angiogenesis will be attenuated or ablated. We expect to find greater muscle
fatigue, persistently lower levels of positive angiogenic proteins, and decreased exercise and
skeletal muscle performance when compared to WT trained animals.
In TSP-1 KO mice, we hypothesize exercise training induced angiogenesis will be
increased, and the time course of capillary adaptation will be accelerated compared to WT
animals. We also expect to find decreased muscle fatigue, higher levels of positive angiogenic
proteins, and increased exercise and skeletal performance when compared to WT trained
animals.
Specific Aim 2: Examine the connection between TNFα-and TSP-1 regulated skeletal muscle
capillarity and exercise capacity
TNFα is an inflammatory cytokine that appears central to many chronic diseases,
including COPD and CVD. We hypothesize that chronic TNFα overexpression will produce
increased chronic systemic inflammation leading to increased skeletal muscle TSP-1 expression,
which in turn will decrease muscle capillarity, decrease exercise capacity, and decrease skeletal
muscle performance compared to control animals.
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Background:
Skeletal muscle dysfunction can be a significant barrier in the daily lives of those
suffering with chronic disease, such as chronic heart failure (CHF), chronic obstructive
pulmonary disease (COPD), diabetes mellitus, and cancer [1-8]. While COPD patients exhibit
altered muscle fiber composition, decreased muscle fiber size, decreased skeletal muscle
capillarity and decreased overall strength [9-11], the origin of chronic skeletal muscle pathology
remains poorly understood.
Skeletal muscle capillarity is an important factor in normal skeletal muscle function. An
increase in skeletal muscle capillarity occurs with exercise training and this in turn helps to meet
the demand for more oxygen and nutrients. In chronic disease decreased skeletal muscle
capillary-to-fiber ratio (C:F) likely contributes to reductions in overall exercise capacity [1, 12].
Indeed, there is a significant decrease in C:F in CHF and COPD, as well as evidence of a
decreased C:F in diabetes mellitus, the metabolic syndrome, and obesity [1, 12-14]. While
decreased C:F is emerging as an important contributor to disease morbidity, the molecular
mediators of this process, and the pathways responsible, are still poorly understood.
Thrombospondin-1 (TSP-1) is a large (450kD) extracellular protein that has a wide array
of functions [15]. First discovered for its role in wound healing, it has been shown to play roles
in apoptosis, inflammation, nitric oxide signaling, and calcium binding [14, 16-19]. Acting
through multiple receptors, including the essential receptors CD36 and CD47, TSP-1 has been
shown to prevent endothelial cell adhesion, growth, and migration, and therefore it is implicated
as a key negative regulator of angiogenesis and vascular homeostasis. Decreased TSP-1 has
been shown to increase tumor vessel growth, and pharmacological administration of several
different TSP-1 mimetics has helped decrease tumor size and disease progression in canines and

4

mice [20-23]. More recently, TSP-1 mRNA and protein levels have been shown to be important
in acute responses to exercise [24], and it’s suggested that TSP-1 may play an important role in
regulating exercise-induced skeletal muscle angiogenesis [25]. Also, recent evidence shows that
hindlimb unloading in rats increases TSP-1 in association with decreases in skeletal muscle C:F
ratio [26]. While these data hint at the importance of TSP-1, they are largely circumstantial and
there is need for direct evidence showing that TSP-1 plays a role in normal physiological
function, as well as in the development of skeletal muscle dysfunction.
It has been suggested that chronic inflammation both contributes to, and results from, the
primary pathologies found in CVD, COPD, diabetes mellitus, and obesity [1, 27-29], and
therefore likely contributes to skeletal muscle dysfunction [31]. While there are many
inflammatory mediators, TNFα has received much attention in COPD and diabetes mellitus [2931], however the mechanisms by which it decreases skeletal muscle function and increases
comorbidity is still unknown. There are data to suggest that TNFα may be at the heart of
capillary rarefaction seen with chronic pathology. Interestingly, there is a proposed connection
between TNFα and TSP-1 that shows TNFα acts to increase human skeletal myoblast expression
of TSP-1 [32] in a tissue specific manner. Additionally, increased systemic TNFα has been
shown to increase circulating TSP-1 protein levels in humans [33]. There is also evidence that
TNFα KO mice have increased running capacity [34], suggesting that TNFα, perhaps via
lowered basal TSP-1 expression, may play a role in altering muscle capillarity. Collectively
these data point to a potential mechanism that may link chronic inflammation, through TNFα, in
the development of skeletal muscle capillary rarefaction, through TSP-1, resulting in overall
muscle dysfunction [35].

5

Significance:
There is little information about the role that angiogenic inhibitors play in the etiology of
skeletal muscle dysfunction. These data will add significantly to the understanding of the role
and importance of TSP-1 in regulating skeletal muscle structure and function in basal
physiology, exercise, and disease. Indeed, if TSP-1 can be confirmed as a central factor in
regulating skeletal muscle angiogenesis and vascular function, it may provide a potential
therapeutic target aimed at alleviating skeletal muscle capillary rarefaction and vascular
dysfunction found in many chronic diseases.

Terms:
3TSR: Type I repeat region of Thrombospondin-1
ABT: 30mg/kg/day ABT-510 Treated Wild-type Mice
ABT-510: Abbot Laboratories Compound 510
bFGF: Basic Fibroblast Growth Factor
C:F: Capillary to Fiber Ratio
CD: Capillary Density
CD36 KO: CD36 whole-body KO mice
CD36: Cluster of Differentiation 36
CD47/IAP: Cluster of Differentiation 47
CHF: Chronic Heart Failure
CON: Control mice
COO region: Carboxy terminal region of TSP-1
COPD: Chronic Obstructive Pulmonary Disease
CVD: Cardiovascular Disease
DM: Diabetes Mellitus
EC: Endothelial Cell
EDL: extensor digitorum longus
EGF: Epidermal Growth Factor
eNOS: Endothelial Nitric Oxide Synthase
FCSA: Fiber Cross Sectional Area
Flk-1/VEGFR-2: Vascular Endothelial Growth Factor Receptor 2
GA: Gastrocnemius
IGF: Insulin-like Growth Factor
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IL: Interluekin
IP: Inducible Protein
LRP-1: lipoprotein receptor-related protein-1
MMP: Matrix Metalloproteinase
mRNA: Messenger Ribonucleic acid
NO: Nitric Oxide
PLT: Plantaris
P-VEGFR-2: Phosphorylated Vascular Endothelial Growth Factor
Receptor 2
sGC: Soluble guanylyl cyclase
sGK-1: soluble glucocorticoid-inducible kinase
SOL: Soleus
TGFβ: Transforming Growth Factor Beta
TNFα: Tumor Necrosis Factor Alpha
TNFα+: Tumor Necrosis Factor Alpha Lung-specific Overexpressing Mice
TSP-1 KO: Full-body Thrombospondin-1 KO
TSP-1: Thrombospondin-1
TSP-2: Thrombospondin-2
VEGF: Vascular Endothelial Growth Factor
WT: Wild-type mice
α3β1: Alpha-3 Beta-1 Integrin
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Skeletal muscle angiogenesis
Skeletal Muscle: A remarkably adaptable organ
Skeletal muscle makes up approximately 30 to 40% of the total mass of the average
healthy adult body, dependent on gender. It is an incredibly plastic organ, allowing it to be both
energetically economical while also providing the necessary adaptation required to respond to a
wide variety of conditions and stimuli. That is, by being extremely adaptable, skeletal muscle
provides maximum performance capacity at the minimum energy cost to the rest of the
organism. The different systems that make up a muscles overall function (e.g. force production,
endurance capacity, etc) respond differently along a spectrum depending on the type and
duration of the stimulus, as well as the genetic and environmental differences between
individuals. This leads to an vast amount of adaptation that can occur across the many different
systems of skeletal muscle, which can include the actual contraction apparatus (i.e. myosin and
actin) as well as all the other associated systems (e.g. neuronal input, calcium handling,
mitochondrial content, vascularity, etc). The variations in muscle contractile and metabolic
systems, and the ability to adapt, gives different muscles throughout the body different functional
capacities and provides the organism with a range of kinetic abilities. These range from highforce anaerobic muscles, to low-force high aerobic muscles, and an almost infinite continuum
between these two extremes. The changes that occur in skeletal muscle in response to
physiological and pathological stimuli have been well reviewed [1-7] and involve a host of
molecular mediators.
One of the changes that can occur in skeletal muscle in response to a physiological or
pathological stimulus (e.g. exercise, chronic inflammation) is angiogenesis, or capillary growth.
Capillaries are the smallest blood vessels in the body and are responsible for the diffusion of
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oxygen and nutrients to the muscle, as well as removal of carbon dioxide and metabolic waste.
This is a vital process in skeletal muscle, as muscle is capable of an extremely high metabolic
rate that requires both high levels of oxygen and nutrients, as well as the constant removal of
various forms of waste. To this end, it has been shown repeatedly in both rodents and humans
that with a chronic exercise stimulus there is an increase in the number of capillaries in skeletal
muscle. This increase has been shown in terms of overall vessel density and in direct
comparison to the number of myocytes, also known as the capillary-to-fiber ratio (C:F) [8-20].
It has been suggested that skeletal muscle capillarity may be one of the most important
adaptations to occur with an exercise stimulus [21-24]. Indeed, genetic differences in angiogenic
factors and angiogenic expression have been linked to overall exercise capacity, illustrating this
important connection [9, 25].
Skeletal Muscle Angiogenesis
The vascular bed in-of-itself is capable of dramatic growth and regression in concert with
the other physiological systems of skeletal muscle. Exercise training studies in humans, rodents,
and other animal models have shown repeatedly that there is a dramatic increase in capillarity
with exercise training in healthy subjects [7, 26, 27], while detraining and chronic disease
decreases capillarity [14, 28]. There are relatively few studies in skeletal muscle examining what
controls angiogenesis, especially when compared to tumorigenesis and other systems in vitro.
Further still, what proteins and molecular mediators trigger the growth and regression of the
vascular bed in skeletal muscle is still relatively unknown. However, from what data does exist
it appears the majority of the angiogenic process in skeletal muscle, and the mediators of this
process, are very similar to that of other angiogenic systems, like tumorigenesis [26, 29].
However, unlike in tumorigenesis where hypoxia appears to be the primary trigger, there are a
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striking number of different stimuli that can trigger angiogenesis in vivo in skeletal muscle.
While hypoxia has been implicated as one of the largest factors in triggering physiological and
pathological angiogenesis in skeletal muscle, pH level, physical stretch of the muscle, nerve
innervation, vibration, and sheer stress have all been implicated in triggering angiogenesis [26,
27, 30-38]. It is likely a combination of all of these factors, and potentially others, which trigger
capillary growth in skeletal muscle. The importance of each may vary depending on an
additional multitude of factors, including genetics and environment [9, 12].
The process of angiogenesis can be broken down into a series of general steps, which will
be summarized very briefly here (figure 1). These steps have been intensely studied in
tumorigenesis as a way to prevent tumor growth and metastasis. The process is first triggered by
a stimulus (e.g. hypoxia, sheer stress) that prompts angiogenic proteins to be released from the
tissue being subjected to the stimulus. Many different tissues and cell types have been shown to
release angiogenic proteins, including endothelial cells (EC), adipocytes, myocytes, and many
others [9, 17, 35, 39-47]. An example of one of these angiogenic proteins that is released from a
variety of tissues is vascular endothelial growth factor (VEGF) [48-55]. However, there are
many other angiogenic factors that can play important roles in angiogenesis [38, 56-58].
Once released angiogenic proteins bind a host of specific and non-specific receptors on
EC’s and cause the cells to become “activated”. This can result in two distinct types of vessel
growth. In development and tumorigenesis, as well as in a more limited capacity in adult tissue,
new vessels can be formed from the existing networks via vessel sprouting. However, in skeletal
muscle and other adult tissues, it is thought that intussusception, or the splitting of intact vessels,
may be the primary form of angiogenesis [59, 60]. Interestingly, depending on the stimulus,
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timing, and amount released, different angiogenic proteins can trigger either or both types of
angiogenesis [26, 60].
The process of sprouting starts when the EC’s push into the surrounding tissue [35, 61].
This requires a complex concert of molecular mediators to break down the basement membrane
that holds the vessel and surrounding tissue together, while still retaining vessel integrity as the
ECs sprout a new vessel bud. The EC’s then migrate along a chemotaxic pathway towards the
area that is in need of increased vascularity [26, 62-64]. Matrix metalloproteinases (MMPs),
another group of important angiogenic proteins, play a critical role in breaking down the
basement membrane and allowing the endothelial cells to migrate forward [58, 65-68].
As the ECs migrate, the extracellular matrix around the vessel is remodeled and stabilized
to facilitate the new vessel. Once the budding vessel has reached the area in need, such as a
tumor or hypoxic region of skeletal muscle, the endothelial cells narrow and flatten, creating a
tube where by plasma and red blood cells can travel to the tissues in need. Finally, the new
vessel is stabilized and continues to grow as it loops back to the existing vasculature to create a
new capillary-venule loop [26, 62, 64, 69].
Intussusception is slightly different than sprouting in that it does not necessarily require
EC migration. Instead, it is the process by which a vessel splits to form two new intact vessels.
This is triggered by many of the same stimuli and angiogenic mediators as sprouting [59, 70-72].
Intussceptive angiogenesis starts when a pillar forms in the existing vessel from the endothelial
cells on each side of the vessel. These pillars eventually reach each other in the middle of the
vessel, and interendothelial cell contact is made. This is stabilized by other cells surrounding the
vessel, like pericytes and myofibroblasts. Collagen is then deposited and the post expands and
leads to a new hole occurring through the vessel that is sealed from the surrounding tissue. This
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continues to enlarge, splitting the vessel, and the vessel diverges into two new branches. If this
continues many times, a single vessel branch can become a mesh-work of new smaller vessels
covering much more area, effectively and dramatically increasing overall vascular density.
Intussception has been suggested to be the primary form of angiogenesis that occurs in adult
tissue [60, 70]. However, both of these processes seem to be occurring in skeletal muscle, yet
what stimulus triggers which, and why, is yet unknown.
Physiological Skeletal Muscle Angiogenesis
Skeletal muscle capillarity has been shown to be a critical component of exercise
training. Dr. Peter Wagner and his colleagues have shown repeatedly that oxygen diffusion to
the myocyte is a critical determinant of overall exercise capacity, and that capillarity plays a
imperative role in this process [13, 21, 26]. Further, in transgenic mouse models, it has been
shown that skeletal muscle angiogenesis is directly linked to whole body exercise capacity [18,
22, 23, 73]. In these studies, animals with more capillaries have increased exercise capacity, and
the opposite is true for those with decreased capillarity. In humans, skeletal muscle angiogenesis
occurs with only a week of aerobic exercise, and in rodents it may occur even more quickly [8,
20]. This adaptation occurs in concert with an increase in expression of positive angiogenic
factors, and a decrease in anti-angiogenic factors [40, 74]. This differential expression has been
suggested to serve as a complicated balance and interplay that controls vessel growth. This idea
of an angiogenic balance was first introduced by Dr. Judith Folkman almost 30 years ago in
tumorigenesis [75], but has since been shown to be applicable to a wide range of physiological
and pathological states, including skeletal muscle [18, 23, 26]. Much work has been done in
identifying the positive angiogenic factors and their roles in angiogenesis, including potent progrowth proteins like fibroblast growth factor (bFGF), insulin like growth factor (IGF), and
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Figure 1: The general steps of sprouting and intussception mediated angiogenesis. In
both sprouting and intussception an angiogenic stimulus (e.g. hypoxia, sheer stress, pH)
triggers the release of angiogenic proteins from those cells and tissues undergoing the
angiogenic stress. This tips the balance towards a pro-angiogenic state, and triggers vessel
growth which is translated through a variety of cell receptors. “Sprouting” induced vessel
growth (top of figure 1) requires activation of endothelial cells (EC) (orange circles), the
breakdown of the basement membrane (dashed lines), proliferation of ECs, EC migration to
the site in need of new vasculature, and finally stabilization and loop formation.
“Intussception” induced vessel growth (bottom of figure 1) requires activation of ECs, the
initiation of an endothelial post that splits the vessel (black circle), proliferation, migration,
and invasion of ECs to complete the split, and finally stabilization of the new branches.
More details can be found on pages 14-19 of chapter 2.
vascular endothelial growth factor (VEGF). Of the long list of positive angiogenic factors
discovered, VEGF has been proven to be one of the most ubiquitous and most potent proangiogenic proteins [9, 48, 49, 51-55, 76]. It has been shown to be essential in many different
vascular systems, including skeletal muscle [18, 23].
For some time it was assumed that VEGF and the positive angiogenic proteins were the
most important factors in controlling vessel growth in all systems, including in skeletal muscle.
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More recently, anti-angiogenic proteins have been identified as being just as important, or more,
than the positive angiogenic proteins [57]. Of these, Thrombospondin-1, or TSP-1, has been
shown to be one of the most critical. TSP-1 has been shown to be vital in controlling tumor
angiogenesis [77-81]. The theory of this control, the idea of an angiogenic balance, is best
explained through the analogy of an automobiles gas and brake pedals. Positive angiogenic
factors can be thought of as the “gas-pedal” in angiogenesis, the negative angiogenic factors
serve as the “brake-pedal”. It has been suggested that without removal of the “brake”, even if
the “gas-pedal” is full “on”, angiogenesis cannot occur. That is, even if pro-angiogenic proteins
are elevated, if anti-angiogenic proteins are also elevated, angiogenesis will not occur, or occur
to a diminished extent [57]. This lends a potentially essential role to TSP-1 and other antiangiogenic proteins as the primary regulators of angiogenesis.
This is shown in skeletal muscle by looking at mRNA responses to exercise training in
the gastrocnemius muscle of rats by two papers [40, 82]. Together these papers show that VEGF
mRNA increases initially with an exercise stimulus- but so does the mRNA of the important
angiogenic regulator thrombospondin-1 (TSP-1). Over a period of 3 days of training, the TSP-1
mRNA response is reduced, while the VEGF response stays elevated. This change in mRNA
expression occurs along the same timeline as the adaptation to exercise, as capillary adaptation
has been shown to occur in rodents between 3 and 7 days [20]. This has led us and others to
suggest that TSP-1 may serve as the primary negative angiogenic protein, or “brake”, in skeletal
muscle angiogenesis.
Thrombospondin-1: An important regulator of angiogenesis
There has been a wide array of angiogenic proteins indentified in vivo and in vitro. Many
of these proteins are responsible for spurring vessel growth and formation. As discussed
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previously, the list of negative angiogenic proteins is relatively smaller, and less well studied,
especially in the context of skeletal muscle [29]. However, it is now hypothesized that
angiogenesis is controlled as much by negative, as positive angiogenic, proteins. Of the growing
list of negative angiogenic proteins, thrombospondin-1 has been shown to be especially potent in
several different physiological and pathological conditions.
TSP-1: A multi-domain, multi-function protein
TSP-1 is a large, 450kD, homo-trimeric extracellular glyco-protein that has been shown
to have a wide array of functions [80, 83-85]. TSP-1 belongs to a family which includes six
different proteins (Thrombospondin-1 through Thrombospondin-6). TSP-1 was the first
discovered, now over 40 years ago, for its role in wound healing. In this setting, it makes up the
majority of the protein content of stimulated α-granules in platelets [86]. Upon activation, TSP-1
is released from the α-granules where it helps in platelet aggregation and stabilization. It wasn’t
until some years later, in 1990, when Good et. al. first showed that an unknown potent inhibitor
of tumor vascularity was identical in structure to that of TSP-1, and indeed was TSP-1 [79].
They further went on to show in vivo that TSP-1 was a potent anti-angiogenic protein, which
could antagonize the actions of other pro-angiogenic proteins under physiological conditions.
They suggested that loss of TSP-1 could be a mechanism by which tumors were able to acquire
and control vascular growth, allowing unbridled expansion [79].
TSP-1 has multiple functional domains that gives it the ability to interact with a variety of
receptors and proteins resulting in a large range of actions throughout many different systems
[78, 80, 83, 85]. TSP-1 has been shown to have 6 distinct regions, with 4 of these being shown
to have significant anti-angiogenic action. This is what is hypothesized to give TSP-1 a greater
angiogenic capacity over the closely related TSP-2 protein (and the other members of the TSP
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family), which lacks several of the regions essential to TSP-1’s antiangiogenic capacity [80, 85,
87]. Of the four regions found to be important in TSP-1’s anti-angiogenic capacity, three are the
most significant and most well studied. These are the amino-terminal region, the type I repeats,
and carboxy-terminal region (figure 2) [85, 88]. This review will focus on these regions,
however for additional information please see selected sources [78, 80, 83, 85].

Figure 2: The important anti-angiogenic regions of TSP-1.
Representative structure of one of the homotrimeric stalks of TSP-1. The important regions
for the regulation of angiogenesis have been highlighted. A) The different regions of TSP-1
and their corresponding receptors and ligands. B) Some of the important functions
mediated by TSP-1 receptor/ligand binding
The first of the important anti-angiogenic regions of TSP-1 is the amino terminal end.
The amino terminal end has been shown to play a role in attachment, migration, and the
endocytosis of TSP-1 in endothelial cells [78, 80, 85]. This region interacts with the α3β1
integrin, which is potentially the most important of several integrins that TSP-1 can bind and
interact with. Integrins in of themselves regulate a wide range of functions, from cell
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attachment, to growth and migration, and have been shown to be important in angiogenesis [8991]. The association between TSP-1 and α3β1 has been revealed to be significant in some
cancers, where it has been suggested that the interaction may play a role in tumorigenic potential
[87, 92, 93]. The association of the amino terminal region with α3β1 has also been shown to
function in the innate inflammatory response in damaged tissue. Chronic inflammation has been
implicated as a potential mediator of the loss in capillarity seen in some diseases, and may have a
component in which TSP-1 plays a pivotal role (discussed in chapter 5, starting on page 96).
The amino terminal end of TSP-1 can also interact with the low-density lipoprotein
receptor-related protein-1 (LRP-1). This receptor has been shown to be important in
internalization of TSP-1 and catabolization of the protein [94, 95]. Endocytosis can play an
important role in the actions of angiogenic proteins, as has been shown in VEGF [54].
Greenaway and colleagues 2007 showed that binding of VEGF by TSP-1directly, and then
internalization of the complex by TSP-1’s binding to LRP-1, could effectively reduce many of
the markers of angiogenesis- including reducing endothelial cell growth, and an increase in
apoptosis [94]. This may be an important mechanism by which TSP-1 indirectly controls
angiogenesis, in concert with its direct effects.
TSP-1 also contains an important region known as the type I repeat region (type I), or
thrombospondin repeat region (TSR). The type I region are an important portion of the stalk of
the protein, where they are repeated three times in succession. This region has been the focus of
much intensive study for its potent ability to control angiogenesis and counter other positive
angiogenic proteins [84]. This region is only found in TSP-1 and TSP-2, while the other
members of the family, TSP-3-6, are missing this important region. The type I region has been
shown to work in concert with the amino terminal region to bind the afore mentioned α3B1
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integrins [96]. It has also been shown to be the region that can bind and activate the latent
antiangiogenic protein transforming growth factor beta (TGF-β) [80, 97-99]. Activation of TGFβ requires the cleavage of a pro-domain from the full length peptide, resulting in a functional
protein. The activation of the TGF-β by TSP-1 requires two specific part of the type I regions,
the first to bind TGF-β (the WSHWSPW region) and the second to activate it (the RFK region)
[80, 85]. While there is some conflicting data, TGF-β has been shown repeatedly to be important
in regulating endothelial cell growth and inhibiting angiogenesis [98-105].

It has been

suggested that a portion of TSP-1’s anti-angiogenic activity is through its activation of latent
TGF-β. While this could certainly play some role in its ability to inhibit endothelial cell growth,
TSP-1 also has its own inherent anti-angiogenic capacity, independent of TGF-β.
One of the most well studied of these inherent anti-angiogenic activities, and one of the
important roles for the type I repeats, is the binding of the CD36 receptor [42, 84, 85, 106-112].
This interaction, first identified by Dawson et. al. in 1997, has since been shown to be vitally
important in tumorigenesis [42, 85, 107, 110, 112]. CD36 is a ubiquitously expressed receptor
with an array of functions. Of these, it’s initial role was thought to be as a simple fatty acid
translocation and cholesterol uptake channel, as well as serving as a general multi-ligand
scavenger receptor [107, 113]. Since these discoveries, it has also been shown repeatedly that
TSP-1 binds CD36 through the 2nd type I repeat region, an area with a conserved CSVTCG
amino sequence [84, 85]. This interaction has been shown to decrease endothelial cell growth
and migration [42]. Additionally, some cancers have been shown to decrease TSP-1 expression,
and CD36 expression has also been associated with colon cancer prognosis [111]. Jimenez et. al.
2000 showed that the inhibition of angiogenesis via TSP-1 is deficient in CD36 KO mice [109],
suggesting a critical role for this interaction. The same study also showed that TSP-1’s
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interaction with CD36 is an important pathway in the induction of endothelial cell apoptosis.
Since this important paper was published, several other studies have provided more evidence that
TSP-1 is a potent stimulator of apoptosis, and that this could be occurring through the CD36
receptor [109, 114-117]. This induction of apoptosis is likely an important pathway in the antiangiogenic capacity of TSP-1.
TSP-1 has also been shown to bind VEGF directly, and this seems to also be occurring
via the type I repeat region. This binding results in the disruption of VEGF induced cell growth
and migration, and can ablate the anti-apoptotic actions of VEGF [84, 118, 119]. Further, the
type I region of TSP-1, in concert with CD36, has been shown to directly bind the VEGF
receptor Flk-1, also known as VEGFR-2, and both decrease VEGF binding as well as inhibit
receptor phosphorylation [110, 120, 121]. This interaction may also require the additional TSP-1
receptor CD47 [122]. VEGFR-2 receptor phosphorylation is critical for the downstream effects
of the receptor-ligand binding, and provides another mechanism by which TSP-1 is preventing
vascular growth and potentially inducing regression [76, 123].
Since the interaction between TSP-1 and CD36 has been identified as an important part
of TSP-1’s antiangiogenic capacity, several type I mimetics specifically targeting CD36 have
been developed to help combat tumorigenesis in human conditions. One example of these is the
TSP-1 mimetic ABT-510, developed by Abbot Pharmaceuticals (Figure 3). ABT-510 is a
mimetic of the 2nd type I repeat of the TSP-1 stalk (figure 3). There have been several novel
substitutions in the amino structure of ABT-510 that result in nanomolar concentrations having
an approximately 1000-fold increase in anti-angiogenic activity compared to endogenous TSP-1
in vitro [124]. ABT-510 has been shown to decrease cell growth, decrease cell adhesion,
counter the actions of VEGF, and induce apoptosis in vitro, as well as decrease tumor size in
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vivo [108, 116, 121, 125-130]. Several other peptides have also been created, and all have
shown varying degrees of success, with and without other forms of cancer treatment [130, 131].
These mimetics are in different stages of clinical trial, and pharmaceutical companies continue to
try and develop and improve new mimetics [127, 129].

Figure 3: ABT-510 is a mimetic of the type I repeat region of TSP-1. ABT-510 is based
on the GVITRIR amino sequence of the 2nd type I repeat of ABT-510. With several novel
additions, ABT-510 has many of the same in vivo actions as endogenous ABT-510. Both
the Type I repeats and ABT-510 have been shown to act through the CD36 receptor at the
CLESH domain.
The next portion of TSP-1 that has been shown to play a critical role in its antiangiogenic activity is the carboxy-terminal region (COO region). Investigation of this region has
identified the important TSP-1 receptor CD47, or integrin associated protein (IAP). CD47, like
CD36, is a multi-functional protein with a variety of functions, including neutrophil activation,
cell adhesion, and cell communication [132, 133]. CD47 has also been shown to be important in
immune system activation, as shown by the susceptibility of the CD47 KO mouse to lethal
infections [134]. Also like CD36, the TSP-1/ CD47 interaction has been shown to be powerfully
anti-angiogenic. The TSP-1/CD47 axis has been shown to be pro-apoptotic, anti-proliferative,
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and can interact with the VEGFR2 receptor to block angiogenesis, independent of CD36 [80,
122, 132, 133, 135-137]. While there have been several different down-stream mechanisms
suggested for TSP-1/CD47’s anti-angiogenic activities, the work by Dr. Jeff Isenberg and
colleagues over the last decade have shown that it is likely due to TSP-1s inhibition of nitric
oxide (NO) [122, 132, 136, 138-140]. Nitric oxide is a small highly reactive molecule that is
critical in signal transduction in many different physiological processes [141]. NO has been
shown to be pro-angiogenic and induces endothelial cell growth [139, 142, 143]. TSP-1, acting
through CD47, has been shown to block the actions of NO through multiple different
mechanisms, including the inhibition of soluble guanylyl cyclase (sGC), cyclic guanosine
monophosphate, and cGMP-dependent kinase type I (sGK-1), which are the proteins that
translate NO into downstream signals within the cell [138-140]. TSP-1/CD47 has also shown to
alter endothelial intracellular calcium release, which is also important in NO signaling [144].
Finally, TSP-1/CD47, as mentioned previously, can block VEGFR-2’s downstream actions,
which include stimulating NO release via endothelial nitric oxide synthase (eNOS) [122].
Isenberg et al. 2012 suggests that through blocking NO signaling, TSP-1/CD47 could serve as a
global regulator of cardiovascular function, which includes it’s ant-angiogenic effect [140].
Thrombospondin-1 in Skeletal Muscle
Through these multitude of effects discussed, TSP-1 has been suggested to be critical in
cancer, tumorigenesis, and in endothelial cells. Hundreds of studies spanning many different
types of cancer suggest it is critical in the regulation of tumor growth. However, the evidence
for TSP-1’s actions in skeletal muscle capillarity is significantly less. There is some work to
suggest that TSP-1 expression increases with muscle damage, which would be in congruence
with its role in wound healing [145]. Also in skeletal muscle, as discussed previously, TSP-1
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mRNA has been shown to increase initially with an exercise stimulus. This has been suggested
to be an evolutionarily evolved trait that provides an initial “brake” against un-needed vascular
adaptation. However, with exercise training, this mRNA response disappears, and as it does, is
associated with vascular adaptation (capillary growth) [40]. Therefore it was suggested that
TSP-1 could act as a master controller of angiogenesis in skeletal muscle under physiological
conditions.
Perhaps the strongest evidence for the importance of TSP-1 in skeletal muscle comes
from [22]. In this study, TSP-1 whole-body knock-outs (TSP-1 KO), were shown to have
dramatically increased skeletal muscle capillarity across three distinct muscle types, as well in
cardiac tissue [22]. These animals also had significantly increased aerobic exercise capacity, as
well as increased levels of VEGF.
Further evidence has shown that in a diabetic insult TSP-1 is increased in skeletal muscle,
and skeletal muscle capillarity is decreased [146, 147]. This is also true of hind-limb unloading,
where TSP-1 expression increases as capillarity decreases [14]. Interestingly, we have also
shown previously that TSP-1 is lower in the plantaris of mice with high-endurance capacity and
increased skeletal muscle capillarity [9]. Finally, CD47 KO and TSP-1 KO mice have been
shown to have decreased mitochondrial content, which may be another important component of
TSP-1’s action on skeletal muscle [148]. Given this relatively small body of work, much still
needs to be done to determine TSP-1’s role and importance in controlling skeletal muscle
capillarity under both pathological and physiological conditions.
Skeletal Muscle Angiogenesis, Chronic Disease, and Chronic Inflammation
Chronic diseases, such as CVD, CHF, COPD, DM, and obesity, are responsible for the
largest percentage of deaths in the United States of America (USA) [149]. These diseases are
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costing the USA billions of dollars a year [150-154]. While each of these disease affects the
bodies systems in different ways, common between all of them is a chronic systemic level of
inflammation that is a result of the primary pathology. This increased chronic systemic
inflammation in-of-itself can be as significant to a patients mortality and morbidity, and in some
pathologies is implicated as being as important a risk of death as the primary pathology [155165].
An additional important co-morbidity in chronic disease, skeletal muscle dysfunction has
been shown in many of the same diseases as chronic systemic inflammation. Indeed, skeletal
muscle dysfunction, as measured by decreased overall muscle force, has been associated with
decreased life span in congestive heart patients, independent of the primary disease state [166]
and it has been shown to be a particularly important comorbidity of COPD [10, 28, 167-173].
Decreased skeletal muscle function has also been shown to be important in a multitude of other
diseases [165, 166, 174-180], as well as in aging, bed rest, and obesity [181-184]. As discussed
previously, skeletal muscle capillarity is an important component of overall skeletal muscle
function, especially endurance capacity. Skeletal muscle capillarity and angiogenesis has been
shown to be decreased in these same diseases with global skeletal muscle dysfunction. Indeed,
in COPD there has been work to try and identify if a decrease in vascularity is occurring and how
it contributes to overall disease morbidity [10, 28, 167, 169, 171, 185], however to this point it
has been mostly correlative in nature.
It has been suggested that chronic systemic inflammation may be the connection between
chronic disease and decreased skeletal muscle function and capillarity. This is due in large part
to the observation that many of the same diseases that have increased systemic inflammation are
associated with decreased skeletal muscle capillarity [155, 158, 162, 183, 186]. Acutely
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inflammation can be pro-angiogenic, but on a chronic systemic level, inflammation has been
shown to negatively affect skeletal muscle and capillarity [158, 168, 183, 185, 187-189].
Inflammation, much like angiogenesis, is controlled by a complex interplay between many
different inflammatory mediators. One of these mediators that is common between many of
these diseases is tumor necrosis factor-alpha (TNFα). TNFα has been shown to be a potent
stimulator of the inflammatory process in vitro, in vivo, and has been implicated in the chronic
systemic inflammation seen many chronic pathologies [156, 165, 186, 187, 190-195].
Interestingly, in COPD those patients with the most severe skeletal muscle dysfunction (muscle
mass loss) also have the most severely elevated TNFα levels [190].
TSP-1 may serve as the axis by which TNFα decreases skeletal muscle capillarity in
chronic pathology. It has been shown in vitro that increased TNFα increases TSP-1 in human
skeletal muscle cells. This does not occur when the cells were treated with a variety of other
inflammatory mediators [196], suggesting a TNFα-TSP-1 specific interaction. This increase of
TSP-1 was also associated with increases in both of the important TSP-1 receptors CD36 and
CD47. Interestingly, it has also been shown that children with defects in the TNFα gene
resulting in a higher TNFα expression also have increased circulating levels of TSP-1 [197].
TNFα also has been shown to decrease striated (cardiac and skeletal) muscle mitochondrial
function and density, potentially by multiple mechanism [186, 198, 199]. This has also been
shown for TSP-1 [148]. It is plausible that the resultant increase in TSP-1 from increased TNFα
could be the mechanism by which TNFα decreases mitochondrial density. Interestingly, TNFα
KO animals also have increased running capacity [200], which leads to speculation that they
have increased skeletal muscle function, and perhaps lower TSP-1 levels. Further, increased
TSP-1 has actually been shown to increase TNFα in brain epithelial cells [201], which may
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suggest a feed-forward system. While this data together does not provide direct evidence for a
TNFα-TSP-1 axis, it does provide a potential mechanism for the decrease in capillarity seen in
skeletal muscle of afore mentioned chronic diseases.
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Abstract

Angiogenesis is an essential process for normal skeletal muscle function. There is a growing
body of evidence suggesting that thrombospondin-1 (TSP-1), a potent antiangiogenic protein in
tumorigenesis, is an important regulator of both physiological and pathological skeletal muscle
angiogenesis. We tested the hypothesis that chronic exposure to a TSP-1 mimetic (ABT-510),
which targets the CD36 TSP-1 receptor, would decrease skeletal muscle capillarity as well as
alter the balance between positive and negative angiogenic proteins under basal conditions.
Osmotic minipumps with either ABT-510 or vehicle (5% dextrose) were implanted
subcutaneously in the subscapular region of C57/BL6 mice for 14 days. When compared to the
vehicle treated mice, the ABT-510 group had a 20% decrease in capillarity in the superficial
region of the gastrocnemius (GA), 11% decrease in the plantaris (PLT), and a 35% decrease in
the soleus (SOL). ABT-510 also decreased muscle protein expression of vascular endothelial
growth factor (VEGF) in both the GA (-140%) and SOL (-62%); however there was no change
in VEGF in the PLT. Serum VEGF was not altered in ABT-510 treated animals. Endogenous
TSP-1 protein expression in all muscles remained unaltered. Tunnel staining revealed no
difference in muscle apoptosis between ABT-510 and vehicle treated groups. These data
provide evidence that the anti-angiogenic effects of TSP-1 are mediated, at least in part, via the
CD36 receptor. It also suggests that under physiologic conditions the TSP-1/CD36 axis plays a
role in regulating basal skeletal muscle microvessel density.
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Introduction
Physiologic angiogenesis and homeostasis of adult blood vessels is a complex process
that is highly regulated by a balance between positive and negative angiogenic proteins. While
there is a substantial body of evidence on the role positive angiogenic factors, such as vascular
endothelial growth factor (VEGF) [1,2,3], the role of negative angiogenic factors is incomplete
and poorly understood [4].
There are a number of known angiogenic inhibitors, of which thrombospondin-1 (TSP-1)
is thought to play a prominent role in skeletal muscle angiogenesis [4]. TSP-1 is a large (450kD)
extracellular protein that has a wide array of functions [5]. First discovered for its role in wound
healing and platelet activation, it also has important roles in apoptosis, inflammation, nitric oxide
signaling, and inhibition of positive angiogenic proteins [6,7,8,9,10]. Acting through CD36 (one
of its receptors), TSP-1 has been shown to prevent endothelial cell adhesion, growth, and
migration, as well as increase apoptosis [11,12,13]. The anti-angiogenic effects of TSP-1 in
cancer pathology are well established. For example, a reduction in TSP-1 has been shown to
increase tumor vessel growth, whereas pharmacological administration of several different TSP1 mimetics has helped decrease tumor size and disease progression in animal models
[14,15,16,17].
Under physiologic conditions, TSP-1 expression has been shown to be responsive to
exercise [18,19], which suggests that TSP-1 may play a role in regulating exercise-induced
skeletal muscle angiogenesis. TSP-1 KO mice have elevated skeletal muscle capillarity
compared to wild-type mice, suggesting a critical role for TSP-1 in the physiological
maintenance of capillaries [4]. Evidence in rats also shows that hindlimb unloading increases
TSP-1 in association with decreases in skeletal muscle capillarity [3]. Recently, TSP-1 and it’s
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receptor CD47 have also been suggested to play a pivotal role in skeletal muscle mitochondrial
biogenesis, and therefore it is likely to be important in overall skeletal muscle function and
adaptation to exercise stress [20].
Given the growing data implicating that importance of TSP-1 as a key angiogenic
regulator in skeletal muscle, we sought to determine the consequences of chronically stimulating
the TSP-1 pathway using ABT-510. ABT-510 is a mimetic of the conserved type I repeat region
of TSP-1 which has been shown previously to inhibit angiogenesis through the CD36 receptor
[12,13,21]. ABT-510 has been synthesized to have a longer half life in circulation than the
native type I repeats of TSP-1 which allows for increased chronic stimulation of the TSP-1/CD36
pathway [22]. ABT-510 has been shown to be a potent inhibitor of vascular growth in
tumorigenesis both in vitro and in vivo [15,23,24,25,26,27,28], which has been attributed to its
binding to the CD36 receptor. Using this peptide we aimed to examine whether increased
stimulation of the CD36 arm of the TSP-1 pathway affected skeletal muscle structure and
function. Given that TSP-1 is a negative angiogenic regulator, we hypothesized that mice
subjected to the ABT-510 would have lower skeletal muscle capillarity, mirrored by an altered
balance between positive and negative angiogenic proteins.
Methods
Animals
This study used 10-12 week old male C57BL/6 mice purchased from Jackson
Laboratories (Strain no. 000664, C57BL/6J, Bar Harbor, ME). Mice were randomly selected to
be placed in two groups (control, n=8; experimental n=8). All procedures that involved animals
were approved by the West Virginia University Institutional Animal Care and Use Committee.
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Osmotic Pump Drug Delivery
The TSP-1 mimetic ABT-510 was generously provided by Abbott (Abbott, IL). This
compound was chosen for use in this study based on previous and preliminary work showing its
effectiveness in decreasing capillarity in tumors, both in vitro and in vivo [15,22,23,24,25,29,30].
ABT-510 was dissolved in 5% dextrose (vehicle) over a 48 hour period to ensure the compound
was fully dissolved, and then inserted into mini-osmotic pumps (Model 1002, Alzet Osmotic
Pumps, Cupertino, CA,). Pumps were filled with either the drug or vehicle solution 24 hours in
advance of implantation as per manufacture instructions. We delivered the maximum
concentration of 30 mg/kg/day based on the maximum pump capacity (100µL), the mass of the
animals, and the solubility of the drug (ABT-510 solubility curves [22]). Pumps were surgically
inserted (flow-moderator first) subcutaneously in the scapular region while the mice were under
anesthesia (2% isoflurane). The surgical site was disinfected with iodine and closed using
sutures. Animals were then housed individually and observed daily for the remainder of the
study for pain or distress. Pumps remained in the animals for 14 days, after which they were
sacrificed and tissue/organ samples were collected and stored at -80° for later analysis.
Morphometry
Hindlimb skeletal muscle was surgically excised and frozen in isopentane cooled by liquid
nitrogen. Frozen tissue was cut using a -20°C cyromicrotome (Jung-Reichert Cryocut 1800:
Cambridge Instruments, Germany) to yield 10µm transverse sections. Great care was taken to
ensure the cryosectioned muscles were cut along the transverse plane. Sections were stained for
dipeptidly-peptidase IV (DPP IV) and alkaline phosphatase (AP) following the method of Lojda
(1979), as applied to skeletal muscle tissue [31,32]. A light microscope (Zeiss primo star, Zeiss,
Oberkochen, Germany) was used to digitally acquire (Axiocam IC c3, Axiovision 4.8.2.0, Zeiss,
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Oberkochen, Germany) 20X images of the gastrocnemius, plantaris, and soleus. Capillary and
myofiber counting was performed by a single individual blinded to group identification. For the
gastrocnemius muscle, we obtained images in a checkerboard fashion across the entire muscle,
thus both superficial and deep regions within the gastrocnemius could be included in the
analysis. For the plantaris and soleus muscles, respectively, the entire muscle was imaged and
analyzed. Counting was performed by visualization from acquired images using a custom
program in MATLAB (version 7.0.0.27, The Mathworks, MA, USA) allowing the operator to
visually mark and count the capillaries and fibers on each image. Capillary-to-fiber ratio (C:F,
number of capillaries/number muscle fibers), capillary density (CD, number of capillaries/mm2
muscle fiber area), and fiber cross sectional area (FCSA) were separately calculated for the
gastrocnemius (GA), soleus (SOL), and plantaris (PLT) (n= 33-101 images/muscle/group).
Protein Analysis
GA, SOL, and PLT muscles from each group were excised and flash frozen in liquid
nitrogen. They were then separately homogenized in a lysis buffer containing 50 mM Tris/HCl
(pH 7.4), 150mM NaCl, 0.5% Triton X-100, and protease inhibitors (Complete Tablet, Roche
Applied Science, Indianapolis, IN). Homogenates were centrifuged at 4°C, at 8,000g for 10
minutes, and supernatants removed and placed in new tubes. Blood samples were obtained from
the heart and allowed to coagulate on ice. They were then centrifuged at 3000 g for 10 minutes
and flash frozen in liquid nitrogen.

Total protein was measured by bradford assay (#23236

Pierce Coomassie Plus Protein Assay Kit, Thermo Scientific, Rockford, IL).
Quantification of VEGF was made from a total of 100μg of protein using a commercially
available ELISA kit according to the manufactures instructions (# MMV00, R&D Systems,
Minneapolis, MN, USA). Quantification of VEGFR-2 and P-VEGFR-2 were made from a total
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of 100μg of protein using a commercially available ELISA kit according to the manufactures
instructions (# 7335S, #7340S, Cell Signaling, Danvers, MA, USA). TSP-1 and CD36 were
analyzed via western blot. In brief, samples were separated on a 3-8% SDS-PAGE (NuPAGE
Novex 3-8% Tris-Acetate Midi Gel, Invitrogen, Burlington, ON, Canada) and blotted onto a 0.45
μm nitrocellulose membrane (Pierce nitrocellulose membrane, Thermo Scientific, Rockford, IL).
After blocking with 5% fat-free milk, membranes were probed using antibodies against TSP-1
(1:1000, clone A6.1, #399300, Invitrogen, Burlington, ON, Canada), β-tubulin (1:1000, #2148,
Cell Signaling), CD36 (1:250 #552544, BD Pharmingen, Franklin Lakes, NJ, USA), secondary
HRP-conjugated anti-mouse (1:1000, #p0260, Dako, GE Healthcare, Piscataway, NJ) and
secondary HRP-conjugated anti-rabbit (1:1000, #p0217, Dako). Proteins were visualized using
chemiluminescence detection (Pierce ECL, Thermo Scientific, Rockford, IL) and digitally
imaged (G:BOX Gel imager, Syngene, Cambridge, UK) using Genesnap software (Ver. 7.01,
Syngene, Cambridge, UK). Equal protein loading was verified by immunodetection of β-tubulin
as our loading control. Quantiﬁcation of protein expression levels were carried out using NIH
Image J Software (v1.62) and expressed as densitometric arbitrary units (AU).
Apoptosis
Nuclei exhibiting apoptotic changes were identified by TdT-mediated dUTP nick end
labeling (TUNEL) according to the manufacturer’s recommendations (Roche Molecular
Biochemicals, Pleasanton, CA). Briefly, muscle cross sections were cut on a cryostat (10µm)
and fixed in 4% paraformaldehyde at room temperature, blocked in 3% H2O2 in 100% methanol
at room temperature, and permeabilized in 0.1% Triton X and 0.1% sodium citrate. TUNEL
reaction mix was added in a 1:7.5 dilution, and the sections were incubated at 37°C for 1 h.
Sections were reacted with fluorescein antibody for 30 min at 37°C, and substrate was added for
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color development. To control for false-positives, samples were then counter stained by DAPI
staining to identify the nucleus. TUNEL staining was performed using a fluorescein TUNEL kit
at 1:7.5 dilution as recommended by the manufacturer (Roche Molecular Biochemicals,
Pleasanton, CA). Positive nuclei were counted, and at high power (x400), it was determined
whether they were associated with the myofiber or with the interstitial space. The number of
positive nuclei is expressed per whole muscle section. Positive controls were created using a
DNase treatment of 1 serial section (# AM1906, DNA-free, Ambion, Austin, TX). Negative
controls were created by staining 1 serial section only for DAPI without TUNEL staining. This
resulted in each sample containing 1 negative, 1 positive, and 2 experimental sections per slide.
Statistics
All data are presented as means +/- SEM. To examine body mass, organ masses, muscle
capillarity and molecular responses we used a student’s T-test. A repeated measures ANOVA
was used to analyze the maximal running test. An alpha level at P < 0.05 was selected for
statistical significance.

Results
Exercise Testing and Morphometry
Body and Muscle Mass: There was no significant difference in the absolute body or
individual hindlimb muscle masses between ABT-510 (mimetic) and vehicle treated groups
(Table 1). Heart and skeletal muscle normalized to body mass were not different between the
groups (Table 1). .
Maximal Running Test: There was no difference in maximal running speed between
vehicle and mimetic treated animals pre- or post-treatment.
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Morphometry: In the superficial region of the gastrocnemius (GA) muscle there was a
20% decrease in C:F (P<0.05) and a similar trend in CD (25% decrease, P=0.055) in the mimetic
group compared to vehicle (Figure 1 & 2). There was no statistical difference in C:F of the deep
portion of the GA between groups, however there was a significant 25% decrease in CD
(P<0.05). FCSA was not significantly different between groups in either portions of the GA.
In the plantaris (PLT) muscle, there was a 11% decrease in the C:F in the PLT in the
mimetic group compared to vehicle (P<0.05) (Figure 3). There was no difference in CD or
FCSA in the PLT.
In the soleus (SOL) muscle, there was a 35% decrease in the C:F in the SOL in the
mimetic group compared to vehicle (P<0.01) (Figure 3). There was no difference in CD
(P=0.08) or FCSA (P=0.09).

Endogenous VEGF, VEGFR-2, p-VEGFR-2, TSP-1, and CD36 Levels
Skeletal muscle VEGF protein expression was decreased by 147% and 62% in the GA
and SOL respectively (P<0.05, Figure 4). In contrast, no significant change in VEGF protein
expression was seen in the in the PLT. Serum VEGF levels were unchanged between ABT-510
and vehicle treated animals.
Total VEGFR-2 and phorphylated-VEGFR-2 (p-VEGFR-2) levels were also assessed in
the GA. There was no difference in total VEGFR-2 levels, p-VEGFR-2 levels, or a ratio of
VEGF-R2/p-VEGF-R2 between ABT-510 and vehicle treated mice (data not shown).
Endogenous TSP-1: protein expression of endogenous TSP-1 was not significantly
different in any of the muscles analyzed (SOL, PLT, GA) between the treated groups (data not
shown).
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CD36 levels: There was no difference in the receptor levels of CD36 in the GA as
assessed by western blot (data not shown).

Apoptosis
Apoptosis was assessed using TUNEL staining for fragmented DNA. There was no
difference in the number of TUNEL positive nuclei in any of the muscles between the two
treated groups (Figure 5).

Discussion
The main finding of this study is that chronic exposure to the TSP-1 mimetic ABT-510
significantly decreases skeletal muscle capillarity (Figure 1). To our knowledge, these are the
first data to show that chronic stimulation of the TSP-1/CD36 pathway in healthy mammals
results in decreased skeletal muscle capillarity. These data are consistent with the antiangiogenic function of TSP-1 and, more importantly, support the notion that TSP-1 through its
CD36 receptor is a critical regulator of skeletal muscle capillarity under physiologic conditions.
Indeed, when coupled with the previous observation that loss of TSP-1 increases skeletal muscle
capillarity (25) these data provide evidence that the actions of TSP-1 directly influence
homeostatic maintenance and/or development of skeletal muscle microvessels.

Skeletal muscle capillarity is decreased in mimetic treated mice.
TSP-1 has been shown previously to be important in maintaining skeletal muscle
capillarity, where TSP-1 KO mice have approximately 2 fold the number of capillaries as WT
controls [33]. Further, TSP-1 has been shown to be important in maintaining capillarity with
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hindlimb unloading [34]. In this manuscript we build upon this small body of evidence for the
importance of TSP-1 in the context of the basal regulation of angiogenesis.
The actions of TSP-1 are complex and multifunctional, due in large part to the diversity
of receptors it binds, such as lipoprotein receptor-related protein 1 (LRP-1), CD47, and CD36
[11,35]. Our use of the TSP-1 mimetic ABT-510, which is a potent CD36 binding peptide,
resulted in a decrease in capillarity across three different distinct skeletal muscles. This suggests
that TSP-1s anti-angiogenic properties in skeletal muscle involve a CD36 mediated mechanism.
Indeed, this is consistent with the physiological activity of CD36 where TSP-1 binding to CD36
has been shown to be anti-proliferative, anti-angiogenic, and pro-apoptotic [12]. The importance
of the TSP1/CD36 pathway has been proven in tumorigenesis, where down regulation of TSP-1
and its binding to CD36 results in a pro-tumorigenesis environment and increase in tumor size
[14,36,37,38]. Here we show similar actions in skeletal muscle under physiological conditions.
This suggests a putative role for TSP-1 in decreasing vascularity across multiple tissues, and not
just in tumors.
Given these findings, it is tempting to speculate that elevated skeletal muscle TSP-1 may
serve as a biomarker for skeletal muscle dysfunction associated with several chronic conditions
known to result in muscle capillary rarefaction, such as that found in diabetes [39,40], and
chronic heart and lung disease [41]. It may even be that therapeutic interventions to limit basal
TSP-1 expression and/or reduce circulating levels of TSP-1 could be clinically exploited to
attenuate the decrements in skeletal muscle function often accompanying these diseases.

Chronic stimulation of the TSP1 / CD36 pathway decreases VEGF.
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It has been shown previously that TSP-1 can counter the effects of VEGF by multiple
mechanisms; including interacting directly with VEGF protein and disrupting its actions at the
receptor level [42,43,44,45,46]. For example, TSP-1 has been suggested to bind VEGF via its
type I repeat region (or 3TSR). Once bound the protein heterodimer is internalized by the
scavenger receptor low density lipoprotein receptor-related protein 1 (LRP-1). Here, we show
that a chronic administration of ABT-510 (a TSP-1 type I repeat mimetic), results in a decrease
in total VEGF protein in both the gastrocnemius muscle and the soleus muscle, along with the
decrease in capillarity. It is unclear why a similar decrease in VEGF protein was not seen in the
PLT which also showed decreased capillarity, nevertheless these data support previous studies
suggesting that TSP-1 may be binding and sequestering VEGF – resulting eventually in
internalization and biological inactivation [42,43,44,45,46]. Explanations for the reduction in
VEGF may also involve suppression of VEGF production and/or VEGF signaling. For example,
there is a growing body of evidence showing that the internalization of the VEGF/VEGFR-2
complex by endocytosis results in downstream activation of several different signaling pathways
[47]. There is also evidence that both CD36 and CD47 can associate with VEGFR-2, and when
TSP-1 is present this association can prevent the VEGF ligand binding to its receptor, as well as
inducing receptor dephosphorylation and preventing dimerization [13,21,48,49]. In this way,
TSP-1 could prevent activation and/or endocytosis of the VEGF receptor, blocking yet another
biologically active arm of VEGF/VEGF-R complex. Regardless of the mechanism, our data
supports the notion that TSP-1 likely plays a regulatory role involving VEGF, thereby enhancing
its already potent inherent anti-angiogenic capacity.
In endothelial cells, TSP-1 can also disrupt VEGF actions at the receptor level by
dephosphorylating the important receptor VEGFR-2 (Flk-1) [50]. TSP-1 can disrupt VEGFR-2
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activation by binding the CLESH region of CD36, triggering a cascade of events which results in
direct binding of VEGFR-2, and a resultant decrease in tyrosine phosphorylation of VEGFR-2
[12,13,21]. This includes dephosphorylating the important tyrosine 1175 region; which is
critical to initiate downstream VEGF signaling. While it has also been shown previously that
ABT-510 significantly decreases the amount and phosphorylation status of VEGFR-2 in
endothelial cells in vitro [24,51], in vivo we found no significant change in the phosphorylation
levels of tyrosine 1175 of VEGFR-2. Given that the mimetic is a type I repeat, and that total
VEGF protein levels were decreased, we were surprised that VEGFR-2 phosphorylation was also
not decreased. But, because we only have one time point, it could be that levels of
phosphorylation were lower earlier in the chronic dosage but by the end of the study returned to
normal levels. While ABT-510 has been shown to decrease VEGFR-2 phosphorylation in
tumors [24], it may be that this response is different in skeletal muscle under physiological
conditions. It could also be that phosphorylation status in vivo is not lowered by endogenous
TSP-1 (or the addition of a mimetic), rather TSP-1 limits or prevents an increase in
phosphorylation levels with a VEGF stimulus. This is yet to be elucidated.
Administration of ABT-510 did not significantly alter endogenous levels of TSP-1 in
skeletal muscle, indicating that there was no feedback response from the mimetic binding to
CD36 to alter endogenous TSP-1 levels in skeletal muscle. However, the reduction of skeletal
muscle VEGF protein levels in association with the mimetic adds support to the idea that
physiologic angiogenesis is controlled by a balance between both positive and negative
angiogenic factors, particularly VEGF and TSP-1. It would have been interesting to deliver a
higher dose of ABT-510 (> 30 ug/kg/day) which may have resulted in greater reductions in
muscle VEGF and capillarity; however the dose used was the maximum we could deliver using

55

the small pumps suitable for mice and the 2-week duration we sought. Although shorter
duration would allow greater concentrations of drug delivery, we opted to deliver the drug for 14
days to ensure that vascular remodeling would have sufficient time to occur. It could be
hypothesized that tipping the scale towards an anti-angiogenic state (stimulated by the presence
of ABT-510) would result in a response of positive angiogenic factors to counter this challenge.
However, at least with respect to VEGF this was not the case. A decrease in VEGF and no
change in endogenous TSP-1 suggests that the muscle has been pushed towards an antiangiogenic phenotype.
Regardless of mechanism, these data show that the altered angiogenic state of the skeletal
muscle can be driven by an increase in a TSP-1 mimetic. The resulting decrease in capillarity
establishes the importance of TSP-1/ CD36 pathway in maintaining and regulating basal skeletal
muscle microvessel density.

Skeletal muscle and endothelial apoptotic levels do not differ between groups.
In addition to its anti-angiogenic properties, TSP-1 is also been known to promote
apoptosis [6,52,53,54,55,56,57,58]. TSP-1 is known to induce apoptosis through the CD36
pathway, as shown in previous studies, including those using ABT-510 [5,24,59]. Endothelial
apoptosis is a natural mechanism by which capillary regression occurs [60,61,62,63], and has
been shown to be central in muscle atrophy during some pathologies, aging, and disuse
[64,65,66,67,68]. Knowing this, we performed TUNEL staining to look at end stage apoptosis
(DNA fragmentation) in all three of the excised muscles. Surprisingly, we found no evidence of
apoptosis in any of the muscles, either myocyte or endothelial. The reason for this remains
unclear. This is, however, the first in vivo report of ABT-510s affects on skeletal muscle and it
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could be that ABT-510 is not sufficient to induce myocyte apoptosis in skeletal muscle under
these conditions. Indeed, much of the work with TSP-1 and apoptosis pertains to cancer models
(e.g. tumorigenesis), endothelial cells, and is typically done in vitro. It is possible that TSP-1 is
not as potent a pro-apoptotic protein in skeletal muscle as that seen in endothelial cells or tumors.
This is supported by the finding that there was no change in muscle fiber cross-sectional area
(Figures 2 and 3). Whether or not the ABT-510, or the TSP-1/CD36 axis, alters in vivo skeletal
muscle myocyte apoptosis will require further study.
However, this does not explain why we saw no endothelial cell apoptosis. As mentioned
previously, our study only examines one time point. It is possible that apoptosis occurred at an
earlier time point than our assessment at the 14 day time point. Indeed, it has been shown
previously that hindlimb unloading results in capillary loss in as little as 5 days [34]. If changes
in endothelial cell number, and therefore total vasculature, are occurring by 5-7 days it may not
be surprising that evidence of apoptosis has been lost by the end of the study (14 days). That is,
perhaps apoptosis has already occurred, the cells cleared from the tissue, and the architecture of
the vascular network at 14 days has already returned to a new steady state condition absent of
apoptotic nuclei. We have yet to elucidate this and more experimentation is needed to determine
exactly when apoptosis and regression is occurring.

Summary
In conclusion, we provide evidence for the importance of TSP-1/CD36 pathway in
regulating basal skeletal muscle capillarity by showing that a chronic dosage of a TSP-1 mimetic
for the CD36 pathway decreases skeletal muscle capillarity and VEGF expression. We did not
find any differences in the VEGFR-2 expression or its phosphorylation status, nor was there
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greater skeletal muscle apoptosis. These data show that, despite the multifunctional effects of
TSP-1 and its CD36 receptor, the primary consequence of elevating circulating TSP-1 (i.e. using
a TSP-1 mimetic targeted to its CD36 receptor) relates to its anti-angiogenic function. These
data may be useful in exploring therapeutic interventions for individuals with skeletal muscle
dysfunction resulting from capillary regression.
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Tables
Table 1: Muscle and Body Masses
Vehicle

ABT-510

Body Mass (g)

27.5 ±1.23

27.1 ±0.87

GA (mg)

136.8 ±4.56

140.8 ±4.09

PLT (mg)

19.7 ±0.90

19.0 ± 0.53

SOL (mg)

7.7 ±0.47

7.8 ±.048

HRT (mg)

123.5 ±5.76

134.3 ±5.82

GA/BM (mg/g)

5.0 ±0.07

5.2 ±0.12

PLT/BM (mg/g)

0.72 ±0.04

0.70 ±0.02

SOL/BM (mg/g)

0.29 ±0.01

0.28 ±0.01

4.4 ±0.26
HRT/BM (mg/g)
Values: Mean ± Standard Error. * P= 0.05

5.0 ±0.17
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Figure Legends

Figure 1: Representative figures of the histology sections. A) Superficial Gastrocnemius Muscle
B) Deep Gastrocnemius Muscle C) Plantaris Muscle, D) Soleus Muscle.

Figure 2: Superficial gastrocnemius capillarity, but not deep, is decreased in the ABT-510
group.
Chronic administration of ABT-510 30mg/kg/day decreased capillary to fiber ratio (C:F) and
capillary density (CD) in the superficial gastrocnemius (GA). Despite a similar trend, no
significant changes in capillarity were seen in the deep GA. There was no change in fiber cross
sectional area in either the deep or superficial portions of the GA. *= P<0.05

Figure 3: Plantaris and soleus capillarity is decreased in the ABT-510 group.
Chronic administration of ABT-510 30mg/kg/day decreased capillary to fiber ratio (C:F) in the
plantaris muscle (PLT) but did not decrease capillary density (CD). ABT-510 decreased
capillary to fiber ratio (C:F) and capillary density (CD) in the soleus (SOL). There was no
change in fiber cross sectional area in either the PLT or SOL muscle. *= P<0.05

Figure 4: Skeletal muscle VEGF protein content is decreased in the ABT-510 group, but not
serum levels.
Chronic administration of the mimetic (ABT-510 30mg/kg/day) decreased VEGF protein in the
GA, and SOL muscles of C57/BLK6 mice. There was no change in the PLT muscle or in
Serum levels. *= P<0.05
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Figure 5: There is no difference in skeletal muscle apoptosis between the mimetic and control
groups
TUNEL staining shows that chronic administration of the mimetic (ABT-510 30mg/kg/day) did
not increase or decrease skeletal muscle apoptosis in any of the muscles tested. Representative
GA samples, PLT and SOL data not shown. A) Representative mimetic GA B) Representative
positive control mimetic GA C) Representative control GA D) Representative positive control
vehicle GA.
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Abstract (195 words):
Thrombospondin-1 (TSP-1) is critical angiogenic mediator in skeletal muscle and recently has
been shown to be a regulator of mitochondrial biogenesis, however its role in controlling
mitochondrial function remains unknown. In this study we hypothesized that the TSP-1 mimetic
(ABT-510) would decrease mitochondrial electron transport enzyme (mETC) activity and
decrease skeletal muscle function, while an opposite effect was expected for whole-body TSP-1
KO mice. We studied 3 month old WT and TSP-1 KO mice. WT mice were given the TSP-1
mimetic systemically using osmotic mini pumps for 14 days. We measured both kinetic and
fatigue characteristics of the soleus (SOL) and extensor digitorum longus (EDL) muscles of all
groups. We found that mimetic treated mice had 29% and 42% decrease in mETC complex III
and IV activity, respectively, with a similar (albeit not statistically significant) 20% decreased
complex I activity (p<0.07). TSP-1 KO mice showed an opposite trend for an increase in
complex IV (p<0.07). Surprisingly, we saw no change in either muscle kinetic or fatigue
characteristics in either the SOL or EDL muscle. This work suggests, in addition to its antiangiogenic effects, TSP-1 can also influence mitochondrial respiration activity through its CD36
receptor pathway.
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Introduction
Thrombospondin-1 (TSP-1) is a large 450kD extracellular protein that has a wide array of
functions. First discovered for its role in wound healing and platelet activation, TSP-1 has also
been shown to influence inflammation, nitric oxide signaling, and matrix remodeling [1-5].
Acting through the CD36 receptor, TSP-1 has proven to prevent endothelial cell adhesion,
growth, and migration as well as potently regulate in vivo capillarity in a variety of models [610]. The anti-angiogenic effects of TSP-1 in cancer pathology are well established, and the
evidence continues to mount for its pivotal role in skeletal muscle [9-12].
TSP-1 has also recently been shown to decrease mitochondrial biogenesis in young
animals [13]. The mechanism by which TSP-1 controls mitochondrial biogenesis and density is
poorly understood, but may be linked to nitric oxide signaling [4, 13-16]. Another mechanism
may also involve TSP-1s inhibition of angiogenesis, particularly in skeletal muscle [9, 10, 17].
Indeed, reduced skeletal muscle capillarity could limit the supply of oxygen and substrate
necessary for mitochondria to produce ATP essential for contractile function and induce a
reduction in mitochondrial density [18, 19].
Acting through the CD36 receptor TSP-1 has also been shown to promote apoptosis, [1,
20-24], however the role of TSP-1 and CD36 in myocyte and endothelial cell apoptosis in vivo is
not well characterized. We have shown previously that a 14 day chronic exposure to the TSP-1
mimetic ABT-510 did not result in apoptosis in skeletal muscle [9]. ABT-510 is a mimetic of
the conserved type I repeat region of TSP-1 [25] that has been shown previously to inhibit
angiogenesis through the CD36 pathway [7, 8, 26] and prevent vascular growth through its proapoptotic actions [27-33]. Nevertheless, we found no signs of apoptosis in skeletal muscle
following 14 days of treatment with ABT-510, leading to the speculation that apoptosis might

77

have occurred at an earlier time point with this treatment. If true, apoptotic cells could have been
removed and the tissue could have been devoid of DNA fragmentation or apoptotic tissue at the
14-day time point. Given that apoptosis is the most likely mechanism by which capillaries losses
are expected [34-37], we hypothesized that skeletal muscle apoptosis would be evident in mice
with 3 and/or 7 days treatment with ABT-510.
Given that we have previously shown that a TSP-1 mimetic decreases capillarity,
whereas whole body loss of TSP-1 increases skeletal muscle capillarity and improves whole
body exercise [9, 10], we evaluated the effect of a CD36-mediated TSP-1 mimetic on skeletal
muscle mitochondrial function. We hypothesized that TSP-1 activation of the CD36 pathway
could significantly influence mitochondrial activity and therefore increase mitochondrial electron
transport chain (ETC) enzyme activity in the TSP-1 KO animals, while a decrease in ETC
activity and muscle function would occur in mice subjected to a chronic treatment with the TSP1 mimetic ABT-510.

Materials and Methods:
Animals
This study used 10-12 week old male C57BL/6 (WT) and TSP-1 knockout (KO) mice
purchased from Jackson Laboratories (Strain no. 000664 and 006141, respectively, Bar Harbor,
ME). Four groups of WT mice were subject to either 3 or 7 days of mimetic (3-ABT or 7-ABT)
or vehicle control (3-CON or 7-CON) (3 Day: N=4/group; 7 Day: N=10/group). Another group
of WT mice were given a 14 day chronic dose of the mimetic (14-ABT) or vehicle control (14CON) (N=8/group). The final group consisted of untreated TSP-1 KO and WT mice (N=7-
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8/group). All procedures were approved by the West Virginia University Institutional Animal
Care and Use Committee.
Osmotic Pump Drug Delivery
The TSP-1 mimetic ABT-510 was generously provided by Abbott (Abbott, IL). This
compound was chosen for use in this study based on previous work showing its effectiveness in
decreasing capillarity in tumors, both in vitro and in vivo [25, 27-30, 38, 39]. ABT-510 was
dissolved in 5% dextrose (vehicle) over a 48 hour period at 4 degrees to ensure the compound
was fully dissolved, and then inserted into mini-osmotic pumps (Model 1002, Alzet Osmotic
Pumps, Cupertino, CA). Pumps were filled with either the drug or vehicle solution 24 hours in
advance of implantation as per manufacture instructions. We delivered the maximum
concentration of 30 mg/kg/day based on the maximum pump capacity (100µL), the mass of the
animals, and the solubility of the drug (ABT-510 solubility curves [25]). Pumps were surgically
inserted (flow-moderator first) subcutaneously in the scapular region while the mice were under
anesthesia (2% isoflurane). The surgical site was disinfected with iodine and closed using
sutures. Animals were then housed individually and observed daily for the remainder of the
study for pain or distress. Pumps remained in the animals for either 3 days (3-CON, 3-ABT), 7
days (7-CON, 7-ABT) or 14 days, (14-CON, 14-ABT) depending on the randomly assigned
treatment group, after which they were sacrificed and tissue/organ samples were collected and
stored at -80° for analysis.
Ex vivo muscle function
Muscle contractile properties were examined in the extensor digitorum longus (EDL) and
soleus (SOL) muscles. Parameters analyzed from isometric contractions included peak isometric
twitch force, time to peak twitch tension, ½ relaxation time of twitch contraction, and peak
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isometric tetanic force, as previously described [40]. Isometric contractions were stimulated in
muscles ex vivo using a bi-phase stimulator at a stimulation frequency of 120Hz for EDL
muscles and 80Hz for soleus muscles, a stimulation current of 28 Volts and lasting 500ms.
Muscle fatigue was analyzed using a repeated stimulation protocol lasting 6 minutes and
consisting of repeated 40Hz tetanic trains that occurred once every second and lasted 330 ms
[41]. Muscle length was adjusted to obtain the maximal twitch response (i.e. L0). Muscles were
stimulated in an oxygenated ringers solution composed of: 100mM NaCl, 4.7mM KCl, 3.4mM
CaCl2, 1.2mM KH2PO4, 1.2mM MgSO4, 25mM HEPES, and 5.5mM D-glucose. Three twitch
contractions and three tetanic contractions were performed all separated by 2 minutes.
Following isometric contractions, the muscles remained in oxygenated ringers for 5 minutes
prior to the repeated stimulation fatigue protocol. The fatigue index was calculated as the
difference in force from the first contraction and every 10th subsequent contraction, and plotted
as a fatigue curve. Muscles were flash frozen in isopentane cooled to the temperature of liquid
nitrogen and stored at -80°C. Muscle fiber cross sectional area (FCSA) was calculated by
dividing the muscle mass by the product of the muscle density coefficient (1.06g.cm3), muscle
optimal length (L0), and the fiber length coefficient (EDL=0.45, SOL=0.69). This whole muscle
CSA value was used to calculate specific force (i.e. absolute force mN.muscle CSA-1) [42, 43].
Cell Death
Total cell death of skeletal muscle homogenate was analyzed from 200ug of tissue using
a commercially available cell death ELISA kit (cat # 11774425001, Roche, Indianapolis, IN,
USA).
Mitochondrial Assessments
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ETC activities of complexes I, III, and IV were measured spectrophotometrically from
whole muscle homogenate as previously described [44-46]. Briefly, complex I activity was
determined by measuring the oxidation of NADH at 340 nm as previously described [45]. The
assay mixture for complex I contained 25 mM potassium phosphate buffer (pH 7.2), 5 mM
MgCl2, 2 mM KCN, 2.5 mg/ml BSA, 50 µM NADH, 10 µM decylubiquinone, and 2 µg/ml
antimycin A. The reaction was initiated by the addition of muscle homogenate, and enzyme
activity was measured for 3 min, with values recorded every 10 s after the initiation of the
reaction. Complex I-specific activity was inhibited by 2 µg/ml rotenone. Complex III activity
was determined as previously described [44, 45] by following the reduction of cytochrome c at
550 nm in the presence of reduced decylubiquinone (50 µM). Briefly, the assay buffer for
complex III consisted of 500 mM sucrose, 2 mM EDTA, 100 mM Tris ·HCl, (pH 7.4), 1 mM
cytochrome c, 200 mM KCN, 1mg/ml antimycin A, and educed decylubiquinone. Finally,
complex IV activity was determined by measuring the oxidation of cytochrome c at 550 nm.
Briefly, the assay mixture for complex IV consisted of 10 mM phosphate buffer (pH 7.4) and 20
µM reduced cytochrome c. Protein content was determined as described previously via the
bradford assay [47], and values are expressed as activities in nmol substrate consumed·min -1·mg
protein-1.
Statistics
All data are presented as means ± SEM. To examine body mass, organ masses, muscle capillarity
ex vivo muscle stimulation, and mETC activity we used a student’s T-test. An alpha level at
P<0.05 was selected for statistical significance.
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Results
Muscle Mass
There was no difference in muscle or body masses between the 3, 7, or 14 day ABT
animals and their respective controls (Table 1). There was also no absolute difference in the
TSP-1 KO muscle mass compared to WT in any of the muscles, but when normalized to for body
mass GA was decreased by 21% in the TSP-1 KO animals compared to WT controls (P<0.01),
and a similar trend for a 12% decrease in the PLT (P=0.051)(Table 1). The SOL was unchanged
when compared to body mass. These data are similar to those previously observed for these
muscles in TSP-1 KO mice [10]
Cell Death
There was no evidence of cell death as measured by cell death ELISA in the skeletal
muscle of either the 3-ABT or 7-ABT groups compared to their respective CON groups (Figure
1). There was also no significant difference in cell death between 3 and 7 day time points.
Mitochondrial enzyme activity
Mice treated with ABT-510 displayed a significant 29% and 42% decrease in complex III
and IV activity (p<0.05), and to a lesser extent a decrease in complex I activity (p<0.07), in the
gastrocnemius muscle (Table 2). In contrast, TSP-1 KO mice tended to display an increase in
gastrocnemius muscle complex IV activity (p<0.07)(Table 2). A similar downward trend was
observed in complex III activity in the SOL muscle (i.e. 50% decrease, p<0.07) of ABT-510
treated mice, but no significance was reached for any of the complexes in that muscle (data not
shown). Likewise, no difference in any of the complexes in the PLT of the ABT treated mice
was seen (data not shown).
Ex vivo muscle function
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There was a trend for a decrease in peak tetanus force (31%, P=0.06) and peak tetanus
force/fiber cross sectional area (30%, P=0.12) in the SOL muscle of 14 day ABT treated mice
compared to CON mice (Figure 2), but neither proved statistically significant. Surprisingly, no
difference in fatigue profiles of either the SOL or EDL muscle were seen (Figure 3). Likewise,
muscle fatigue response was not different between TSP-1 KO and WT mice (Figure 4). There
was no difference in any muscle anatomical or physiological parameter measured during tetanus
contractions (Tables 3 and 4)

Discussion
The main finding of this study is that mitochondrial complex III and IV activity is
decreased in the gastrocnemius of mice given the TSP-1 mimetic ABT-510, while global
deletion of TSP-1 resulted in a trend for higher complex IV enzyme activities, suggesting that the
TSP-1/CD36 pathway can also influence mitochondrial function. Surprisingly, however we did
not find any difference in ex vivo muscle function between any of the groups and their respective
controls. Moreover, contrary to our hypothesis, we found no evidence of apoptosis (as measured
by cell death) in skeletal muscle of mice treated with the TSP-1 mimetic, suggesting that losses
in skeletal muscle capillary are not mediated by apoptosis driven by the TSP-1/CD36 pathway.
Skeletal muscle mETC activity is altered by TSP-1
TSP-1 has recently been identified as a potential mediator of mitochondrial biogenesis
[13]. While both TSP-1 KO and CD47 KO animals have been reported to have increased
mitochondrial density, as well as evidence of increased markers of mitochondrial biogenesis
[13], these are the first data examining the functional measures of mitochondrial respiration
when stimulating the TSP-1-CD36 receptor pathway. Although, we and others have previously
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shown that CD36 is important in controlling capillary growth [7, 9, 26, 48-50], and it has also
been shown that CD36 is found on the mitochondrial membrane [51], these are the first data to
suggest the TSP-1/CD36 pathway may also influence mitochondrial activity. Indeed, we find
that pharmacological overexpression of the TSP-1 mimetic ABT-510 significantly decreased
complex III and IV mETC activity, and to some extent complex I activity as well. It could be
that the decrease in mETC activity is due to a decrease in mitochondria number associated with
an increase in TSP-1. This decrease could be driven by a decrease in oxygen delivery, due to
fewer capillaries, as hypoxia has been shown to decrease mitochondrial content [19, 52].
Supporting this observation is the finding that TSP-1 KO mice, which have been reported to have
elevated muscle capillarity [10], displayed an opposite trend for greater complex IV mETC
activity compared to WT mice. These data suggest that TSP-1 can influence mitochondrial
biogenesis using the CD36 pathway, in addition to the CD47 pathway, but further studies will be
needed to better understand the individual effects and/or differential contributions of these two
TSP-1 receptor pathways.
The fact that the GA and SOL were more affected than the PLT could point to a fiber
type specific response. That is, the SOL and the deep portion of the GA are both primarily
oxidative, while the PLT is primarily glycolytic in nature. Oxidative fibers have been shown to
have high levels of mitochondria density, so it could be that these regions are affected first.
However, previously TSP-1 has been shown to decrease mitochondria in the quadriceps which is
a primarily glycolytic muscle [13]. Additional analysis of fiber type will need to be addressed to
answer this question.
Ex vivo Muscle Function is not different in TSP-1 manipulated mice
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Because mitochondria are essential for sustaining aerobic exercise we hypothesized that
muscle fatigue would be increased in animals subjected to a TSP-1 mimetic, and decreased in
mice lacking TSP-1. However we found that ex vivo muscle fatigue remained unaltered in TSP1 KO and TSP-1 mimetic treated mice. The lack of difference in ex vivo muscle function and
fatigue could point to the muscle vascular bed as the potential primary cause for the decrease in
whole body exercise capacity seen previously in response to TSP-1 [53], and not the decrease in
mitochondria function per se. Our findings here suggests that even with decreased mitochondrial
activity, the muscles can still function normally provided that it has unlimited substrate (as in the
ex vivo preparation).
Short term chronic exposure to a TSP-1 mimetic does not increase cell death
In earlier work we showed that capillarity was decreased with 14-day delivery of ABT510 [9]. Despite the reduction in capillarity, we did not see evidence of apoptosis with muscle
TUNEL staining in those mice. This was counter to our hypothesis, and the prevailing theory
that apoptosis is the principle mechanism by which capillary regression occurs in skeletal muscle
vascular remodeling [20, 24, 35, 37, 54]. While we speculated that apoptosis might have
occurred at an earlier time point, we were again surprised to still find no evidence of cell death
with either 3 or 7 day treatment with ABT-510. These data imply that the reduction in muscle
capillarity that occurs with chronic exposure to a TSP-1 mimetic is not mediated by a traditional
cell death mechanism (e.g. apoptosis).
One hypothesis that could be made is that the capillary network is being effectively
shrunk, without removal of endothelial cells. Indeed, it has been shown previously that there is
capillary recruitment with exercise stimulus, so it could be that recruitment or vascular
availability is decreased under the ABT-510 exposure [55-58]. However, it is likely that our
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methodology used to stain for capillaries would still show these intact, but non-functional
networks. It could be that the mimetic is causing high levels of autophagy, resulting in ultimate
cell dysfunction and death. Autophagy has been shown to be important in other systems, and in
skeletal muscle [59-61]. While not directly linked to CD36, recently TSP-1/CD47 directed
mechanisms have been shown to increase autophagy in cancer cells without causing apoptosis
[62]. It has also been shown that other anti-angiogenic proteins, such as endostatin and K5, can
trigger autophagy, which results in inhibition of angiogenesis [63]. While only speculative at
this point, this could be a non-apoptotic mechanism for the removal of endothelial cells in
skeletal muscle, or reduction in their viability, and hence a resultant shrinking of the capillary
network.
The lack of cell death in the whole skeletal muscle leads to the conclusion that the TSP-1
mimetic has no effect on the myocyte apoptosis, as suggested previously [9]. This also agrees
with our functional data showing no difference in both contractile characteristics and fatigue in
the SOL and EDL muscles of those given a 14 day dosage of ABT-510.

Summary
In summary, we found that ABT-510 does not increase cell death in 3 and 7 day chronic
exposures. However it does decrease mitochondrial electron transport chain enzyme activities,
whereas the opposite appears true for mice lacking TSP-1, which have a trend for an increase in
electron transport enzyme activities. Surprisingly no change in ex vivo muscle function was
found to occur in association with the decrease ETC activity. Nevertheless, these data show that
in addition to TSP-1 anti-angiogenic effects, it can also influence mitochondrial respiration
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activity through its CD36 receptor pathway. The importance of this finding and what component
this plays in muscle function, and/or whole body exercise, remains to be elucidated.
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Table 1.

3-CON
81±0
Age (Days)
25.7±0.7
Body Mass (g)
139±4
GA (mg)
19.0±0.6
PLT (mg)
8.0±0.4
SOL (mg)
5.0±0.01
GA/BM (mg · g-1)
0.70±0.02
PLT/BM (mg · g-1)
0.30±.01
SOL/BM (mg · g-1)
All values ± SE. * P<0.05 from WT

3-ABT
81±0
25.4±0.3
135±2
18.0±0.4
7.0±.0.6
5.0±0.10
0.70±0.02
0.30±0.02

7-CON
102±0
28.3±0.6
146±5
21.0±0.4
10.0±0.2
5.0±0.01
0.67±0.05
0.36±0.05

7-ABT
102±0
28.6±0.4
146±3
21.0±0.8
9.0±0.3
5.0±.07
0.70±0.01
0.30±0.01

14-CON
82±5
27.5±1.2
137±5
19.7±0.9
7.7±0.5
5.0±0.1
0.72±0.04
0.29±0.01

14-ABT
90±6
27.1±0.9
141±4
19.0±0.5
7.8±0.5
5.2±0.1
0.70±0.02
0.28±0.01

WT
94±0
22.8±1.7
133±16
14.66±0.8
9.4±1.4
5.8±0.4
0.65±0.05
0.41±0.04

TSP-1 KO
94±1
25.3±1.2
116±5
14.59±1.3
7.6±0.4
4.6±0.1 *
0.57±0.04 *
0.31±0.02
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Table 2: Mitochondrial Electron Transport Enzyme Activities
Vehicle

ABT-510

WT

TSP-1 KO

Complex I

26 ± 4

17 ± 2 †

19 ± 2

16 ± 1

Complex III

59 ± 5

42 ± 6 *

49 ± 5

42 ± 3

Complex IV

62 ± 11

36 ± 5 *

91 ± 8

131 ± 18 ††

All Values ± SE. * P<0.05 compared to Vehicle;
† P<0.07 compared to Vehicle; †† P<0.07 compared to WT
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Table 3: Anatomical and physiological characters of the EDL
Vehicle
ABT-510
WT
TSP-1 KO
EDL
11.40 ± 0.33

11.06 ± 0.38

9.99 ± 0.84

10.31 ± 0.48

2.03 ± 0.05

2.00 ± 0.09

1.90 ± 0.10

1.90 ± 0.12

11.76 ± 0.22

11.61 ± 0.23

10.96 ± 0.50

11.46 ± 0.27

Contraction
time (ms)

20.0 ± 3.1

23.8 ± 1.8

23.8 ± 1.8

25.7 ± 2.0

½ relaxation
time (ms)

37.14 ± 1.8

37.50 ± 1.64

41.25 ± 2.27

37.14 ± 2.85

Muscle Mass
(mg)
CSA (mm2)

L0 (mm)

All Values ± SE. * P<0.05 compared to Vehicle;
† P<0.07 compared to Vehicle; †† P<0.07 compared to WT
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Table 4: Anatomical and physiological characters of the soleus
Vehicle
ABT-510
WT
TSP-1 KO
SOLEUS
9.06 ± 0.42

8.61 ± 0.31

7.30 ± 0.38

8.63 ± 0.38

1.26 ± 0.06

1.18 ± 0.04

1.80 ± 0.10

2.13 ± 0.18

9.81 ± 0.16

9.85 ± 0.16

8.50 ± 0.23

7.7 ± 0.44

Contraction
time (ms)

42.9 ± 5.2

41.3 ± 3.0

52.5 ± 2.5

36.7 ± 6.7

½ relaxation
time (ms)

80 ± 7

65 ± 5

82.5 ± 11.1

70.0 ± 5.8

Muscle Mass
(mg)
CSA (mm2)

L0 (mm)

All Values ± SE. * P<0.05 compared to Vehicle;
† P<0.07 compared to Vehicle; †† P<0.07 compared to WT
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Figure Legends
Figure 1: 3 & 7 days of ABT-510 treatment does not increase cell death. ABT-510 animals
were given 30mg/Kg/day systemic dose delivered by mini-osmotic pump, while vehicle animals
received 5% dextrose. Cell death was measured from 100ug of total protein by Cell Death
ELISA. Values reported at A.U. absorbance values divided by total protein. N=4/group 3 day
exposure; N=10/group 7 day exposure.
Figure 2: There is a trend for lower peak tetanus force in the SOL of ABT-510 treated
animals. While not reaching statistical significance, there was a trend for lower peak tetanus
(P=0.06) and peak tetanus force/fiber cross sectional area (CSA) (P=0.11) forces of 14 day ABT510 treated animals in the SOL muscle. There was no difference in EDL isometrics between
groups (not shown).
Figure 3: No change in ex vivo muscle fatigue between vehicle and ABT-510 treated mice.
There is no difference between the fatigue curves of 14 day ABT-510 and vehicle treated
animals in either the EDL or SOL muscle. Open Boxes; Vehicle. Closed Diamonds; ABT-510.
Figure 4: No change in ex vivo muscle fatigue between WT and TSP-1 KO treated mice.
There is no difference between the fatigue curves of TSP-1 KO and WT animals in either the
EDL or SOL muscle. Open Circles; WT. Closed Triangles; KO.
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Abstract
Tumor necrosis factor alpha (TNFα) is an important inflammatory cytokine that is
implicated in several co-morbidities. High levels of systemic TNFα may be the link between
chronic inflammation and skeletal muscle dysfunction found in many chronic diseases.
Thrombospondin-family proteins (such as TSP-1 and TSP-2) are found in skeletal muscle and
have been shown to be important in capillary rarefaction. Evidence from cell culture
experiments also shows that TNFα may act to increase TSP-1 in a skeletal muscle specific
manner. We hypothesized that a chronic increase in systemic TNFα would increase TSP-1
and/or TSP-2 resulting in capillary rarefaction and skeletal muscle dysfunction. We used a lungspecific TNFa overexpressing transgenic mouse model (TNFα+) which exhibits a chronic
~300% increase in circulating TNFα levels to evaluate the effects of elevated circulating TNFα
on skeletal muscle structure and function. Whole body endurance capacity was decreased by
120% in the TNFα+ animals, however in vivo muscle stimulated fatigue remained unchanged
between TNFα+ and litter mate controls (CON). Capillarity was decreased by 16% in the soleus
(SOL) of TNFα+ animals (P<0.02), but no change was found in the plantaris (PLT), compared to
CON. TSP-2, but not TSP-1, was significantly increased by ~80% (p<0.02) in muscle of
TNFα+ compared to CON. Mitochondrial electron transport chain enzyme activity for complex
III increased by 170% in the SOL, while complex IV activity increased 74% in the PLT of
TNFα+ compared to CON (P<0.05). No evidence of altered reactive oxygen species was found.
These data suggest that chronic systemic elevation of TNFα can alter TSP-2 which could
contribute to losses in skeletal muscle capillary. Reducing systemic TNFα+ may serve as a
therapeutic target to reduce skeletal muscle dysfunction associated with capillary rarefaction.
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Introduction
Tumor necrosis factor alpha (TNFα) is an important inflammatory cytokine that is
implicated in the co-morbidities, such as skeletal muscle dysfunction, of many chronic diseases
[1-6]. For example, associations between elevated systemic TNFα and muscle dysfunction are
often found with chronic obstructive pulmonary disease (COPD), chronic heart failure, and
diabetes [2, 4, 6-10] Interestingly, in a mouse model of TNFα overexpression (TNFα+), Zuo et
al. have shown increased soleus (SOL) muscle fatigue and disrupted contractile kinetics in the
extensor digitorum longus (EDL) of TNFα+ mice [11]. Tang et al. [12] also showed that in situ
muscle endurance was decreased in this same mouse model. In humans, COPD is also well
known to decrease skeletal muscle exercise capacity, which is also associated with an increased
circulating level of TNFα. It has been proposed that skeletal muscle capillary loss in chronic
disease could be a significant contributor to overall skeletal muscle dysfunction and comorbidity
[2, 13-18]. The mechanism(s) by which increased circulating TNFα may disrupt skeletal muscle
function and/or capillarity are undetermined.
Angiogenesis is controlled by both positive and negative angiogenic proteins [19-21].
There is growing evidence that negative angiogenic regulators, such as the thrombospondins [2126] and endostatin [21, 27, 28], are critical microvessel regulators in both pathological and
physiological skeletal muscle angiogenesis. Thrombospondin (TSP)-1 and TSP-2 are large
extracellular matrix multi-domain proteins that inhibit angiogenesis in vitro and in vivo [29-33].
They share multiple binding receptors, such as CD36, CD47 and LRP-1, which inhibit
endothelial cell proliferation, migration, tube formation, and induce apoptosis [29, 30, 32, 34].
TSP-1 appears to play an important role in skeletal muscle capillary rarefaction occurring with
hindlimb unloading [25] and has been implicated as an important regulator of whole body
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exercise capacity through its powerful anti-angiogenic actions [24]. The role of TSP-2 in
regulating skeletal muscle capillarity and its effects on exercise capacity are less well studied.
Evidence from cell culture experiments have shown that TNFα can act to increase TSP-1
in a myoblast specific manner [35], and increased systemic TNFα has been shown to increase
circulating TSP-1 protein levels in humans [36]. Interestingly, TNFα knockout mice also
display increased running capacity compared to controls [37]. It is tempting to speculate that the
absence of TNFα might lower basal expression of TSP-1 and/or TSP-2 and thereby increase
skeletal muscle capillarity that could explain the greater capacity for exercise. Collectively these
data hint to a potential mechanism that may link TNFα mediated chronic systemic inflammation
to muscle expression of TSP-1/TSP-2, which could be responsible for skeletal muscle capillary
rarefaction and muscle dysfunction [38].
In this study we examined the effects chronic systemic elevation of TNFa has on skeletal
muscle structure and function. We used a lung specific TNFα overexpressing transgenic mouse
model known to exhibit increased systemic TNFa. We hypothesized that chronic systemic
elevation of circulating TNFα would increase expression of TSP-1 and/or TSP-2 in skeletal
muscle, and therefore decrease skeletal muscle capillarity. We also hypothesized that elevated
thrombospondin levels would lead to decreased in vivo muscle function, as well as impaired
skeletal muscle mitochondrial function.
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Methods
Animals: Lung specific TNFα overexpressing mice were obtained as a gift from Dr. Peter
Wagner (University of California, San Diego). All procedures that involved animals were
approved by the West Virginia University Institutional Animal Care and Use Committee. These
mice use a surfactant protein-C promoter to overexpress TNFα in the lung [39]. Transgenic
TNFα overexpressing (TNF++, n=30) and littermate control (CON, n=25) mice were studied at
5-6 months of age.

Whole body and in vivo skeletal muscle exercise testing
Whole body exercise capacity was assessed on a sub-set of animals (TNFα+ N=9, CON
N=7). The exercise endurance test was performed at least 48 hours before any tissues were taken
for morphometric or molecular analysis. This time frame was selected to ensure that the exercise
bout did not influence basal protein levels in muscles harvested on the final study day [40].
Exercise capacity was measured using a commercially available treadmill (Columbus
Instruments, Columbus, OH). The mice were allowed to warm-up at 4 meters/minute (m/min)
for 5 minutes, at a 10 degree incline. Thereafter, the treadmill speed was gradually increased to
20 m/min over 10min. The animals then ran as long as possible at 20m/min until they were
exhausted or refused to run. Exhaustion was defined as the inability of the animal to maintains
its normal running position on the moving belt of the treadmill, and/or more than 5 seconds spent
on the shock grid (at the rear of the treadmill). Animals were continually encouraged to keep
running by using noise from forced air jets and the electrical deterrence (<0.2 mA) via a shock
grid at the rear of the treadmill. Total run time was recorded and used as an assessment of whole
body exercise capacity.
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In vivo muscle fatigue in the hindlimb muscle of anesthetized mice was measured by
stimulating the tibial nerve (TNFα+ N=15, CON N=7). In vivo analysis was performed in an
effort to keep the endogenous blood supply intact and most accurately reflect what is occurring
in the conscious exercising animal. Briefly, mice were anesthetized with isoflourane (2%) and
the left knee was secured in flexion by placing a metal rod on the lateral side of the knee. The
left foot was then secured to a footplate connected to a servomotor (Cambridge Technology Inc.
Model 6350*350, Cambridge, MA). The ankle joint was then aligned with the axis of rotation of
the servomotor and electrically evoked via the tibial nerve by insertion of platinum electrodes
through the skin (Grass Medical Instruments). The electrodes were placed through the skin so
that they were flanking either side of the nerve. The left plantar flexor muscle group from each
animal was subjected to standardized pulses to determine correct electrode placement (10v, 100
Hz, 200 μs pulses). Once completed, the animals were subjected to stimulation protocol (12v,
40hz, 333ms, every second for 180 seconds) designed to mimic the modified Bruce protocol
used in humans [41]. Fatigue was defined by a reduction to 60% of peak force during the
protocol.

Muslce Morphometry
Hindlimb skeletal muscle was surgically excised and frozen in isopentane cooled by liquid
nitrogen. Frozen tissue was cut using a -20°C cyromicrotome (Jung-Reichert Cryocut 1800:
Cambridge Instruments, Germany) to yield 10µm transverse sections. Great care was taken to
ensure the cryosectioned muscles were cut along the transverse plane. Sections were stained for
dipeptidly-peptidase IV (DPP IV) and alkaline phosphatase (AP) following the method of Lojda
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[42, 43]. A light microscope (Zeiss primo star, Zeiss, Oberkochen, Germany) was used to
digitally acquire (Axiocam IC c3, Axiovision 4.8.2.0, Zeiss, Oberkochen, Germany) 20X images
of the gastrocnemius, plantaris, and soleus. Capillary and myofiber counting was performed by a
single individual blinded to group identification. For the gastrocnemius muscle, we obtained
images in a checkerboard fashion across the entire muscle, thus both superficial and deep regions
within the gastrocnemius could be included in the analysis. For the plantaris and soleus muscles,
respectively, the entire muscle was imaged and analyzed. Counting was performed by
visualization from acquired images using a custom program in MATLAB (version 7.0.0.27, The
Mathworks, MA, USA) allowing the operator to visually mark and count the capillaries and
fibers on each image. Capillary-to-fiber ratio (C:F, number of capillaries/number muscle fibers),
capillary density (CD, number of capillaries/mm2 muscle fiber area), and fiber cross sectional
area (FCSA) were separately calculated for the gastrocnemius (GA), soleus (SOL), and plantaris
(PLT) (N=19-30 images/muscle/group), (TNFα+ N=15; CON N=7 per muscle).

Protein Preparation
GA, SOL, and PLT muscles from each group were excised and flash frozen in liquid nitrogen.
For molecular analysis, muscle were then separately homogenized in a lysis buffer containing 50
mM Tris/HCl (pH 7.4), 150mM NaCl, 0.5% Triton X-100, and protease inhibitors (Complete
Tablet, Roche Applied Science, Indianapolis, IN). Homogenates were centrifuged at 4°C, at
10,000g for 10 minutes, and supernatants removed and placed in new tubes. For citrate synthase
(CS) activity, 10-50mg of muscle, depending on size of muscle, was separately homogenized in
a simple homogenization buffer (175mM KCl, 2mM EDTA in DDH2O) as described previously
[12, 44]. This was then spun for 1 minute at 8000 g. These samples were then freeze-thawed
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several times to stabilize protein content. Blood samples were obtained from the heart and
allowed to coagulate on ice. They were then centrifuged at 3000 g for 10 minutes and flash
frozen in liquid nitrogen. Total protein was measured from all samples by Bradford assay
(#23236 Pierce Coomassie Plus Protein Assay Kit, Thermo Scientific, Rockford, IL) [45].

Protein Analysis
An Angiogenic Protein Array was performed on 100ug of SOL muscle using a protein
array kit per manufacturer’s instructions (#ARY015, R&D Systems, Minneapolis, MN, USA).
(TNFα+ N=2; CON N=2 per muscle)
Quantification of VEGF was made from a total of 100μg of protein using a commercially
available ELISA kit according to the manufactures instructions (# MMV00, R&D Systems,
Minneapolis, MN, USA). All samples were run in duplicate. (TNFα+ N= 22; CON N=13 per
muscle)
Quantification of TNFα was made from a total of either 50µL of serum or 100µg of
muscle homogenate using a commercially available ELISA kit according to the manufactures
instructions. All samples were run in duplicate. (TNFα+ N=6, CON N=6 per muscle)
TSP-1 was analyzed via western blot. In brief, samples were separated on a 3-8% SDSPAGE (NuPAGE Novex 3-8% Tris-Acetate Midi Gel, Invitrogen, Burlington, ON, Canada) and
blotted onto a 0.45μm nitrocellulose membrane (Pierce nitrocellulose membrane, Thermo
Scientific, Rockford, IL). After blocking with 5% fat-free milk, membranes were probed using
antibodies against TSP-1 (1:500 #59887, Santa Cruz, Dallas, TX, USA), β-tubulin (1:1000,
#2148, Cell Signaling), secondary HRP-conjugated anti-mouse (1:1000, #p0260, Dako, GE
Healthcare, Piscataway, NJ) and secondary HRP-conjugated anti-rabbit (1:1000, #P0217,
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Dako). Proteins were visualized using chemiluminescence detection (Pierce ECL, Thermo
Scientific, Rockford, IL) and digitally imaged (G:BOX Gel imager, Syngene, Cambridge, UK)
using Genesnap software (Ver. 7.01, Syngene, Cambridge, UK). Equal protein loading was
verified by immunodetection of β-tubulin as our loading control. Quantiﬁcation of protein
expression levels were carried out using NIH Image J Software (v1.62) and expressed as
densitometric arbitrary units (AU). All blots were run in duplicate to confirm results. (TNFα+
N= 8, CON N=8 per muscle)

Reactive Oxygen Species
DCF Assay: Total reactive oxygen species was measure in fresh tissue homogenates by
dichlorofluoroscein (DCF) as described previously, with some modification [46]. In brief, the
dichlorofluoroscin acetate (DCFH-DA) stock solution was made fresh by dissolving 1.25mM of
DCF in 100% ethanol and storing it in the dark at -20°C. DCFH-DA was dissolved in ethanol to
aid in the transport across membranes. 2.5µL of PLT and 5µL of SOL homogenate were added
to each well of a 96-well black walled plate containing 50µL of freshly made 0.1 M phosphate
buffer (pH 7.2), and 40 μl of 1.25 mM DCFH-DA (total volume 92.5 or 95µL, SOL, PLT
respectively). Samples were run in duplicate, and each plate contained 2 blanks containing the
phosphate buffer and DCFH-DA but no protein to serve as background controls. The assay
mixture was incubated for 20 min at 37°C to allow the DCFH-DA to cross any membranes. DCF
formation was determined fluorometrically (FlexStation 3 plate reader, Molecular Devices,
California, United States) at excitation wavelength of 488 nm and emission wavelength of 525
nm at 37°C. Measurements were made every 10 min for 60 min, and the linear DCF production
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rate was determined relative to the amount of protein added to each well. (TNFα+ N=6; CON
N=6 per muscle)
Lipid peroxidation:
Lipid Peroxidation Assay Kit from Oxford biosciences was used per manufacturer's instructions.
Total lipid quantification was adapted from Cheng et al. 2010 [47]. (TNFα+ N=6; CON N=6 per
muscle)

Mitochondrial Assessments
Electron transport chain (ETC) complex activities:
ETC activities of complexes I, III, and IV were measured spectrophotometrically from whole
muscle homogenate as previously described [48-50]. Briefly, complex I activity was determined
by measuring the oxidation of NADH at 340 nm as previously described [49]. The assay mixture
for complex I contained 25 mM potassium phosphate buffer (pH 7.2), 5 mM MgCl2, 2 mM
KCN, 2.5 mg/ml BSA, 50 µM NADH, 10 µM decylubiquinone, and 2 µg/ml antimycin A. The
reaction was initiated by the addition of muscle homogenate, and enzyme activity was measured
for 3 min, with values recorded every 10 s after the initiation of the reaction. Complex I-specific
activity was inhibited by 2 µg/ml rotenone. Complex III activity was determined as previously
described [48, 49] by following the reduction of cytochrome c at 550 nm in the presence of
reduced decylubiquinone (50 µM). Briefly, the assay buffer for complex III consisted of 500 mM
sucrose, 2 mM EDTA, 100 mM Tris ·HCl, (pH 7.4), 1 mM cytochrome c, 200 mM KCN,
1mg/ml antimycin A, and educed decylubiquinone. Finally, complex IV activity was determined
by measuring the oxidation of cytochrome c at 550 nm. Briefly, the assay mixture for complex
IV consisted of 10 mM phosphate buffer (pH 7.4) and 20 µM reduced cytochrome c. Protein
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content was determined as described previously via the bradford assay [45], and values are
expressed as activities in nmol substrate consumed per min -1 per mg protein-1. (TNFα+ N=6;
CON N=6 per muscle)
Statistics
All data are presented as means ± SEM. To examine body mass, organ masses, muscle capillarity
ex vivo muscle stimulation, and mETC activity we used a student’s T-test. An alpha level at
P<0.05 was selected for statistical significance.

Results
Body and Muscle Mass
Shown in Table 1, TNFα+ animals were 19% smaller than CON animals (P<0.001).
There was a significant decrease in muscle mass of the GA and SOL muscle of the TNFα+ when
compared to the CON. The GA was decreased by 13% (P<0.01) and the SOL was decreased by
15% (P= 0.01) in TNFα+ compared to CON. Lung mass was also increased 180% (P<0.001).
There was no difference in the PLT or heart (HRT) mass between TNFα+ and CON (Table 1).
When muscle masses were normalized to body mass, to account for the size of the
animal, none of the skeletal muscle/body masses were different between the TNFα+ and CON.
However, HRT mass/body mass was significantly increased by 10% (P<0.01). Lung mass/body
mass was increased by over 200% (P<0.001) (Table 1).
Exercise capacity and muscle function.
The TNFα+ animals had a 120% decrease in endurance running capacity (P=0.02)
(Figure 1), but there was no difference in in vivo muscle fatigue between the TNFα+ and CON
animals (Figure 2).
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TNFα serum and muscle levels
TNFα serum levels were increased by 299% in the TNFα+ animals (P<0.001) (Figure 3).
There was no difference in TNFα levels of the SOL, PLT, or GA muscles between the TNFα+
and the CON (Table 2).
Skeletal muscle capillarity
There was a 16% decrease in capillary-to-fiber ratio (C:F) in the SOL muscle of the
TNFα+ animals when compared to the CON (P<0.02) (Figure 3). There was no change in the
PLT capillarity (Figure 4). There was also no difference in either of the muscles in capillary
density (CD) or fiber cross sectional area (FCSA) (Figures 3 & 4)
Angiogenic protein content
There was no difference in TSP-1 in either of the muscles tested (SOL, PLT) (Figures 3
and 4). There was also no difference in VEGF levels in either of the muscles tested (Figures 3
and 4).
An angiogenic protein array was used to screen a wide set of angiogenic regulators that
could be altered in the TNFα+. These data revealed that only TSP-2 was significantly increased
(by 87%, p<0.05) (Figure 5). Despite a similar trend seen in other factors, such as keratinocyte
growth factor (+158%, P=0.06), matrix metalloproteinase 9 (+182%, P=0.07), and coagulation
factor III (+88%, P=0.06), only TSP-2 resulted in a statistically significant outcome (Figures 5).
Mitochondrial ETC Activity
There was a significant 170% increase in complex III activity in the SOL of the TNFα+
mice when compared to the CON (P<0.01) (Table 3). There was no difference in the complex
activities of either complex I or IV in the SOL.
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In the PLT, there was also a significant 74% increase in complex IV activity (P<0.05)
(Table 3). However there was no difference in any of the activities of the other complexes.
Reactive oxygen species (ROS) assessment
DCF analysis revealed that there was no significant difference in gastrocnemius (GA)
ROS production between the TNFα+ and CON animal (Figure 6). The lipid peroxidation assay
revealed that there was also no increase or decrease in lipid oxidation in the SOL or PLT of the
TNFα+ compared to the CON. This remained true when corrected for both total lipid and total
protein content (Figure 7).

Discussion
The main finding of this study was that there was a significant decrease in soleus muscle
capillarity of mice with increased levels of systemic circulating TNFα that is associated with an
elevated expression of TSP-2, but not TSP-1. This suggests that TNFα could play a role in
skeletal muscle dysfunction that may be mediated by TSP-2.

Increased systemic TNFα decreases capillarity
Angiogenesis, the process of vessel growth from the existing vascular network, plays an
essential role in meeting the metabolic demands of skeletal muscle. It is not surprising that
capillary regression is associated with decreased exercise tolerance in several pathological
conditions [2, 13, 14, 16, 18, 51-54], but the molecular mediators responsible for capillary
regression in many of these conditions are still unknown. In this study, we showed that a TNFα
overexpressing mouse model resulted in a ~300% increase in circulating TNFα compared control
mice. A finding similar to that previously reported in this TNFα+ mouse model [12, 55]. Despite
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a significant decrease in SOL capillarity in TNFα+ mice, we found no change in capillarity of the
PLT muscle. While a full explanation for this difference is not immediately evident, it has been
shown previously in this same model of TNFα overexpression that the SOL muscle function is
more greatly affected by TNFα when compared to less oxidative muscles [12]. Those data, and
that of our manuscript, may seem to suggest that there is a fiber-type specific response to chronic
systemic inflammation, as the SOL is composed of primary slow MHC fibers, while the PLT is
primarily fast MHC fibers. The reasons for this fiber type specific response also remain
unknown. However, in human diseases such as COPD, there is decreased overall aerobic
capacity, which coincides with similar fiber type specific changes. Indeed, a reduction in the
number of type I fibers in human quadriceps muscle is correlated with a decrease in overall
exercise capacity more strongly in those with COPD than healthy controls [15]. Also, in
previous work with this mouse model, it was shown that there was a shift in muscle fiber type
composition in the SOL towards a faster fiber phenotype [12]. Further work will be needed to
tease out this fiber specific response.

Increased systemic inflammation leads to an increase in TSP-2
Our protein analysis revealed a trend for an overall greater increases in angiogenic
regulatory proteins in TNFa+ compared to controls, however of the over 50 proteins examined
only TSP-2 was significantly altered in the TNFα+. TSP-2 was found to be increased by over
80% compared to CON. Surprisingly, we saw no change in TSP-1. While the function and
expression of TSP-1 has been examined in skeletal muscle [23, 25, 52], the role of TSP-2 in
skeletal muscle is relatively unknown. Our finding suggests that TSP-2 could be playing a role in
skeletal muscle capillary regression that has not been previously recognized. Indeed, TSP-2 is
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closely related to TSP-1 in both structure and function, and has been shown to decrease
capillarity in tumor models [56, 57]. TSP-2 is found to be important in development [29, 33, 58]
and in connective tissue structure and cardiac tissue healing [58-61]. TSP-2 also shares many of
the common motifs of TSP-1 and has been shown to function through many of the same
receptors as TSP-1 [29, 32, 33, 57, 60]. Collectively, we believe these data suggest that TSP-2
may play a role in inflammatory induced skeletal muscle capillary regression.

In vivo muscle stimulation, exercise capacity, and mitochondrial function
Unlike previous studies which have used invasive stimulation models [11, 12], we chose
in vivo muscle stimulation because it is minimally invasive and allows us to keep all of the
vasculature and connective tissue intact, and therefore more closely reflects muscle activity in a
conscious exercising animal. Using this paradigm we did not find greater muscle fatigue in the
TNFα+ mice. It should be noted, this in vivo stimulation paradigm reflects the fatigue of the
whole hindlimb tricep complex and therefore can not differentiate between different muscle
types (e.g. oxidative vs. glycolytic). Given that we only found capillarity to be altered in the
SOL, it is perhaps not surprising that there is no change in in vivo muscle function, as the SOL
makes up the smallest contribution to overall force production in the hindlimb.
Despite no evidence of muscle contractile dysfunction, TNFα+ mice exhibited a
significant decrease in whole body exercise capacity (i.e. running endurance). This is most likely
a consequence of the central lung pathology found in this model, which is similar to that
observed in COPD [39]. Our data support the recent finding of decreased maximal running
capacity observed in male TNFα+ mice [12]. Surprisingly, however, the previous study found no
effect on exercise capacity in female mice [12]. Our study included both males and females, but
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we did not find significant difference between the sexes. At present, the reason for this
discrepancy between these studies is unknown, but will required further investigation.
It has been shown recently that PGC-1α expression and citrate synthase activity is
decreased in the SOL of TNFα+ mice [12]. Based on this observation, we expected that
mitochondrial electron transport chain enzyme activity might be reduced. To the contrary, we
found a 170% increase in complex III activity in the SOL and a 74% increase in complex IV
activity in the PLT of the TNFα+, with a similar trend (albeit not statistically significant) for
increased mitochondrial ETC activity across almost all of the complexes for both the SOL and
PLT muscles. This may be a mechanism by which skeletal muscle mitochondria are
compensating for fewer mitochondria (i.e. decrease in CS activity). Further work with electron
microscopy will need to be conducted to elucidate what is happening with mitochondrial density.
To further evaluate mitochondria function in the skeletal muscle of TNFα+ mice, we also
measured total ROS content and lipid oxidation (LPO). We saw no change in LPO and/or any
alterations in ROS production in the skeletal muscle. Both measures are non-specific
measurements of overall ROS activity and suggest that the degree of muscle capillarity loss seen
in the SOL muscle is not likely linked to a ROS mediated event. Given the prior evidence of
reduced PGC1-α and citrate synthase activity in this mouse model [12], and our measurements
showing no changes in ROS, it seems likely that TNFα+ mice simply have less mitochondria,
rather than dysfunctional mitochondria per se. This is also supported by the finding that
mitochondrial ETC data were not decreased in TNFα+ mice, but rather, in some cases actually
increased.
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Summary
In summary, we show that increased systemic TNFα decreases skeletal muscle
capillarity. This rarefaction appears to be specific to oxidative skeletal muscle, and may be
linked to TSP-2 expression. While endurance exercise capacity was reduced, muscle
mitochondrial electron transport chain activity was increased and muscle contractile function
was not changed, suggesting the exercise intolerance is not at the mitochondrial or muscle
contractile level. While the mechanisms that connects capillary rarefaction and systemic
inflammation still remain obfuscated, our data suggest that chronic elevation of TNFα may act
by stimulating TSP-2 expression and that this TNFα/TSP-2 axis may provide a fruitful
therapeutic target aimed at combating skeletal muscle co-morbidities.
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Figure Legends
Figure 1: Endurance running capacity is significantly decreased in TNFα+ mice. There was a
120% decrease in running capacity in the TNFα+ group compared to WT. Mice ran at 20m/min
at a 10° angle for as long as possible. Values ± SE.

Figure 2: In vivo muscle fatigue is unchanged in TNFα+ mice. The whole triceps surae complex
was subjected to a fatigue protocol (12v, 40hz, 333ms, every second for 180 seconds ) via
stimulation of the tibial nerve. A) Absolute values. B) % Change from first time point Values ±
SE.

Figure 3: Soleus capillarity is decreased in TNFα+ animals, while TSP-1 and VEGF remain
unchanged. A) There was a 16% reduction in capillary-to-fiber ratio (C:F) in the SOL. B) & C)
Despite a trend (P=0.01) there was no change in capillary density (CD), or fiber cross sectional
area (FCSA). D) & E) There was no change in VEGF measured via ELISA or TSP-1 levels
measured via western blot. F) Representative TSP-1 blot. Values ± SE.

Figure 4: Plantaris capillarity, TSP-1, and VEGF remain unchanged in TNFα+ mice. A-C) There
was no change in capillary-to-fiber ratio (C:F), capillary density (CD) or fiber cross sectional
area (FCSA) in the PLT. D) & E) There was no change in VEGF measured via ELISA or TSP1 levels measured via western blot. F) Representative TSP-1 blot. Values ± SE.
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Figure 5: Angiogenic array reveals of 53 proteins measured, only TSP-2 is changed in TNFα+
mice. 100ug of total protein was analyzed for 53 different angiogenic proteins. The only protein
that was statistically changed in the TNFα+ was TSP-2 (82% increased, P=0.02) . Values ± SE.

Figure 6: No change in overall ROS content in TNFα+ mice. The DCF assay revealed no change
in overall ROS content in the SOL or PLT of TNFα+ animals. A) SOL, B) PLT. Values ± SE.

Figure 7: No change in lipid oxidation in TNFα+ mice. There was no change in lipid oxidation
as measured by the LPO assay in the GA of TNFα+ mice. A) Absorbance/total lipid content B)
Absorbance/total protein content. Values ± SE.
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Chapter 6: General Discussion
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Thrombospondin-1 is critical in physiological angiogenesis, but it does not play a role in
inflammatory induced capillary regression
While TSP-1 was discovered almost half a century ago, it wasn’t until 1990 that it was
shown in vivo to be a potent anti-angiogenic protein [1], and it wasn’t until some years later that
it was suggested to be important in skeletal muscle [2, 3]. Since then, the body of work
supporting the role of TSP-1 in skeletal muscle has grown, but a void continues to exist and
critical questions remain unanswered. While TSP-1 has been shown to be important in cancer,
only a limited amount of work has been performed on its role in physiological skeletal muscle
angiogenesis [2-5], and an even smaller body of work has been published on its potential role in
pathological skeletal muscle angiogenesis [5-7].
In chapter 3, we showed that TSP-1 is critical in controlling physiological skeletal muscle
angiogenesis. Through the chronic administration of a TSP-1 mimetic, we showed that the
actions of TSP-1 result in a decrease of skeletal muscle capillarity across three distinct muscle
types (oxidative, glycolytic, and mixed muscles). Further, because the mimetic used in this study
is a CD36 agonist, this provides evidence that TSP-1’s anti-angiogenic properties in skeletal
muscle involve a CD36 mediated mechanism. Indeed, this is consistent with previous work
showing the binding of TSP-1 to CD36 is anti-proliferative, anti-angiogenic, and pro-apoptotic
[8-12]. Because we showed this same response in skeletal muscle under physiological
conditions, there appears to be a putative role for TSP-1/CD36 in decreasing vascularity across
multiple tissues. In combination with the findings that TSP-1 KO’s having increased
capillarity[3], these data provide clear evidence thatTSP-1 is a physiological regulator of skeletal
muscle vascularity. Indeed, further work from our lab supports the importance of TSP-1 by
showing there is a reduction in TSP-1 protein in response to training during the time that
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capillary adaptation is occurring (figure 1 of the appendix). This supports previous work with
mRNA [2], and suggests that TSP-1 may serve in the course of training as a vascular regulatory
protein, furthering TSP-1’s role beyond the basal control of capillarity seen in chapter 3. These
data then sets the ground work to study aberrant skeletal muscle angiogenesis and /or capillary
rarefaction in chronic disease conditions.
In chapter 5, we pursued one of the mechanisms that is potentially important in skeletal
muscle co-morbidities of chronic disease. Chronic systemic inflammation has been suggested to
play a crucial role in skeletal muscle capillary rarefaction associated with chronic conditions.
Chronic sytemic inflammation has been shown to be important in a host of syndromes and
diseases [13-16], where it has been suggested to be linked to both co-morbidities and overall
health outcomes [17]. The chronic-inflammatory model we chose for chapter 5 is a lung specific
overexpressor of TNFα. TNFα is an important inflammatory cytokine that is linked to many of
the secondary effects of chronic disease [13-16, 18, 19]. The lung specific overexpression in this
model results in a spill over systemically, resulting in higher circulating TNFα. This mouse line
has been suggested to be representative of chronic lung disease in humans, such as chronic
obstructive pulmonary disease (COPD) [20-22]. COPD is also associated (by an unknown
mechanism) with skeletal muscle dysfunction [5, 23-29], and it has been suggested this could be
due in part to alterations in skeletal muscle capillarity [5, 24, 30].
The main finding of our studies in chapter 5 was that there was a reduction in skeletal
muscle capillarity in association with increased systemic TNFα. The reduction in capillarity was
only found in the soleus, and not the plantaris. Although we cannot establish a direct cause-andeffect relationship between TNFα and muscle capillarity based solely on these data, there are
numerous studies that find elevated circulating TNFα in concert with reduced skeletal muscle

142

capillarity [14, 21, 23-25, 28, 31-33]. This work, in combination with our data, points to a
causative role of TNFα in the reduction of skeletal muscle capillarity, and establishes the
importance of TNFα in chronic inflammation induced muscle dysfunction.
We hypothesized a TNFα-TSP-1 axis mediated mechanism for capillary rarefaction
based on in vitro work pointing to a skeletal muscle specific TNFα-TSP-1 connection [34].
Surprisingly, we found that skeletal muscle TSP-1 protein levels were unchanged in vivo with
elevated systemic TNFα. This was true for both muscles where capillarity was changed (soleus)
and those that remained unchanged (plantaris). This led us to conclude that, at least in the
context of TNFα systemic overexpression, TSP-1 is not the key player linking chronic systemic
inflammation to a loss in capillarity.
However, given the apparent importance of TPS-1 in physiological angiogenesis, as
shown in chapter 3, we also examined TSP-1’s expression in three other rodent models of
systemic inflammation- two obesity models and a cigarette smoke exposure model. Previously,
it has been shown that all of these have increased general levels of systemic inflammation, and
increased levels of TNFα specifically [35, 36]. Supporting the work in chapter 5, none of these
models showed any change in skeletal muscle TPS-1, despite clear previous evidence of
decreased capillarity [33, 37].
Given the lack of change in skeletal muscle TSP-1 in all of these models, we can only
conclude that TSP-1 does not play an important role in TNFα driven, systemic inflammation
induced, pathological capillary regression. This is despite its apparent critical role in
physiological angiogenesis (as seen in Chapter 3). Supporting this notion, in a recent publication
looking at what controls skeletal muscle angiogenesis in human COPD patients, basal levels of
TSP-1 are unchanged between COPD patients and sedentary controls, yet the COPD individuals
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have decreased capillarity [5]. However, with six weeks of exercise training TSP-1 levels drop
significantly, which was not shown in the control group. This lack of a baseline difference, but a
retained response to an exercise stimulus, further suggests that TSP-1 is not important in the
pathological loss of capillaries, but is important in the physiological response to an angiogenic
stimulus.

The Thrombospondins play an important role in the angiogenic balance
An altered TSP-1 to VEGF ratio is thought to be important in the control of skeletal
muscle capillarity [6, 38]. In chapter 3 we found a decrease in VEGF with chronically elevated
levels of TSP-1, supporting these previous findings. These data also support previous in vitro
studies suggesting that TSP-1 may be binding and sequestering VEGF – resulting eventually in
internalization and biological inactivation [39-43]. Explanations for the reduction in VEGF in
chapter 3 may also involve suppression of VEGF production and/or VEGF signaling. For
example, there is a growing body of evidence showing that internalization of the VEGF/VEGFR2 complex by endocytosis results in downstream activation of several different signaling
pathways [44]. There is also evidence that both CD36 and CD47 can associate with VEGFR-2,
and when TSP-1 is present this association can prevent the VEGF ligand binding to its receptor,
as well as inducing receptor dephosphorylation and preventing dimerization [45-48]. In this
way, TSP-1 could prevent activation and/or endocytosis of the VEGF receptor, blocking yet
another biologically active arm of VEGF/VEGF-R complex. Co-precipitation pull down assays
could be used to deteremine what TSP-1 is interacting with directly. These studies could also
yield important answers to when specific interactions are occurring in the angiogenic process, as
the timeline of binding is unknown. Regardless of the mechanism, our data supports the notion
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that TSP-1 likely plays a regulatory role that also involves VEGF, thereby enhancing its already
potent inherent anti-angiogenic capacity under physiological situations.
Unlike chapter 3, the data in chapter 5 does not directly support the theory of a TSP1/VEGF balance, however it is not inconsistent. While it trended downward, we did not see any
change in VEGF in either of the muscles tested in chapter 5, as well as no change in TSP-1 as
discussed previously. While not what we anticipated, this null change in VEGF and TSP-1 still
fits within the context of the balance theory. That is, no change in the negative protein TSP-1
would therefore spur no change in the positive angiogenic protein VEGF, with the converse also
being true. The lack of change in VEGF also suggests, as we argue for TSP-1, that there may be
divergent pathways that regulate physiological vs. pathological angiogenesis, despite previous
data to suggest VEGFs role in pathological skeletal muscle dysfunction [49]. Still, since there
was a significant decrease in skeletal muscle capillarity in chapter 5 (yet no change in TSP-1 or
VEGF) our data suggests that some other mediator(s), potentially specific to chronic systemic
inflammation induced capillary loss, may be at play with chronic systemic inflammation that
may or may not be common to physiologically induced angiogenesis. Little information exists
as to which negative angiogenic proteins are most important in skeletal muscle angiogenesis
[50], so more work will need to be done to identity which proteins are important in TNFα driven
chronic systemic inflammation.
To try and answer what proteins could be responsible for this pathological/inflammation
induce capillary regression, we conducted a proteomic angiogenic array in chapter 5.
Interestingly, we found that TSP-2 was the only protein of the 53 tested that was significantly
changed (up by over 80% in the TNFα+ animals). As discussed in chapter 1 (literature review)
TSP-1 belongs to a family of six different proteins that all share some homology and functional
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overlap [51-53]. Of those, TSP-1 and TSP-2 are the most closely related in terms of both form
and function, with TSP-2 only lacking a limited number of the distinct regions of TSP-1, such as
the TGF-β activating region [8]. TSP-2 has been shown to be anti-angiogenic in skeletal muscle
[54], however its role in skeletal muscle is poorly studied. Further work will be needed to clarify
if TSP-2 is a central player in inflammatory induced capillary regression. Still, we suggest here
for the first time that TSP-2 could be the link between chronic systemic inflammation and
skeletal muscle capillary rarefaction, thereby serving as a therapeutic target for the treatment of
this important comorbidity in chronic disease.
Given that TSP-2 is up-regulated in chapter 5, and VEGF is trending downwards or
unchanged, this still agrees with the hypothesis that an altered angiogenic balance controls
vascular growth, as seen in skeletal muscle under physiological settings (as in chapter 3 and
other studies [6, 38]). It is important to point out that while there is one publication showing
increased skeletal muscle capillarity with the knock-out of TSP-2 [55] no further work has been
done to build upon this. Therefore, it has yet to be answered if TSP-2 has a controlling role in
physiological or exercise induced capillary growth/regression (vs. pathological angiogenesis). It
would be interesting to see if TSP-2 has a decreased role in physiological angiogenesis, given
TSP-1’s apparent dominant role. Studies using the dual TSP-1/TSP-2 knockout suggests that
wound healing is dictated by TSP-1 and not TSP-2 [56], which might suggest further that under
normal (physiological) conditions TSP-1 is more important compared to TSP-2. However,
interestingly TSP-2 seems to be acting through the same CD36 receptor as TSP-1 in cancer, so
the differences may be subtle [57]. If TSP-2 is indeed less important in physiological
angiogenesis, but more important in pathological angiogenesis, it could suggest distinct and
pivotal roles for the two closely related TSP family members.
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We also observed that in the angiogenic array all of the 53 proteins tested, both positive
and negative, are trending upwards in the TNFα+ animal. Indeed, this includes 13 proteins with
P values of less than 0.10. This may suggest that under a chronic systemic inflammatory
challenge with TNFα, as seen in our model, skeletal muscle could be in a constant state of
angiogenic stimulus. The increase in TNFα could be driving an increase in TSP-2 expression,
and that of other potentially yet-unknown negative angiogenic markers (like IL-10, IP-10, or
MMP-9 as suggested by the angiogenic array), resulting in a decrease in capillarity, and a
rebound response in positive angiogenic proteins. We hypothesize that constant elevated TNFα
is increasing negative angiogenic factors causing a feed-forward loop. As the muscle reacts to
the drop in capillarity caused by this increase in negative angiogenic proteins, it could spur a
high expression of positive angiogenic factors as a compensatory mechanism. This could then
further stimulate an increase in negative proteins, causing a feed-forward consequence. This
could explain the general trend for increases in all angiogenic proteins. In this way, the balance
is constantly trying to be reestablished, potentially resulting in a state of high-angiogenic protein
production. Supporting this theory, preliminary work from our lab shows that both TSP-1 and
VEGF are increased with physical detraining, even after capillarity is returned to baseline (figure
3 of appendix). It could be that an increase in TSP-1 drives the decrease in capillarity seen in
that study, and VEGF is responding (increasing) to prevent too much capillary rarefaction, or
slow the rarefaction, from occurring. In this way, VEGF would be serving as a feedback
mechanism. Without a constant input, like that from TNFα as in chapter 5, this allows the
system to be tightly regulated. It is only when you have this constant TNFα mediated chronic
systemic inflammatory insult that you push the system into a feed-forward response. This is an
intriguing hypothesis that will need further evidence for support.
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Connecting this notion to those findings in chapter 3, endogenous TSP-1 and its CD36
receptor are trending downward in response to exogenous chronic stimulation of a negative
angiogenic pathway (TSP-1). As discussed previously, VEGF is also decreased in these studies
of chapter 3. This suggests that skeletal muscle is reacting to an increase in the stimulation of
the TSP-1 anti-angiogenic pathway, and the decreased expression of VEGF, by altering
expression of endogenous TSP-1 and its receptors, likely in an effort to maintain homeostasis.
This would be a similar feedback system as argued previously. While we admit in chapter 3 it
could simply be that exogenous TSP-1 is directly binding and resulting in the endocytosis of
VEGF (as argued previously in this discussion), these data is not inconsistent with this theory of
a tightly controlled balance.
Regardless, chapters 3 and 5, in combination with the available literature, not only point
to TSP-1 and TSP-2 as important components in controlling skeletal muscle angiogenesis, but
also build upon and add significantly to the hypothesis that skeletal muscle capillarity is
regulated by a balance between negative and positive angiogenic proteins.

TSP-1 appears to affect oxidative muscles preferentially
It is interesting to point out that in chapter 3 soleus capillarity is affected to a greater
degree than that of the plantaris or gastrocnemius. While it is true that capillarity of the
gastrocnemius and plantaris are both decreased in chapter 3, the soleus has the largest reduction
in capillary-to-fiber ratio (35% reduction in the soleus vs. 20% in the gastrocnemius and 15% in
the plantaris). Interestingly, the gastrocnemius has the second greatest decrease, and it is the
second most oxidative of the three muscles, with the plantaris being the least. This may suggest
that TSP-1 affects slow-fiber type muscles (i.e. oxidative) to a larger extent than the fast-fiber
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muscles (i.e. glycolytic), as the soleus is comprised of a significantly greater proportion of slow
muscle fibers when compared to either of the other muscles tested (i.e. type I and type IIa).
Indeed, supporting this theory, in previous studies soleus capillarity in hind-limb unloading
seems to be affected to a greater extent when compared to the plantaris [6], and only the soleus
shows an increase in TSP-1 in this same model (again compared to the plantaris).
Paralleling the findings in chapter 3, chapter 5 provides further proof that the soleus is the
muscle preferentially affected. In chapter 5 the soleus is the only muscle with capillary
reduction. However, potentially contrary to our hypothesis that TSP-1 may be driving this
muscle-specific response, we only found a change in TSP-2, and not TSP-1, of the soleus in
chapter 5. This may suggest the preferential loss of capillaries is purely based on the fact that
this muscle (soleus) generally has more capillaries, so may have a greater capacity to lose
vasculature without affecting function. That is, the soleus may be capable of absorbing some of
the vascular loss because of its already high inherent capillarity. However, this seems unlikely
based on previous findings showing that there is decreased muscle function in the soleus [21,
22].
It is more likely that there is a greater sensitivity in the soleus to the various forms of
angiogenic stimuli (e.g. hypoxia, sheer stress, pH, etc.). This could be related to the soleus
having higher endothelial cell content, as endothelial cells are known to be angiogenic sensors,
and significant contributors of angiogenic proteins [58-60]. Interestingly, when compared
between the different muscles under untreated conditions in chapter 3, VEGF is significantly
higher in the soleus when compared to the plantaris (P<0.01), and trends higher in the
gastrocnemius (P=0.17). This is also true of TSP-1 in chapter 5, which trends to be higher under
basal conditions in the soleus when compared to the plantaris (P=0.2). This may mean the soleus
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has the greatest capacity for changes in angiogenic protein expression, which could explain its
relative sensitivity to capillary growth/loss, as suggested previously [6].
These differential effects on the soleus may explain why we do not see
exercise/functional differences in chapters 3 and 5 as well. In chapter 3 we do not see a change
in maximal running speed. While this has been shown to be an appropriate exercise model in
other studies previously [3, 61, 62], it is limited in two important ways. First, it is a
measurement of the whole-body exercise capacity of the animal, and secondly it can be
potentially limited by the biomechanics of the animal. If it is true that oxidative muscles are
more affected than glycolytic then it may also be true that the aerobic/endurance systems are also
more affected, and hence these systems should be identified and tested. It may be that in our
studies it is more appropriate to use endurance testing, where the animals are put on a treadmill
and allowed to run for as long as possible at a set speed. Indeed, we decided to use endurance
testing in chapter 5, based on this theory and the findings in chapter 3, and found a significant
decrease in endurance time of TNFα+ mice, despite previous evidence suggesting no change in
maximal running speed [22]. Supporting these findings further, in vivo muscle stimulation
which tests the whole tricep surea yielded no significant difference in muscle fatigue between the
TNFα+ and control mice. Since the plantaris was shown to have no change in capillarity, and
preliminary evidence suggests the gastrocnemius is also unchanged (not shown), and the soleus
makes up the smallest contribution to the hindlimb muscle triad, it may not be surprising we saw
no difference in function. This would then agree with previous findings, where Tang et al.
showed in TNFα+ mice soleus fatigue was increased, while the EDL remained unchanged in situ
[22], again suggesting an oxidative specific response.
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In summary, it appears that there is a capillary-specific loss in the soleus. This could be
significant in terms of overall function, and muscle function, in humans. We rely heavily upon
our aerobic muscles for daily tasks such as climbing stairs and walking. In concert with a
reduced exercise capacity from central pathological contributors found in many chronic diseases
(e.g. lung function, cardiac output) [25-27, 63-65], even a small additional loss in
capillarity/oxidative capacity of skeletal muscle could translate into large functional deficits. In
COPD there is a documented reduction in muscle function, VO2max, capillarity, and the number
of type I fibers in human quadriceps muscle [24, 27]. The loss of type I fibers is correlated with
a decrease in overall exercise capacity more strongly in those with COPD than healthy controls
[27], thus pointing towards an important role for this potential muscle specific reduction in
capillarity. Despite the work here, what role TSP-1 plays in this specific response remains
unclear, however chapter 3 points towards a potential regulatory role.

The role of TSP-1 in skeletal muscle endothelial cell apoptosis remains unclear
TSP-1 has been shown to be promote apoptosis acting through multiple mechanisms,
including the CD36 receptor [66-71]. Endothelial apoptosis is a naturally occurring mechanism
by which capillary regression can take place [72-75], and myocyte apoptosis has been shown to
be central in muscle atrophy under some pathological conditions as well as aging and disuse [7680]. However, the role of TSP-1 and CD36 in myocyte and endothelial cell apoptosis in vivo is
not well characterized.
In chapter 3 we performed TUNEL staining to look at end stage apoptosis (DNA
fragmentation) in response to a chronic administration of the TSP-1/CD36 agonist ABT-510.
Surprisingly, we found no evidence of apoptosis in any of the muscles, either in myocyte or

151

endothelial cells. The reason for this remains unclear. This is, however, the first in vivo report
of ABT-510s affects on skeletal muscle and it could be that ABT-510 is not sufficient to induce
myocyte apoptosis in skeletal muscle. This is supported by a lack of change in muscle fiber
cross-sectional area (FCSA) in both chapters 3 & 4, despite both long and short-term chronic
doses of the TSP-1 mimetic in each study, respectively. However, much of the work with TSP-1
and apoptosis pertains to cancer models (e.g. tumorigenesis), endothelial cells, and is typically
done in vitro [66, 67, 70, 81]. Despite circumstantial evidence suggesting that removal of TSP1/CD47 can protect skeletal muscle from radiation injury [82], it could be that a TSP-1/CD36
mechanism does not play a role in skeletal muscle apoptosis.
However, this does not explain why we saw no endothelial cell apoptosis in chapters 3 or
4. However, chapter 3 examined only one time point. We hypothesized that apoptosis could
have occurred at an earlier time point than our single assessment at 14 days. Indeed, it has been
shown previously that hindlimb unloading results in capillary loss in as little as 5 days [6]. For
this reason in chapter 4 we hypothesized that evidence of endothelial cell death would be present
in the muscles of ABT-510 treated mice at 3 and/or 7 days. Surprisingly, we still found no
evidence of apoptosis, or necrosis (cell death), with either of these shorter time points. The data
from chapter 3 and chapter 4 together imply that the reduction in muscle capillarity that occurs
with chronic exposure to a TSP-1 mimetic is not mediated by a traditional cell death mechanism
(e.g. apoptosis). This is an intriguing and novel finding that could have impact on the direction
of further research into this area.
It could be that there are increased levels of autophagy in response to the TSP-1 mimetic,
resulting ultimately in cell dysfunction and death. Autophagy has been shown to be important in
other systems, including skeletal muscle [83-85]. While not directly linked to CD36, recently
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the TSP-1 receptor CD47 has been implicated in autophagy, where CD47 agonists increase
autophagy in cancer cells, as well as decreasing the capillary supply of tumors, all without
causing any apoptosis [86]. It has also been shown that other anti-angiogenic proteins, such as
endostatin, can trigger autophagy which results in inhibition of angiogenesis [87]. Interestingly,
endostatin has been shown to up-regulate TSP-1, but what role this connection has in autophagy
remains to be seen [88, 89]. While only speculative at this point, autophagy could be a nonapoptotic mechanism for the removal of endothelial cells in skeletal muscle, or reduction in their
viability, and hence a resultant shrinking of the capillary network.
It is also important to point out possible experimental limitations in our methods to
measure apoptosis in chapters 3 & 4. While TUNEL has been a time-tested quality measurement
of end stage apoptosis in many models [90-93], it only captures those nuclei undergoing DNA
fragmentation. With the number of endothelial cell nuclei being relatively low in a 10µm serial
muscle section, it could be that we are simply not capturing enough sample to see significant
apoptosis occurring. But it does seem unlikely that the number of apoptotic nuclei would be
significantly lower between groups and yet undetectable, given previous findings using similar
methods [94].
This is why we chose the cell death ELISA in chapter 4, as it does not rely on 1 single
snap shot of a muscle section, but rather captures what is going on in the entirety of the muscle.
We hypothesized then that it would identify all cells undergoing cell death (including all
endothelial cells) found in the tissue (skeletal muscle). However, the ELISA is limited in that it
does not specifically measure apoptosis, but measures total cell death (apoptosis, necrosis). Still,
it has been used to quantify endothelial cell death previously [95]. Regardless of these
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limitations, we argue that the combination of the TUNEL staining and the ELISA together
establish the lack of apoptosis in skeletal muscle endothelial cells in chapters 3 and 4.

TSP-1 influences mitochondrial enzyme activity
It was shown previously that TSP-1 can control mitochondrial biogenesis in young
animals [96] and that TSP-1 KO animals have more intact mitochondria after an 8 weeks of
treatment with radiation compared with wild-type animals [82]. While this suggests a regulatory
role for TSP-1 in mitochondrial biogenesis and integrity, both of these studies are missing any
direct measurement of mitochondrial function. In chapter 4 we showed that mitochondrial
electron transport chain (mETC) enzyme activity is decreased in response to increased TSP-1,
and increased in TSP-1 KO. In combination with decreasing capillarity, TSP-1’s control of
mitochondrial function could be an additive response in its control of total muscle function. That
is, mitochondria have been shown to be vital in total exercise capacity [65, 97-102], and
regulation of their oxidative capacity would therefore have a significant role in overall muscle
function. While mitochondria have been shown to be regulated by many different proteins, TSP1 could be an important player in this process [96, 103-105].
The mechanism by which TSP-1 decreases mETC activity in chapter 4 is unknown. It
has been suggested that it could be due to TSP-1’s control of nitric oxide (NO) [96, 106-109].
NO is a stimulator of mitochondrial biogenesis [110-112]. However, TSP-1’s control of NO has
been shown to occur through its CD47 receptor [107, 113, 114]. In our studies in chapter 3 and
4, we did not investigate CD47, rather we targeted the TSP-1/CD36 axis to examine how it
affected capillarity and mitochondria function. The work shown here is the first evidence that
TSP-1 may be influencing mitochondria function through TSP-1/CD36. There is only one other
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study looking at CD36s role in mitochondria oxidative function, and that study found no
difference in mitochondrial fatty acid enzyme activity in a whole-body CD36 KO [115].
Interestingly, CD36 has been found in the mitochondrial membrane, where it is thought to
control fatty acid translocation [116]. Whether TSP-1 is binding cell surface receptors and
triggering a protein cascade, or is being translocated and binding CD36 on the mitochondria
directly, is yet unknown.
It could be that the decrease in mETC activity is simply due to a decrease in mitochondria
number (i.e. less mitochondria, less total enzyme), as shown previously [96]. Long term hypoxia
has also been shown previously to decrease mitochondrial density [117, 118], and so the antiangiogenic actions of TSP-1 could also be indirectly influencing mitochondria density and
function. The lack of any difference in the CD36 KO mitochondrial function [115, 116], but a
decrement in our TSP-1 exposure model in chapter 3, may suggest that this is truly a TSP-1
mediated function, and not a CD36 function per se. It also supports the previous notion that
perhaps TSP-1’s regulation of mitochondria is controlled by CD47’s regulation of nitric oxide
[96], and not by CD36. Further studies directed at TSP-1, CD36, CD47, will provide answers to
these questions.
Given the change in mitochondrial enzyme activity, we hypothesized that muscle
function and whole body exercise capacity would be decreased with changes in TSP-1.
However, in chapters 3 we show no change in overall exercise capacity in terms of maximal
running speed, and in chapter 4 we show no change in ex vivo muscle function. It could be that
the changes we see are not enough to result in isolated muscle/whole body functional
differences; however this seems unlikely, because the changes in mitochondrial enzyme activity
found here are larger than those shown previously to occur with six weeks of exercise training
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[119]. Further, a decrease in soleus capillarity of the magnitude found in chapter 3 is at least
equal in magnitude to the increase in capillarity that exercise training stimulates. This magnitude
of change has been shown previously by our lab and others to affect overall exercise function
[120-122], and is greater in magnitude than that seen with 9 days of hindlimb unloading [6].
Therefore we must conclude that this is a functionally relevant decrease. It is much more likely
that while maximal running speed has been shown to be a good surrogate for VO2max in mice, as
discussed previously, it may not be the best test to have performed in the context of this study
(i.e. an endurance run test could have been a more appropriate test).
This same concept could also be applied to the ex vivo preparation. The strength of ex
vivo muscle stimulation is that it removes central factors from the regulation of skeletal muscle
function (i.e. the heart and lungs), and focuses solely on the muscle. However, it is not the best
reflection of the aerobic/endurance systems of the muscle. That is, because the endogenous
vascular network is removed in the process of excising the muscle, ex vivo stimulation divorces
blood flow from its influence on muscle function. Still, it is surprising we saw no change in ex
vivo function in the TSP-1 KOs, as they have been shown to have increased endurance capacity
as well as increased maximal running speed [3]. Of course, the mETC activities that we tested
only make up one part of the oxidative capacity of the mitochondria, and it could be that the
change in these specific enzymes are not enough to cause an overall change, especially since we
are removing the muscles from their endogenous system. The changes in the mETC enzymes
may only be functionally relevant with the corresponding changes in vascularity (i.e. increased
C:F in the KO and decreased C:F in the mimetic treated animals) since the ex vivo preparation
provides a super-physiologic amount of metabolic substrate, and divorces endogenous blood
flow. In situ or in vivo muscle stimulation could answer these questions, as they keep the
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endogenous vascular and metabolic systems intact. Indeed, the reason we chose to do in vivo
muscle stimulation in chapter 6 is precisely because of the findings in chapter 5. If we want to
answer what is occurring with aerobic exercise and muscle function in the future, these
limitations will need to be addressed.
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Chapter 7: Future Directions
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Given the findings in all chapters of this dissertation, there are significant new questions
that now will require further investigation.
One interesting future direction would be to analyze what role TSP-2 has in both
pathological and physiological angiogenesis. It appears TSP-2 may be playing a role in
pathological capillary regression, but the work in this dissertation is the first and only data to
suggest this (chapter 5, figure 5). Indeed, there is almost no work on TSP-2 in skeletal muscle
under any conditions, and the data that does exist does not directly analyze what role TSP-2
plays in skeletal muscle angiogenesis. The potential importance of TSP-2 becomes even more
intriguing when taken in context with the finding that TSP-1 likely has little or no role in chronic
systemic inflammatory induced capillary rarefaction, yet seems to play an important role in
physiological angiogenesis (chapter 5). It would be interesting to look at TSP-2 in normal
healthy animals, as well and also to determine what effects exercise training has on TSP-2. This
could yield further information as to TSP-2s role in controlling physiological angiogenesis, as
exercise is one of the strongest stimulus for angiogenesis. Further work with the TSP-2 KOs to
see how their exercise capacity and skeletal muscle capillarity compares to normal animals
would also yield powerful information not only on the role of TSP-2, but how TSP-2 compares
to TSP-1 in this context. These potentially divergent roles for the closely related TSP-1 and
TSP-2 proteins have not yet been characterized. Further, since capillary loss and an altered
angiogenic response are strongly correlated with the muscle dysfunction in chronic disease
finding a major regulator that could serve as either a) a biomarker or b) a therapeutic target of
this dysfunction is of high interest to both scientists and clinicians alike. We suggest that TSP-2
could be this protein.
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We have eliminated TSP-1 and VEGF as potential markers/mediators of capillary
regression in a TNFα induced chronic systemic inflammatory insult, despite their apparent
critical roles in physiological angiogenesis. To date, we have speculated that the pathways that
control pathological and physiological angiogenesis are regulated by the same protein mediators
based on the available literature, however little evidence exists to either support or refute our
hypothesis in skeletal muscle. Our data suggests that there may be differences in the regulatory
pathways of skeletal muscle angiogenesis that relate to specific conditions. That is, we suggest
that there are divergent pathways that control physiological vs. pathological angiogenesis in
skeletal muscle. Identifying these different pathways and the molecular mediators important to
each could be important in a variety of settings, from exercise training prescription to clinical
treatment of disease. This suggests future work with broad-scope proteomics may help to
identify how divergent pathways and proteins regulate pathological vs. physiological
angiogenesis.
Based on the data from chapters 3 and 4, we suggest it is now important to determine if
autophagy is the mechanism by which capillaries are lost in skeletal muscle regression. This is a
new and untested hypothesis. Autophagy is a critical regulatory process in many tissues and
proven to be important in skeletal muscle. While autophagy is a known to be an apoptotic
trigger, very recent evidence suggesting that TSP-1 mediated autophagy does not trigger
apoptosis, yet can still decrease vascularity [1]. While this study was performed in cancer cells, it
fits well with our findings. That is, we show no apoptosis or necrosis in the presence of a TSP-1
mimetic, yet a decrease in capillarity (chapters 3 and 4). At present, we are unaware of any
studies that examine what role autophagy plays in skeletal muscle angiogenesis. Further still, no
data exists on TSP-1’s role in autophagy in any tissue beyond that recently reported in the
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context of cancer. While only speculative at this point, autophagy could be a non-apoptotic
mechanism for the removal of endothelial cells in skeletal muscle, or reduction in their viability,
and hence a resultant shrinking of the capillary network. This is a potentially exciting new role
for TSP-1 in skeletal muscle.
One important protein that was not examined in this dissertation is CD47. CD47 is a
TSP-1 receptor that has been shown to be a critical component of the TSP-1 anti-angiogenic
pathway. However, its role in skeletal muscle is poorly studied. Since CD47 is speculated to be
a powerful global regulator of nitric oxide, it certainly could be playing an important role in
skeletal muscle, as nitric oxide has a variety of functions that are important to skeletal muscle.
The current work established that CD36 is important in skeletal muscle capillary rarefaction
(chapters 3 and 4), however it would also be interesting and important to see how manipulation
of CD47 affects skeletal muscle structure and function. Indeed, CD47 has been shown to have
overlapping functions with CD36, and may work in concert with CD36 to decrease vascularity.
If this is true, we may see greater deficits with the manipulation of both CD36 and CD47, versus
just CD36 alone. This may also be why we do not see functional differences in muscle shown in
chapters 3 and 4.
Finally, our the work showing that TSP-1 is influencing mitochondrial function suggests
further work in isolated mitochondria could yield an intriguing role for TSP-1 in skeletal muscle.
The role that TSP-1 plays in mitochondrial function remains almost entirely unexplored, with the
only work done in mitochondria and TSP-1 relating to biogenesis, and not function. Indeed, if
TSP-1 decreases mitochondrial number and/or function, as suggested by our data in chapter 4, it
only strengthens the role for TSP-1 in controlling overall muscle function. Our data in chapter 4
is also the first to suggest that this regulation of mitochondria may occur through CD36, and not
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CD47 as previously suggested [2]. Parsing out the pathways that are important in this potential
TSP-1 control of mitochondrial number/function will provide important mechanistic
understanding on TSP-1 role in muscle function. Also, it would be interesting to determine what
differential affects, if any, TSP-1 has on mitochondrial subpopulations in skeletal muscle
(subsarcolemmal vs. interfibrillar), as each has been suggested to have distinct and important
roles.
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Capillary adaptation
first occurs here

Figure 1: Time course protein expression of TSP-1 following training. Control mice are
untrained, all others voluntarily trained using a running wheel for 3, 5, 7, 14, or 28 days (n=12/group). Following
training, half of the mice per group (n=6) were evaluated under basal conditions (black bars), and the other half
(n=6) performed a single bout of acute exercise (1 hour, 20 m/min, 10° incline) with muscles harvested 4-hours post
exercise (gray bars). A.U.= arbitary densitometry units (normalized to GAPDH). Animals from this study showed
significant capillary increase (as measured by capillary-to-fiber ratio) by 7 days, which continued to increase
through 28 days. #: Significantly different compared to 14-day trained Basal levels, p<0.05; &: significantly
different compared to 28-day trained Basal levels, p<0.05; $: signifies p ≤0.10 compared to Basal control. Adapted
from Data submitted to The Journal of Physiology (May2013, preliminary acceptance) “Temporal response of positive and negative regulators
in response to acute and chronic exercise training in mice” Sara A. Olenich, Navarre Gutierrez-Reed, Gerald N. Audet, and I. Mark Olfert
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Figure 2: Chronic systemic inflammation does not change skeletal muscle TSP-1 levels in
several different rodent models. Thrombospondin-1 remained unchanged in the A) obese
db/db(N=4/group) and B) chronic cigarette smoke mouse models (N=8-10/group). The db/db mice have a
genetically induced leptin deficiency which results in obesity and increased systemic inflammation. Mice in panel B
were subjected to 6 months of direct cigarette smoke exposure. Mice were subjected to 12 cigarettes over 60
minutes, 5 days a week. Cigarette smoke has been shown previously to induce systemic inflammation. C) Obese
Zucker rats (N=6/group) also have no increased TSP-1 in two distinct muscles (SOL and PLT). Obese Zucker rats
are similar to the db/db mice in that they have dysfunctional leptin signaling and grow extremely obese and have
been shown to have increased systemic inflammation. Unpublished data
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B

C

Figure 3: Detraining results in a loss of capillaries, along with increased TSP-1 and VEGF.
Animals underwent 21 days of training where they had free 24 hour access to running wheels. Animals spent
apporximately 300-360 minutes per day running (data not shown). A) After 21 days the D1 group was sacrificed,
while groups D7-D28 had wheels removed but were allowed free range of their cages for either 7 (D7), 14 (D14), or
28 days (D28). After 21 days of training there was a signfiicant increase in capillarity, as expected. After 7 days
without the wheels (i.e. detraining), there was significant drop in capillarity that remained low through 28 days. B)
This reduction in capillarity at 7 days coincided with an increase in TSP-1 protein levels. C) Surprisingly, VEGF
levels were increased from D1-D14. * P<0.05 from control; † P<0.05 from D1. Adapted from data to be submitted to The
Journal of Physiology (August 2013) “Effects of Detraining on the Temporal Expression of Key Positive and Negative Angioregulatory Proteins
in Skeletal Muscle” Sara A. Olenich, Gerald N. Audet, Kathleen A. Roberts, and I. Mark Olfert
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Chronic Delivery of a Thrombospondin-1 Mimetic
Decreases Skeletal Muscle Capillarity in Mice
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Abstract
Angiogenesis is an essential process for normal skeletal muscle function. There is a growing body of evidence suggesting
that thrombospondin-1 (TSP-1), a potent antiangiogenic protein in tumorigenesis, is an important regulator of both
physiological and pathological skeletal muscle angiogenesis. We tested the hypothesis that chronic exposure to a TSP-1
mimetic (ABT-510), which targets the CD36 TSP-1 receptor, would decrease skeletal muscle capillarity as well as alter the
balance between positive and negative angiogenic proteins under basal conditions. Osmotic minipumps with either ABT510 or vehicle (5% dextrose) were implanted subcutaneously in the subscapular region of C57/BL6 mice for 14 days. When
compared to the vehicle treated mice, the ABT-510 group had a 20% decrease in capillarity in the superficial region of the
gastrocnemius (GA), 11% decrease in the plantaris (PLT), and a 35% decrease in the soleus (SOL). ABT-510 also decreased
muscle protein expression of vascular endothelial growth factor (VEGF) in both the GA (2140%) and SOL (262%); however
there was no change in VEGF in the PLT. Serum VEGF was not altered in ABT-510 treated animals. Endogenous TSP-1 protein
expression in all muscles remained unaltered. Tunnel staining revealed no difference in muscle apoptosis between ABT-510
and vehicle treated groups. These data provide evidence that the anti-angiogenic effects of TSP-1 are mediated, at least in
part, via the CD36 receptor. It also suggests that under physiologic conditions the TSP-1/CD36 axis plays a role in regulating
basal skeletal muscle microvessel density.
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Under physiologic conditions, TSP-1 expression has been
shown to be responsive to exercise [18,19], which suggests that
TSP-1 may play a role in regulating exercise-induced skeletal
muscle angiogenesis. TSP-1 KO mice have elevated skeletal
muscle capillarity compared to wild-type mice, suggesting a critical
role for TSP-1 in the physiological maintenance of capillaries [4].
Evidence in rats also shows that hindlimb unloading increases
TSP-1 in association with decreases in skeletal muscle capillarity
[3]. Recently, TSP-1 and it’s receptor CD47 have also been
suggested to play a pivotal role in skeletal muscle mitochondrial
biogenesis, and therefore it is likely to be important in overall
skeletal muscle function and adaptation to exercise stress [20].
Given the growing data implicating that importance of TSP-1
as a key angiogenic regulator in skeletal muscle, we sought to
determine the consequences of chronically stimulating the TSP-1
pathway using ABT-510. ABT-510 is a mimetic of the conserved
type I repeat region of TSP-1 which has been shown previously to
inhibit angiogenesis through the CD36 receptor [12,13,21]. ABT510 has been synthesized to have a longer half life in circulation
than the native type I repeats of TSP-1 which allows for increased
chronic stimulation of the TSP-1/CD36 pathway [22]. ABT-510
has been shown to be a potent inhibitor of vascular growth in
tumorigenesis both in vitro and in vivo [15,23,24,25,26,27,28],
which has been attributed to its binding to the CD36 receptor.
Using this peptide we aimed to examine whether increased

Introduction
Physiologic angiogenesis and homeostasis of adult blood vessels
is a complex process that is highly regulated by a balance between
positive and negative angiogenic proteins. While there is a
substantial body of evidence on the role positive angiogenic
factors, such as vascular endothelial growth factor (VEGF) [1,2,3],
the role of negative angiogenic factors is incomplete and poorly
understood [4].
There are a number of known angiogenic inhibitors, of which
thrombospondin-1 (TSP-1) is thought to play a prominent role in
skeletal muscle angiogenesis [4]. TSP-1 is a large (450 kD)
extracellular protein that has a wide array of functions [5]. First
discovered for its role in wound healing and platelet activation, it
also has important roles in apoptosis, inflammation, nitric oxide
signaling, and inhibition of positive angiogenic proteins
[6,7,8,9,10]. Acting through CD36 (one of its receptors), TSP-1
has been shown to prevent endothelial cell adhesion, growth, and
migration, as well as increase apoptosis [11,12,13]. The antiangiogenic effects of TSP-1 in cancer pathology are well
established. For example, a reduction in TSP-1 has been shown
to increase tumor vessel growth, whereas pharmacological
administration of several different TSP-1 mimetics has helped
decrease tumor size and disease progression in animal models
[14,15,16,17].
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stimulation of the CD36 arm of the TSP-1 pathway affected
skeletal muscle structure and function. Given that TSP-1 is a
negative angiogenic regulator, we hypothesized that mice subjected to the ABT-510 would have lower skeletal muscle capillarity,
mirrored by an altered balance between positive and negative
angiogenic proteins.

the transverse plane. Sections were stained for dipeptidly-peptidase
IV (DPP IV) and alkaline phosphatase (AP) following the method
of Lojda (1979), as applied to skeletal muscle tissue [31,32]. A light
microscope (Zeiss primo star, Zeiss, Oberkochen, Germany) was
used to digitally acquire (Axiocam IC c3, Axiovision 4.8.2.0, Zeiss,
Oberkochen, Germany) 206 images of the gastrocnemius,
plantaris, and soleus. Capillary and myofiber counting was
performed by a single individual blinded to group identification.
For the gastrocnemius muscle, we obtained images in a
checkerboard fashion across the entire muscle, thus both
superficial and deep regions within the gastrocnemius could be
included in the analysis. For the plantaris and soleus muscles,
respectively, the entire muscle was imaged and analyzed. Counting
was performed by visualization from acquired images using a
custom program in MATLAB (version 7.0.0.27, The Mathworks,
MA, USA) allowing the operator to visually mark and count the
capillaries and fibers on each image. Capillary-to-fiber ratio (C:F,
number of capillaries/number muscle fibers), capillary density
(CD, number of capillaries/mm2 muscle fiber area), and fiber
cross sectional area (FCSA) were separately calculated for the
gastrocnemius (GA), soleus (SOL), and plantaris (PLT) (n = 33–
101 images/muscle/group).

Methods
Animals
This study used 10–12 week old male C57BL/6 mice purchased
from Jackson Laboratories (Strain no. 000664, C57BL/6J, Bar
Harbor, ME). Mice were randomly selected to be placed in two
groups (control, n = 8; experimental n = 8). All procedures that
involved animals were approved by the West Virginia University
Institutional Animal Care and Use Committee.

Exercise Testing Protocol
Whole body exercise capacity was assessed using a graded
maximal exercise test (max test) 48 hours before pump implantation and then again 48 hours before muscle harvest (12 days
after implantation). This was done to ensure that the exercise bout
did not influence protein levels in muscles harvested on the final
study day (Day 14) [18]. Maximal run test procedure: mice were
given a 5 minute warm-up (speed ,4 m/min) at a 10 degree
incline on a commercially available rodent treadmill (Columbus
Instruments, Columbus, OH). After the warm-up period, the
treadmill was increased 2 m/min every 30 seconds until the
animals reached exhaustion. Exhaustion was defined by a single
observer as the inability of the animal to stay on the treadmill at a
given speed, and/or more than 3 seconds spent on the shock grid.
Animals were encouraged to run as fast and as long as possible by
using forced air and a weak electrical deterrence. Final run time
and velocity were recorded and compared between groups.

Protein Analysis
GA, SOL, and PLT muscles from each group were excised and
flash frozen in liquid nitrogen. They were then separately
homogenized in a lysis buffer containing 50 mM Tris/HCl
(pH 7.4), 150 mM NaCl, 0.5% Triton X-100, and protease
inhibitors (Complete Tablet, Roche Applied Science, Indianapolis,
IN). Homogenates were centrifuged at 4uC, at 8,000 g for
10 minutes, and supernatants removed and placed in new tubes.
Blood samples were obtained from the heart and allowed to
coagulate on ice. They were then centrifuged at 3000 g for
10 minutes and flash frozen in liquid nitrogen. Total protein was
measured by bradford assay (#23236 Pierce Coomassie Plus
Protein Assay Kit, Thermo Scientific, Rockford, IL).
Quantification of VEGF was made from a total of 100 mg of
protein using a commercially available ELISA kit according to the
manufactures instructions (# MMV00, R&D Systems, Minneapolis, MN, USA). Quantification of VEGFR-2 and P-VEGFR-2
were made from a total of 100 mg of protein using a commercially
available ELISA kit according to the manufactures instructions (#
7335S, #7340S, Cell Signaling, Danvers, MA, USA). TSP-1 and
CD36 were analyzed via western blot. In brief, samples were
separated on a 3–8% SDS-PAGE (NuPAGE Novex 3–8% TrisAcetate Midi Gel, Invitrogen, Burlington, ON, Canada) and
blotted onto a 0.45 mm nitrocellulose membrane (Pierce nitrocellulose membrane, Thermo Scientific, Rockford, IL). After
blocking with 5% fat-free milk, membranes were probed using
antibodies against TSP-1 (1:1000, clone A6.1, #399300, Invitrogen, Burlington, ON, Canada), b-tubulin (1:1000, #2148, Cell
Signaling), CD36 (1:250 #552544, BD Pharmingen, Franklin
Lakes, NJ, USA), secondary HRP-conjugated anti-mouse (1:1000,
#p0260, Dako, GE Healthcare, Piscataway, NJ) and secondary
HRP-conjugated anti-rabbit (1:1000, #p0217, Dako). Proteins
were visualized using chemiluminescence detection (Pierce ECL,
Thermo Scientific, Rockford, IL) and digitally imaged (G:BOX
Gel imager, Syngene, Cambridge, UK) using Genesnap software
(Ver. 7.01, Syngene, Cambridge, UK). Equal protein loading was
verified by immunodetection of b-tubulin as our loading control.
Quantification of protein expression levels were carried out using
NIH Image J Software (v1.62) and expressed as densitometric
arbitrary units (AU).

Osmotic Pump Drug Delivery
The TSP-1 mimetic ABT-510 was generously provided by
Abbott (Abbott, IL). This compound was chosen for use in this
study based on previous and preliminary work showing its
effectiveness in decreasing capillarity in tumors, both in vitro and
in vivo [15,22,23,24,25,29,30]. ABT-510 was dissolved in 5%
dextrose (vehicle) over a 48 hour period to ensure the compound
was fully dissolved, and then inserted into mini-osmotic pumps
(Model 1002, Alzet Osmotic Pumps, Cupertino, CA,). Pumps were
filled with either the drug or vehicle solution 24 hours in advance
of implantation as per manufacture instructions. We delivered the
maximum concentration of 30 mg/kg/day based on the maximum pump capacity (100 mL), the mass of the animals, and the
solubility of the drug (ABT-510 solubility curves [22]). Pumps were
surgically inserted (flow-moderator first) subcutaneously in the
scapular region while the mice were under anesthesia (2%
isoflurane). The surgical site was disinfected with iodine and
closed using sutures. Animals were then housed individually and
observed daily for the remainder of the study for pain or distress.
Pumps remained in the animals for 14 days, after which they were
sacrificed and tissue/organ samples were collected and stored at
280u for later analysis.

Morphometry
Hindlimb skeletal muscle was surgically excised and frozen in
isopentane cooled by liquid nitrogen. Frozen tissue was cut using a
220uC cyromicrotome (Jung-Reichert Cryocut 1800: Cambridge
Instruments, Germany) to yield 10 mm transverse sections. Great
care was taken to ensure the cryosectioned muscles were cut along
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Morphometry. In the superficial region of the gastrocnemius
(GA) muscle there was a 20% decrease in C:F (P#0.05) and a
similar trend in CD (25% decrease, P = 0.055) in the mimetic
group compared to vehicle (Figure 1 & 2). There was no statistical
difference in C:F of the deep portion of the GA between groups,
however there was a significant 25% decrease in CD (P#0.05).
FCSA was not significantly different between groups in either
portions of the GA.
In the plantaris (PLT) muscle, there was a 11% decrease in the
C:F in the PLT in the mimetic group compared to vehicle
(P#0.05) (Figure 3). There was no difference in CD or FCSA in
the PLT.
In the soleus (SOL) muscle, there was a 35% decrease in the C:F
in the SOL in the mimetic group compared to vehicle (P#0.01)
(Figure 3). There was no difference in CD (P = 0.08) or FCSA
(P = 0.09).

Apoptosis
Nuclei exhibiting apoptotic changes were identified by TdTmediated dUTP nick end labeling (TUNEL) according to the
manufacturer’s recommendations (Roche Molecular Biochemicals, Pleasanton, CA). Briefly, muscle cross sections were cut on a
cryostat (10 mm) and fixed in 4% paraformaldehyde at room
temperature, blocked in 3% H2O2 in 100% methanol at room
temperature, and permeabilized in 0.1% Triton X and 0.1%
sodium citrate. TUNEL reaction mix was added in a 1:7.5
dilution, and the sections were incubated at 37uC for 1 h. Sections
were reacted with fluorescein antibody for 30 min at 37uC, and
substrate was added for color development. To control for falsepositives, samples were then counter stained by DAPI staining to
identify the nucleus. TUNEL staining was performed using a
fluorescein TUNEL kit at 1:7.5 dilution as recommended by the
manufacturer (Roche Molecular Biochemicals, Pleasanton, CA).
Positive nuclei were counted, and at high power (6400), it was
determined whether they were associated with the myofiber or
with the interstitial space. The number of positive nuclei is
expressed per whole muscle section. Positive controls were created
using a DNase treatment of 1 serial section (# AM1906, DNA-free,
Ambion, Austin, TX). Negative controls were created by staining 1
serial section only for DAPI without TUNEL staining. This
resulted in each sample containing 1 negative, 1 positive, and 2
experimental sections per slide.

Endogenous VEGF, VEGFR-2, p-VEGFR-2, TSP-1, and CD36
Levels
Skeletal muscle VEGF protein expression was decreased by
147% and 62% in the GA and SOL respectively (P#0.05,
Figure 4). In contrast, no significant change in VEGF protein
expression was seen in the in the PLT. Serum VEGF levels were
unchanged between ABT-510 and vehicle treated animals.
Total VEGFR-2 and phorphylated-VEGFR-2 (p-VEGFR-2)
levels were also assessed in the GA. There was no difference in
total VEGFR-2 levels, p-VEGFR-2 levels, or a ratio of VEGFR2/p-VEGF-R2 between ABT-510 and vehicle treated mice (data
not shown).
Endogenous TSP-1. protein expression of endogenous TSP1 was not significantly different in any of the muscles analyzed
(SOL, PLT, GA) between the treated groups (data not shown).
CD36 levels. There was no difference in the receptor levels of
CD36 in the GA as assessed by western blot (data not shown).

Statistics
All data are presented as means+/2SEM. To examine body
mass, organ masses, muscle capillarity and molecular responses we
used a student’s T-test. A repeated measures ANOVA was used to
analyze the maximal running test. An alpha level at P,0.05 was
selected for statistical significance.

Results
Exercise Testing and Morphometry
Body and Muscle Mass. There was no significant difference
in the absolute body or individual hindlimb muscle masses
between ABT-510 (mimetic) and vehicle treated groups (Table 1).
Heart and skeletal muscle normalized to body mass were not
different between the groups (Table 1).
Maximal Running Test. There was no difference in
maximal running speed between vehicle and mimetic treated
animals pre- or post-treatment.

Table 1. Muscle and Body Masses.

Vehicle

ABT-510

Body Mass (g)

27.561.23

27.160.87

GA (mg)

136.864.56

140.864.09

PLT (mg)

19.760.90

19.060.53

SOL (mg)

7.760.47

7.86.048

HRT (mg)

123.565.76

134.365.82

GA/BM (mg/g)

5.060.07

5.260.12

PLT/BM (mg/g)

0.7260.04

0.7060.02

SOL/BM (mg/g)

0.2960.01

0.2860.01

HRT/BM (mg/g)

4.460.26

5.060.17

Figure 1. Representative figures of the histology sections. A)
Superficial Gastrocnemius Muscle B) Deep Gastrocnemius Muscle C)
Plantaris Muscle, D) Soleus Muscle.
doi:10.1371/journal.pone.0055953.g001

Values: Mean 6 Standard Error.
*P = 0.05.
doi:10.1371/journal.pone.0055953.t001
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Figure 2. Superficial gastrocnemius capillarity, but not deep, is decreased in the ABT-510 group. Chronic administration of ABT-510
30 mg/kg/day decreased capillary to fiber ratio (C:F) and capillary density (CD) in the superficial gastrocnemius (GA). Despite a similar trend, no
significant changes in capillarity were seen in the deep GA. There was no change in fiber cross sectional area in either the deep or superficial portions
of the GA. * = P#0.05.
doi:10.1371/journal.pone.0055953.g002

of TSP-1 directly influence homeostatic maintenance and/or
development of skeletal muscle microvessels.

Apoptosis
Apoptosis was assessed using TUNEL staining for fragmented
DNA. There was no difference in the number of TUNEL positive
nuclei in any of the muscles between the two treated groups
(Figure 5).

Skeletal muscle capillarity is decreased in mimetic treated
mice
TSP-1 has been shown previously to be important in
maintaining skeletal muscle capillarity, where TSP-1 KO mice
have approximately 2 fold the number of capillaries as WT
controls [33]. Further, TSP-1 has been shown to be important in
maintaining capillarity with hindlimb unloading [34]. In this
manuscript we build upon this small body of evidence for the
importance of TSP-1 in the context of the basal regulation of
angiogenesis.
The actions of TSP-1 are complex and multifunctional, due in
large part to the diversity of receptors it binds, such as lipoprotein
receptor-related protein 1 (LRP-1), CD47, and CD36 [11,35].
Our use of this the TSP-1 mimetic ABT-510, which is a potent
CD36 binding peptide, resulted in a decrease in capillarity across
three different distinct skeletal muscles. This suggests that TSP-1s

Discussion
The main finding of this study is that chronic exposure to the
TSP-1 mimetic ABT-510 significantly decreases skeletal muscle
capillarity (Figure 1). To our knowledge, these are the first data to
show that chronic stimulation of the TSP-1/CD36 pathway in
healthy mammals results in decreased skeletal muscle capillarity.
These data are consistent with the anti-angiogenic function of
TSP-1 and, more importantly, support the notion that TSP-1
through its CD36 receptor is a critical regulator of skeletal muscle
capillarity under physiologic conditions. Indeed, when coupled
with the previous observation that loss of TSP-1 increases skeletal
muscle capillarity (25) these data provide evidence that the actions
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Figure 3. Plantaris and soleus capillarity is decreased in the ABT-510 group. Chronic administration of ABT-510 30 mg/kg/day decreased
capillary to fiber ratio (C:F) in the plantaris muscle (PLT) but did not decrease capillary density (CD). ABT-510 decreased capillary to fiber ratio (C:F) and
capillary density (CD) in the soleus (SOL). There was no change in fiber cross sectional area in either the PLT or SOL muscle. * = P#0.05.
doi:10.1371/journal.pone.0055953.g003

clinically exploited to attenuate the decrements in skeletal muscle
function often accompanying these diseases.

anti-angiogenic properties in skeletal muscle involves a CD36
mediated mechanism. Indeed, this is consistent with the physiological activity of CD36 where TSP-1 binding to CD36 has been
shown to be anti-proliferative, anti-angiogenic, and pro-apoptotic
[12]. The importance of the TSP1/CD36 pathway has been
proven in tumorigenesis, where down regulation of TSP-1 and its
binding to CD36 results in a pro-tumorigenesis environment and
increase in tumor size [14,36,37,38]. Here we show similar actions
in skeletal muscle under physiological conditions. This suggests a
putative role for TSP-1 in decreasing vascularity across multiple
tissues, and not just in tumors.
Given these findings, it is tempting to speculate that elevated
skeletal muscle TSP-1 may serve as a biomarker for skeletal muscle
dysfunction associated with several chronic conditions known to
result in muscle capillary rarefaction, such as that found in
diabetes [39,40], and chronic heart and lung disease [41]. It may
even be that therapeutic interventions to limit basal TSP-1
expression and/or reduce circulating levels of TSP-1 could be
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Chronic stimulation of the TSP1/CD36 pathway
decreases VEGF
It has been shown previously that TSP-1 can counter the effects
of VEGF by multiple mechanisms; including interacting directly
with VEGF protein and disrupting its actions at the receptor level
[42,43,44,45,46]. For example, TSP-1 has been suggested to bind
VEGF via its type I repeat region (or 3TSR). Once bound the
protein heterodimer is internalized by the scavenger receptor low
density lipoprotein receptor-related protein 1 (LRP-1). Here, we
show that a chronic administration of ABT-510 (a TSP-1 type I
repeat mimetic), results in a decrease in total VEGF protein in
both the gastrocnemius muscle and the soleus muscle, along with
the decrease in capillarity. It is unclear why a similar decrease in
VEGF protein was not seen in the PLT which also showed
decreased capillarity, nevertheless these data support previous
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Figure 4. Skeletal muscle VEGF protein content is decreased in the ABT-510 group, but not serum levels. Chronic administration of the
mimetic (ABT-510 30 mg/kg/day) decreased VEGF protein in the GA, and SOL muscles of C57/BLK6 mice. There was no change in the PLT muscle or in
Serum levels. * = P#0.05.
doi:10.1371/journal.pone.0055953.g004

decrease in tyrosine phosphorylation of VEGFR-2 [12,13,21].
This includes dephosphorylating the important tyrosine 1175
region; which is critical to initiate downstream VEGF signaling.
While it has also been shown previously that ABT-510 significantly
decreases the amount and phosphorylation status of VEGFR-2 in
endothelial cells in vitro [24,51], in vivo we found no significant
change in the phosphorylation levels of tyrosine 1175 of VEGFR2. Given that the mimetic is a type I repeat, and that total VEGF
protein levels were decreased, we were surprised that VEGFR-2
phosphorylation was also not decreased. But, because we only
have one time point, it could be that levels of phosphorylation
were lower earlier in the chronic dosage but by the end of the
study returned to normal levels. While ABT-510 has been shown
to decrease VEGFR-2 phosphorylation in tumors [24], it may be
that this response is different in skeletal muscle under physiological
conditions. It could also be that phosphorylation status in vivo is not
lowered by endogenous TSP-1 (or the addition of a mimetic),
rather TSP-1 limits or prevents an increase in phosphorylation
levels with a VEGF stimulus. This is yet to be elucidated.
Administration of ABT-510 did not significantly alter endogenous levels of TSP-1 in skeletal muscle, indicating that there was
no feedback response from the mimetic binding to CD36 to alter
endogenous TSP-1 levels in skeletal muscle. However, the

studies suggesting that TSP-1 may be binding and sequestering
VEGF – resulting eventually in internalization and biological
inactivation [42,43,44,45,46]. Explanations for the reduction in
VEGF may also involve suppression of VEGF production and/or
VEGF signaling. For example, there is a growing body of evidence
showing that the internalization of the VEGF/VEGFR-2 complex
by endocytosis results in downstream activation of several different
signaling pathways [47]. There is also evidence that both CD36
and CD47 can associate with VEGFR-2, and when TSP-1 is
present this association can prevent the VEGF ligand binding to its
receptor, as well as inducing receptor dephosphorylation and
preventing dimerization [13,21,48,49]. In this way, TSP-1 could
prevent activation and/or endocytosis of the VEGF receptor,
blocking yet another biologically active arm of VEGF/VEGF-R
complex. Regardless of the mechanism, our data supports the
notion that TSP-1 likely plays a regulatory role involving VEGF,
thereby enhancing its already potent inherent anti-angiogenic
capacity.
In endothelial cells, TSP-1 can also disrupt VEGF actions at the
receptor level by dephosphorylating the important receptor
VEGFR-2 (Flk-1) [50]. TSP-1 can disrupt VEGFR-2 activation
by binding the CLESH region of CD36, triggering a cascade of
events which results in direct binding of VEGFR-2, and a resultant
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regression occurs [60,61,62,63], and has been shown to be central
in muscle atrophy during some pathologies, aging, and disuse
[64,65,66,67,68]. Knowing this, we performed TUNEL staining to
look at end stage apoptosis (DNA fragmentation) in all three of the
excised muscles. Surprisingly, we found no evidence of apoptosis
in any of the muscles, either myocyte or endothelial. The reason
for this remains unclear. This is, however, the first in vivo report of
ABT-510s affects on skeletal muscle and it could be that ABT-510
is not sufficient to induce myocyte apoptosis in skeletal muscle
under these conditions. Indeed, much of the work with TSP-1 and
apoptosis pertains to cancer models (e.g. tumorigenesis), endothelial cells, and is typically done in vitro. It is possible that TSP-1 is
not as potent a pro-apoptotic protein in skeletal muscle as that seen
in endothelial cells or tumors. This is supported by the finding that
there was no change in muscle fiber cross-sectional area (Figures 2
and 3). Whether or not the ABT-510, or the TSP-1/CD36 axis,
alters in vivo skeletal muscle myocyte apoptosis will require further
study.
However, this does not explain why we saw no endothelial cell
apoptosis. As mentioned previously, our study only examines one
time point. It is possible that apoptosis occurred at an earlier time
point than our assessment at the 14 day time point. Indeed, it has
been shown previously that hindlimb unloading results in capillary
loss in as little as 5 days [34]. If changes in endothelial cell number,
and therefore total vasculature, are occurring by 5–7 days it may
not be surprising that evidence of apoptosis has been lost by the
end of the study (14 days). That is, perhaps apoptosis has already
occurred, the cells cleared from the tissue, and the architecture of
the vascular network at 14 days has already returned to a new
steady state condition absent of apoptotic nuclei. We have yet to
elucidate this and more experimentation is needed to determine
exactly when apoptosis and regression is occurring.

Figure 5. There is no difference in skeletal muscle apoptosis
between the mimetic and control groups. TUNEL staining shows
that chronic administration of the mimetic (ABT-510 30 mg/kg/day) did
not increase or decrease skeletal muscle apoptosis in any of the muscles
tested. Representative GA samples, PLT and SOL data not shown. A)
Representative mimetic GA B) Representative positive control mimetic
GA C) Representative control GA D) Representative positive control
vehicle GA.
doi:10.1371/journal.pone.0055953.g005

reduction of skeletal muscle VEGF protein levels in association
with the mimetic adds support to the idea that physiologic
angiogenesis is controlled by a balance between both positive and
negative angiogenic factors, particularly VEGF and TSP-1. It
would have been interesting to deliver a higher dose of ABT-510
(.30 ug/kg/day) which may have resulted in greater reductions
in muscle VEGF and capillarity; however the dose used was the
maximum we could deliver using the small pumps suitable for
mice and the 2-week duration we sought. Although shorter
duration would allow greater concentrations of drug delivery, we
opted to deliver the drug for 14 days to ensure that vascular
remodeling would have sufficient time to occur. It could be
hypothesized that tipping the scale towards an anti-angiogenic
state (stimulated by the presence of ABT-510) would result in a
response of positive angiogenic factors to counter this challenge.
However, at least with respect to VEGF this was not the case. A
decrease in VEGF and no change in endogenous TSP-1 suggests
that the muscle has been pushed towards an anti-angiogenic
phenotype.
Regardless of mechanism, these data show that the altered
angiogenic state of the skeletal muscle can be driven by an increase
in a TSP-1 mimetic. The resulting decrease in capillarity
establishes the importance of TSP-1/CD36 pathway in maintaining and regulating basal skeletal muscle microvessel density.

Summary
In conclusion, we provide evidence for the importance of TSP1/CD36 pathway in regulating basal skeletal muscle capillarity by
showing that a chronic dosage of a TSP-1 mimetic for the CD36
pathway decreases skeletal muscle capillarity and VEGF expression. We did not find any differences in the VEGFR-2 expression
or its phosphorylation status, nor was there greater skeletal muscle
apoptosis. These data show that, despite the multifunctional effects
of TSP-1 and its CD36 receptor, the primary consequence of
elevating circulating TSP-1 (i.e. using a TSP-1 mimetic targeted to
its CD36 receptor) relates to its anti-angiogenic function. These
data may be useful in exploring therapeutic interventions for
individuals with skeletal muscle dysfunction resulting from
capillary regression.
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Mrázková O, Grim M, Carlson BM (1986) Enzymatic heterogeneity of the
capillary bed of rat skeletal muscles. American Journal of Anatomy 177: 141–
148.
Lojda Z (1979) Studies on dipeptidyl(amino)peptidase IV (glycyl-proline
naphthylamidase). Histochemistry 59: 153–166.
Malek MH, Olfert IM (2009) Global deletion of thrombospondin 1 increases
cardiac and skeletal muscle capillarity and exercise capacity in mice.
Experimental physiology 94: 749–760.
Roudier E, Gineste C, Wazna A, Dehghan K, Desplanches D, et al. (2010)
Angio-adaptation in unloaded skeletal muscle: new insights into an early and
muscle type-specific dynamic process. The Journal of Physiology 588: 4579.
Bornstein P (2009) Thrombospondins function as regulators of angiogenesis.
Journal of Cell Communication and Signaling 3: 189–200.
Lawler J (2000) The functions of thrombospondin-1 and-2. Current opinion in
cell biology 12: 634–640.
Zhang X, Lawler J (2007) Thrombospondin-based antiangiogenic therapy.
Microvascular research 74: 90–99.
Lawler J, Detmar M (2004) Tumor progression: the effects of thrombospondin-1
and -2. The International Journal of Biochemistry & Cell Biology 36: 1038–
1045.
Kivela R, Silvennoinen M, Lehti M, Jalava S, Vihko V, et al. (2008) Exerciseinduced expression of angiogenic growth factors in skeletal muscle and in
capillaries of healthy and diabetic mice. Cardiovascular Diabetology 7: 13.
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Expression of angiogenic regulators and skeletal muscle
capillarity in selectively bred high aerobic capacity mice
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Selective breeding for high voluntary wheel running in untrained mice has resulted in a
‘mini muscle’ (MM) phenotype, which has increased skeletal muscle capillarity compared
with muscles from non-selected control lines. Vascular endothelial growth factor (VEGF) and
thrombospondin-1 (TSP-1) are essential mediators of skeletal muscle angiogenesis; thus, we
hypothesized that untrained MM mice with elevated muscle capillarity would have higher
basal VEGF expression and lower basal TSP-1 expression, and potentially an exaggerated VEGF
response to acute exercise. We examined skeletal muscle morphology and skeletal muscle protein
expression of VEGF and TSP-1 in male mice from two (untrained) mouse lines selectively bred
for high exercise capacity (MM and Non-MM), as well as one non-selected control mouse
line (normal aerobic capacity). In the MM mice, gastrocnemius (GA) and plantaris (PLT)
muscle capillarity (i.e. capillary-to-fibre ratio and capillary density) were greater compared with
control mice (P < 0.05). In Non-MM mice, only muscle capillarity in PLT was greater than in
control mice (P < 0.001). The soleus (SOL) showed no statistical differences in muscle capillarity
among groups. In the GA, MM mice had 58% greater basal VEGF (P < 0.05), with no statistical
difference in basal TSP-1 when compared with control mice. In the PLT, MM mice had a 79%
increase in basal VEGF (P < 0.05) and a 39% lower basal TSP-1 (P < 0.05) compared with the
control animals. Non-MM mice showed no difference in basal VEGF in either the GA or the PLT
compared with control mice. In contrast, basal TSP-1 was elevated in the PLT, but not in the
GA, of Non-MM mice compared with control mice. Neither VEGF nor TSP-1 was significantly
different in SOL muscle among the three mouse lines. In response to acute exercise, MM mice
displayed a 41 and 28% increase (P < 0.05) in VEGF in the GA and PLT, respectively, whereas
neither control nor Non-MM mice showed a significant VEGF response to acute exercise. In
contrast, TSP-1 levels were decreased by 90% in GA (P < 0.05) but increased by 50% in PLT
(P < 0.05) in response to acute exercise in MM mice. The SOL showed no response to exercise for
either VEGF or TSP-1 for any of the mouse lines. These data, with the exception of the Non-MM
plantaris muscle, suggest that elevated capillarity is associated with altered balance between
positive and negative angiogenic regulators (i.e. VEGF versus TSP-1, respectively). Based on the
greater capillarity and significant VEGF response to exercise in MM mice, these data suggest
that VEGF expression may, at least in part, be genetically determined.
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The importance of genetic influences in determining
aerobic exercise capacity has been highlighted by selective
breeding approaches used to developed high aerobic
capacity lines of rodents (Swallow et al. 2009; Feder
et al. 2010). For example, Koch & Britton (2001) have
developed separate high (HCR) and low aerobic capacity
rat (LCR) lines via respective breeding of rats for either
high or low endurance capacity on a motorized treadmill.
This has resulted in a diverging phenotype, where HCRs
have a higher cardiovascular (Koch et al. 1999; Howlett
et al. 2009) and respiratory capacity (Henderson et al.
2002) and increased skeletal muscle metabolism (Howlett
et al. 2003), underpinning their greater innate aerobic
endurance capacity compared with LCRs. Data obtained
from this artificial selection experiment also highlights the
importance of reduced/impaired physical activity for the
pathogenesis of chronic disease, as the incidence of some
cardiovascular risk factors is significantly greater in LCRs
compared with HCRs (Wisloff et al. 2005).
Continuous selective breeding for high voluntary wheel
running in laboratory house mice has also resulted in
the development of four replicate lines of mice with a
significantly increased aerobic exercise capacity (Swallow
et al. 1998a,b; Garland et al. 2011). The ‘gene pool’ of
the original outbred population of mice from which this
experiment originated included a Mendelian recessive
allele whose most notable feature is to cause a 50%
reduction in hindlimb muscle mass when present in the
homozygous condition (Garland et al. 2002; Houle-Leroy
et al. 2003). This ‘mini-muscle’ phenotype was favoured by
the selective breeding regimen and increased in frequency
in two of the four replicate selected lines (Garland
et al. 2002). Further study of the mini-muscle mice
(MM mice) has indicated several distinct physiological
characteristics that may be advantageous with respect to
wheel running. The most distinct feature is a significant
reduction in the mass of most hindlimb muscles, but also
includes fibre-type alterations favouring more oxidative
fibres, increased tibia length (Syme et al. 2005; Guderley
et al. 2008; McGillivray et al. 2009; Wong et al. 2009),
increased mitochondrial enzymatic activity (Guderley
et al. 2006), a smaller overall body mass (Swallow et al.
1999) and an increased maximal oxygen uptake (V̇O2 max )
when tested in hypoxia (Rezende et al. 2006a,b). More
recently, it has also been shown that MM mice exhibit
greater capillarity in the gastrocnemius compared with
mice that have normal-sized muscles, especially around
the medium and large fibres (>2000 μm2 ; Wong et al.
2009).
Given that oxygen delivery to skeletal muscle is
dependent on gas exchange across the microvascular
capillary bed, one important mechanism to increase
oxygen delivery to working muscle is to increase the
number and density of capillaries surrounding the fibres
(Andersen & Henriksson, 1977; Wagner, 2003). Two
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potentially important mediators in the angiogenic process
are vascular endothelial growth factor (VEGF; a positive
angiogenic factor) and thrombospondin-1 (TSP-1; a
negative angiogenic factor). In normal skeletal muscle,
it has been shown that acute aerobic exercise increases
VEGF (Breen et al. 1996; Gavin & Wagner, 2001; Olfert
et al. 2001; Gustafsson et al. 2002; Lloyd et al. 2003)
and TSP-1 gene expression (Olfert et al. 2006), and that
chronic or repeated exercise bouts ultimately decrease
TSP-1 mRNA while VEGF mRNA remains elevated
(Gavin & Wagner, 2001; Olfert et al. 2001; Waters et al.
2004). Indeed, the importance of VEGF in regulating
skeletal muscle capillarity is emphasized by recent evidence
demonstrating that significant losses in VEGF result in
reduced skeletal muscle capillarity (Tang et al. 2004; Olfert
et al. 2009) and altered vascular function (Lee et al. 2007).
Moreover, training-induced skeletal muscle angiogenesis
is absent in VEGF-deficient mice (Olfert et al. 2010).
By the same token, the importance of TSP-1 expression
in preventing hypercapillarization of the skeletal muscle
vascular bed has been shown using TSP-1 knockout mice
(Malek & Olfert, 2009).
Given the importance of VEGF and TSP-1 to skeletal
muscle structure and function, we sought to examine
VEGF and TSP-1 expression from two of the four selected
mouse lines with inherited high aerobic capacity [one
with the MM phenotype and another without the MM
phenotype (i.e. Non-MM)] compared with a non-selected
control line. We chose to examine two high capacity
lines in our study, MM (Garland designated line 3) and
Non-MM (Garland designated line 8), in order to more
generally evaluate the high aerobic capacity phenotype,
and not only the MM phenotype, compared with a
non-selected control line (Garland designated line 2). In
essence, the Non-MM mouse serves as an additional
high capacity experimental group compared with the
control line, but also as an additional high capacity group
compared with MM mice (which have a very distinctive
mini-muscle phenotype). For each of the three mouse
lines, we examined basal expression and the response to
acute exercise of VEGF and TSP-1 protein in the triceps
surae hindlimb muscle. As both the MM and the NonMM mice have increased maximal oxygen consumption
and treadmill endurance capacity during forced exercise
compared with mice from control lines (Meek et al. 2009),
and it has been shown that MM mice display elevated
gastrocnemius muscle capillarity (Wong et al. 2009), it
was first hypothesized that Non-MM mice would also
have elevated skeletal muscle capillarity compared with
control mice and second, that basal levels of VEGF would
be higher in both MM and Non-MM high aerobic capacity
mice compared with control mice. Moreover, given that
all three mouse lines were untrained, we reasoned that
we might see an exaggerated gene response to acute
exercise in the high aerobic capacity lines compared with
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control animals due to the selection of genetic influences
(resulting from the selected breeding strategy) that would
favour greater skeletal muscle capillarity and high aerobic
capacity mice, in the absence of training. On the other
hand, as the high aerobic capacity lines are expected to
have elevated muscle capillarity (and in normal mice
elevated skeletal muscle capillarity has been associated
with reduced VEGF responsiveness to exercise, at least in
the context of training), it could also be hypothesized that
simply having elevated capillarity (even in the absence of
training) might diminish or attenuate the VEGF response
to exercise in the high capacity selected lines compared
with control mice.
In this study, we report data from the triceps surae
muscles (which are known to have varying oxidative
and glycolytic capacity) in order to identify potential
differences in the skeletal muscle angiogenic response
between muscles; but more specifically, we sought to
exploit the innate difference between the respective mouse
lines as an approach that might be a useful in unravelling
the environmental versus genetic influences on skeletal
muscle vascularization.
Methods
Animals

Male MM mice (laboratory designation selected line 3,
n = 12), Non-MM mice (selected line 8, n = 12) and
control mice (line 2, n = 12) were bred and raised at the
University of California, Riverside. For a comprehensive
review on the breeding and selection process, please see
Swallow et al. (1998a). Briefly, eight independent lines
of mice were created in the early 1990s from a common
population of outbred Hsd:ICR laboratory mice. All lines
were provided with running wheels for 6 days when the
mice were ∼6–8 weeks of age. In the four selected lines,
the top-running male and female from within each of ∼10
families, each generation, were used for breeding and the
continuation of the line. The breeders were selected for the
greatest distance run on the fifth and sixth day of wheel
exposure. The other four lines were bred at random with
respect to the amount of running, and served as control
lines. After ∼16 generations, the four ‘high runner’ lines
ran approximately 2.7 times as far as the control lines, and
had begun to display a number of characteristics unique
to these lines (Swallow et al. 1998b, 2001, 2009; Koteja
et al. 1999). In the present study, the mouse lines we
examined came from the 54th generation, at which time
the four selected lines were running more than three times
further than control lines on a daily basis (T. Garland,
unpublished observations). All procedures that involved
animals were approved by the University of California,
Riverside, Institutional Animal Care and Use Committee.

Exp Physiol 96.11 pp 1138–1150

Acute exercise protocol

A subgroup of mice (n = 6) in each line were randomly
assigned to perform a single bout of acute exercise in order
to access growth factor response to an angiogenic stimulus.
These mice ran in a custom-built treadmill (Meek et al.
2009). The clear Plexiglass lane in which the mouse ran
had dimensions 6.5 cm wide, 12.5 cm high and 44 cm long.
All animals were familiarized with the treadmill for 5 min
prior to the acute exercise bouts. After this initial period,
mice ran for 1 h at 20 m min−1 with 10 deg incline. A run
time of 1 h was selected because it has been shown to
elicit a robust exercise-induced angiogenic gene response
in rodents (Breen et al. 1996; Olfert et al. 2001). Animals
were killed 4 h after the acute exercise at a time point
known to correspond to peak VEGF protein expression
(I. M. Olfert, unpublished data).
Tissue preparations

Each animal was killed by CO2 inhalation, and the triceps
surae [gastrocnemius (GA), soleus (SOL) and plantaris
(PLT)] muscles from each leg were immediately excised.
Muscles from the right leg were weighed and immediately
flash frozen in liquid N2 , then later processed for VEGF
protein expression. Muscles from the left leg were mounted
on cork disks and quickly frozen in isopentane cooled
in liquid N2 , then processed later for morphometrical
analysis. All samples were then stored at –80◦ C until
processed for molecular or morphological analyses.
Morphometry

Frozen tissue was cut using a –20◦ C cyromicrotome
(Jung-Reichert Cryocut 1800; Cambridge Instruments,
Nussloch, Germany) to yield 10-μm-thick transverse
sections. Great care was taken to ensure that the
cryosectioned muscles were cut along the transverse
plane. All tissues were stained for capillarity using the
lead nitrate-ATPase method described by Rosenblatt
et al. (1987). A light microscope (Nikon Eclipse 80i;
Nikon Instruments Inc.) was used to digitally acquire
(Photometrics CoolSnap ES; Photometrics, Tucson, AZ,
USA) ×20 images of sectioned muscles in a checkerboard
fashion across the entire muscle. Capillary and myofibre
counting was performed by a single individual, who
was blinded to the identity of each of the samples.
For the gastrocnemius muscle, we obtained images in a
checkerboard fashion across the entire muscle, thus both
superficial and deep regions within the gastrocnemius
were included in the analysis. For the plantaris and
soleus muscles, the entire muscle was imaged and
analysed. Counting was performed by visualization from
acquired images using a custom program in MATLAB
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Table 1. Body, heart and hindlimb muscle mass (means ± SEM)
Control
Body mass (g)
Heart mass (mg)
Heart mass/body mass (mg g−1 )
Gastrocnemius mass (mg)
Gastrocnemius mass/body mass (mg g−1 )
Plantaris mass (mg)
Plantaris mass/body mass (mg g−1 )
Soleus mass (mg)
Soleus mass/body mass (mg g−1 )

32.8
152.4
4.65
123.9
3.78
14.2
0.43
7.6
0.23

±
±
±
±
±
±
±
±
±

0.56
3.18
0.11
4.23
0.08
0.53
0.03
0.93
0.02

MM
29.9
161.2
5.39
59.2
1.98
9.8
0.33
9.8
0.51

±
±
±
±
±
±
±
±
±

0.83∗ †
4.81
0.08∗ †
2.08∗ †
0.05∗ †
0.62∗ †
0.03∗
0.93∗ †
0.02∗ †

Non-MM

P value for
three-group comparison

±
±
±
±
±
±
±
±
±

0.01
0.24
< 0.01
< 0.01
< 0.01
0.01
0.049
< 0.01
< 0.01

32.5
154.5
4.76
134.3
4.13
12.9
0.40
6.4
0.20

0.55
3.04
0.12
3.22
0.08∗
0.35
0.03
1.04
0.01

Student’s unpaired t tests indicate ∗ P < 0.05 compared with control line; and †P < 0.05 compared with Non-MM line.

(version 7.0.0.27; The Mathworks, Natick, MA, USA),
allowing the operator to visually mark and count the
capillaries and fibres on each image. Capillary-to-fibre
ratio (C:F; number of capillaries/number muscle fibres),
capillary density (CD; number of capillaries/muscle fibre
area) and fibre cross-sectional area (FCSA) were separately
calculated for the gastrocnemius, soleus and plantaris from
a minimum of 175 images per mouse line.
Protein analysis

The GA, SOL and PLT muscles from each group were
separately homogenized in a lysis buffer containing 50 mM
Tris–HCl (pH 7.4), 150 mM NaCl, 0.5% Triton X-100 and
protease inhibitors (CompleteTM Tablet; Roche Applied
Science, Indianapolis, IN, USA). Homogenates were
centrifuged at 4◦ C, 8000g for 10 min, and supernatants
removed and placed in new tubes. Total protein was
measured by the bicinchoninic acid method (BCA protein
assay kit; Bio-Rad laboratories, Hercules, CA, USA).
Quantification of VEGF was made from a total of
100 μg of protein using a commercially available ELISA
kit according to the manufacturer’s instructions (Model
MMV00; R&D Systems, Minneapolis, MN, USA).
Denatured samples (20 μg) from GA and PLT muscles
were separated on a 3–8% SDS-PAGE and blotted onto a
0.45 μm nitrocellulose membrane (Pierce nitrocellulose
membrane; Thermo Scientific, Rockford, IL, USA).
After blocking with 5% fat-free milk, membranes were
probed using antibodies against TSP-1 (1:250 dilution;
clone A6.1, no. 399300; Invitrogen, Burlington, ON,
Canada), β-tubulin (1:1000 dilution; no. 2148; Cell
Signaling, Danvers, MA, USA), horseradish peroxidaseconjugated anti-mouse (1:1000 dilution; no. p0260;
Dako, GE Healthcare, Piscataway, NJ, USA) and
horseradish peroxidase-conjugated anti-rabbit (1:1000
dilution; no. p0217; Dako). Proteins were visualized
using chemiluminescence detection (Pierce ECL; Thermo
Scientific) and digitally imaged (G:BOX Gel imager;
Syngene, Cambridge, UK). Images were captured using
Genesnap software (version 7.01; Syngene). Equal protein
loading was verified by immunodetection of β-tubulin as

our loading control. Quantification of protein expression
levels were carried out using NIH ImageJ Software
(version 1.62) and expressed as densitometric arbitrary
units (a.u.). The TSP-1 expression was normalized to
β-tubulin expression level. Owing to insufficient sample
volume, we were not able to run Western analysis of TSP-1
on the SOL muscle.
Statistics

All data are presented as means ± SEM. To examine body
mass, organ masses and muscle capillarity (measured
only in basal conditions), we used a one-way ANOVA
comparing the three lines of mice. To examine protein
expression, we used a two-way ANOVA comparing the
three lines of mice in basal conditions and in response
to acute exercise, while also testing for an interaction
between line and exercise condition. Separate analyses
were performed for each of the three muscles studied
(StatView, 5.0.1). When a main effect was observed,
post hoc testing was performed using Student’s unpaired
t test. An α level of P < 0.05 was selected for statistical
significance.
Results
Body and muscle masses

Body mass differed significantly among lines (P = 0.006).
As seen in Table 1, MM mice had 9% lower body mass than
Non-MM mice (P = 0.008) and 10% lower than control
mice (P = 0.003). The MM mice also had a 16% larger
heart mass (per gram body mass) compared with control
line mice (P < 0.001) and a 13% increase over the NonMM line (P < 0.001). There was no statistical difference in
relative heart mass between the Non-MM and the control
animals.
All three muscles of the triceps surae differed
significantly in mass among all lines (GA, P < 0.001; SOL,
P < 0.01; and PLT, P < 0.05), even when expressed relative
to body mass (GA, P < 0.001; SOL, P < 0.001; and PLT,
P < 0.05; Table 1). The MM mice had a 56% decrease in
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GA mass compared with Non-MM line (P < 0.001) and a
52% reduction compared with control mice (P < 0.001).
The Non-MM line also had 8% greater GA mass than
control mice (P = 0.036). On a mass-specific basis, the
MM mice had a 48% reduction compared with the control
mice (P < 0.001) and a 52% reduction compared with the
Non-MM line (P < 0.001). The Non-MM line also had
an 8% increase when corrected for body mass compared
with the control mice (P < 0.001). As expected (Guderley
et al. 2008; Wong et al. 2009), superficial portions of the
GA muscle in MM mice showed the distinct appearance
of many small fibres not present in either of the other lines
(Fig. 1).
The PLT of the MM mouse was also 32% smaller than
in the Non-MM line (P = 0.039) and 45% smaller than in
control mice (P = 0.004). There was no difference between
the Non-MM line and control mice. On a mass-specific
basis, only the MM mice and control mice showed any
statistical difference, with a 30% reduction in the MM
PLT mass (P = 0.015) compared with the control animals.
The SOL of MM mice was 53% larger than in the NonMM mice (P < 0.001) and 29% larger than in the control
mice (P = 0.005). There was no statistical difference
between the Non-MM line and the control mice. On a
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mass-specific basis, the MM line had 155% greater SOL
mass than the Non-MM line (P < 0.001) and a 122%
greater mass than the control line (P < 0.001). There was
no difference between the Non-MM line and the control
animals after correcting for body mass.
Morphometry

There was a significant main effect for C:F, CD and FCSA
among all groups for the GA (all P < 0.001) and PLT (all
P < 0.05), but not for the SOL muscle. In the GA, MM
mice had a 25% greater C:F and 43% greater CD than the
Non-MM line (P < 0.001) and 38% greater C:F and 46%
greater CD than the control mice (P < 0.001; Fig. 2). There
was no difference in C:F or CD between the Non-MM and
control mice for the GA. The GA FCSA was decreased by
39 and 36% in the MM mice compared to Non-MM and
control mice, respectively (P < 0.001; Fig. 2).
In the PLT, there was no difference in C:F, CD and
FCSA between MM mice and the Non-MM line (Fig. 2);
however, the MM mice and Non-MM mice had a 35
(P = 0.002) and 27% (P = 0.005) greater C:F, and a 24
(P < 0.034) and 31% (P < 0.003) greater CD in the PLT
compared with control mice (Fig. 2).

Figure 1. Representative images of triceps surea muscles
A, superficial gastrocnemius. B, soleus. C, plantaris. Capillaries were stained using lead-ATPase appear as black
dots outside the muscle. The presence of very small muscle fibres in the gastrocnemius muscle (A) is evident in MM
mice compared with control and Non-MM mice. Capillary-to-fibre ratio is significantly elevated in gastrocnemius
muscle of MM mice (A) compared with control and Non-MM mice (P < 0.001), and significantly greater in plantaris
muscle of MM mice (B) compared with control mice (P < 0.001), but not Non-MM mice. No difference in soleus
muscle capillarity was observed between the groups (C).
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Table 2. Muscle fibre-type composition
Type I (%)
Control
Gastrocnemius (deep)
Gastrocnemius (superficial)
Plantaris
Soleus

20
2
38
40

±
±
±
±

4
1
6
2

MM
30
12
38
32

±
±
±
±

Type II (%)

Non-MM

4†
3∗
1
5

24
7
39
39

±
±
±
±

3
3
2
4

P value

Control

0.18
0.04
0.96
0.32

79
98
62
61

±
±
±
±

4
1
6
3

MM
70
89
62
68

±
±
±
±

4†
3∗
2
5

Non-MM

P value

±
±
±
±

0.15
0.02
0.91
0.29

75
95
61
61

3
2
2
3

P value represents ANOVA comparison among three groups; ∗ P < 0.05 compared with control line; and †P = 0.07
compared with control line.

There was not a significant main effect for C:F, CD or
FCSA in the SOL (data not shown).
There was a significant main effect for fibre type for the
superficial GA between the mouse lines (P < 0.05). Post
hoc analysis revealed that MM mice had 86% more type I
fibres (P = 0.014) and 10% fewer type II fibres (P = 0.007)
than control mice (Table 2). In the deep GA, a significant
main effect for fibre type was not found between the mouse
lines (type I, P = 0.179; and type II, P = 0.154); however,
this region of the GA exhibited a similar trend towards
having an increase in the proportion of type I and decrease
in proportion of type II myofibres in MM compared with
control mice. There was no significant difference between
MM mice and Non-MM mice in either portion of the GA.
No significant differences in fibre type between the mouse
lines in either the PLT or SOL were observed.
Protein expression of VEGF
Basal levels. There was a main effect among mouse lines

for basal VEGF expression in the GA (P = 0.017) and the
PLT muscles (P = 0.031). In the GA, MM mice had a 58%

higher basal expression of VEGF compared with control
mice (P = 0.006; Fig. 3). Although basal VEGF expression
was also 33% greater in Non-MM compared with control
mice, this difference did not reach statistical significance
(P = 0.055). There was no significant difference in basal
VEGF expression between MM and Non-MM mice.
In the PLT muscle, we observed 79% greater VEGF
expression in MM mice compared with control mice
(P = 0.010), but no significant difference between MM
and Non-MM mice (P = 0.081). There was also no
significant difference between Non-MM mice and control
mice, despite a similar tendency for 28% greater VEGF
levels in Non-MM mice (P = 0.251), like that seen in the
gastrocnemius.
No significant main effect for basal VEGF expression
was observed in the SOL muscle (data not shown).
Response to acute exercise. There was a main effect

for VEGF response among mouse lines (P = 0.0003)
and a significant exercise × line interaction in the GA
(P = 0.047; Fig. 3). Only the MM mice showed a
significant VEGF response to acute exercise, resulting in

Figure 2. Capillary-to-fibre ratio (C:F), capillary density (CD) and fibre cross-sectional area (FSCA) of the
triceps surae muscles
In the gastrocnemius, MM mice had an increase in C:F and CD and a decrease in FCSA compared with both
control and Non-MM mice. In plantaris, MM and Non-MM had an increased C:F and CD compared with control
mice. ∗ P < 0.05 compared with control mice; and †P < 0.05 compared with Non-MM mice.
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a 41% increase in VEGF in the GA from basal levels
(P = 0.009). The control mice had a very similar 38%
increase in VEGF from baseline, but this did not reach
statistical significance (P = 0.081), which was probably
due to the greater variability observed in the VEGF
response to exercise in these mice. Surprisingly, there was
no VEGF response to exercise in the Non-MM line GA.
There was no statistically significant interaction
between the VEGF response to exercise and line in either

Exp Physiol 96.11 pp 1138–1150

of the other muscles studied (i.e. PLT and SOL). However,
similar to the GA, VEGF in the PLT increased 28% in
response to exercise in MM mice (P = 0.038). Non-MM
mice showed a non-significant increase (21%;P = 0.158)
for VEGF in the plantaris, while control mice did not
respond to exercise.
No significant difference between groups for the VEGF
response to exercise was observed in the SOL muscle (data
not shown).

Figure 3. Comparison of basal and postexercise levels of vascular endothelial growth factor (VEGF) and
thrombospondin-1 (TSP-1) in the triceps surae muscles
A, there was a statistically significant interaction between acute exercise and VEGF levels in the gastrocnemius
(GA) and plantaris (PLT). In both muscles, MM mice had increased basal levels of VEGF compared with control
animals, and a significant VEGF response to acute exercise. The VEGF levels did not differ between the Non-MM
and control mice in either muscle, although there was a trend for an increase in the GA (P = 0.055). B, there was
a statistically significant interaction between acute exercise and TSP-1 levels in the GA and PLT. In basal conditions
in the PLT, the MM mice had lower TSP-1 levels than either the control or Non-MM mice, and in the GA and PLT
the MM mice had a significant TSP-1 response to acute exercise. The Non-MM mice had significantly higher basal
levels of TSP-1 in the PLT than control mice. Also in the PLT, control animals had a significant TSP-1 response to
acute exercise. C, representative Western blots from TSP-1 analysis (B). ∗ P < 0.05 compared with control mice,
same exercise state (basal or acute exercise); and #P < 0.05 compared with basal levels.
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Protein expression of TSP-1
Basal levels. Basal levels of TSP-1 in the GA muscle were
not different among mouse lines. However, a significant
main effect for basal TSP-1 expression in the PLT was
observed among mouse lines. In the PLT, MM mice
had 39% lower TSP-1 levels compared with control mice
(P < 0.01) and 58% lower compared with the Non-MM
mice (P < 0.01; Fig. 3). Non-MM mice exhibited a 46%
increase in basal TSP-1 compared with control mice
(P < 0.001; Fig. 3).
Response to acute exercise. There was a significant
exercise × line interaction in the GA (P = 0.014; Fig. 3).
In the GA, control mice and Non-MM mice showed
no statistical TSP-1 response to acute exercise, whereas
MM mice exhibited a 90% decrease in TSP-1 (P = 0.003).
In the PLT, there was also a significant effect for TSP-1
in response to acute exercise (P = 0.005), where TSP-1
expression increased by 47% (P < 0.01) in control mice
and by 55% (P < 0.05) in MM mice (Fig. 3). There was
no significant acute exercise response in Non-MM mice
(Fig. 3).

Discussion
The main finding of this study is that elevated skeletal
muscle capillarity in MM mice bred for high aerobic
capacity is associated with an altered balance between
VEGF and TSP-1 protein expression (Fig. 3). These data
are consistent with the observations that VEGF and
TSP-1 are essential regulators of the skeletal muscle
microvascular bed. Surprisingly, in Non-MM mice a
similar diverging correlation between VEGF and TSP1 in relation to changes in muscle capillarity was not
found in the PLT muscle. In general, however, these
data support the notion that VEGF and TSP-1 are key
physiological regulators of angiogenesis within skeletal
muscle. Moreover, when comparing the basal expression
of these factors in MM mice against control mice, these are
among the first data to suggest that muscle capillarity and
the capacity for exercise-induced angio-adaptation may,
in part, be accounted for by inherited traits related to the
expression of VEGF, and possibly TSP-1, within skeletal
muscle.
Basal expression of VEGF and TSP-1 correlates with
elevated skeletal muscle capillarity in MM mice,
but not in Non-MM mice

In this study, we report that MM mice have increased
capillarity in the both the GA and the PLT (Fig. 2), which
is associated with elevated basal expression of VEGF in
each muscle (Fig. 3). At the same time, we observed no
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difference in basal skeletal muscle TSP-1 expression in
the GA, but a significant decrease in the PLT (Fig. 3)
which, when combined with the elevated expression of
VEGF in both GA and PLT, is consistent with a proangiogenic environment within the muscle. In contrast,
neither capillarity nor VEGF expression was different in
the SOL muscle of MM or Non-MM mice compared with
control mice.
In Non-MM mice, which are also high aerobic capacity
mice but without the unique ‘mini-muscle’ phenotype, we
found that only the PLT had elevated capillarity, whereas
neither GA nor SOL muscle capillarity was different
compared with control animals (Fig. 2). Although there
was a trend for elevated basal VEGF expression in
the PLT of Non-MM mice (P = 0.07), we also found
elevated basal TSP-1 expression (P < 0.01), which together
could be argued as an anti-angiogenic state rather than
pro-angiogenic. Nonetheless, an increase in PLT muscle
capillarity was observed in Non-MM mice (Fig. 2). In
contrast, no significant changes in basal VEGF were seen in
either the GA or SOL muscles of Non-MM mice. Likewise,
TSP-1 was not different in GA muscle, and no differences
in capillarity were seen in either the GA or the SOL of
Non-MM mice compared with control animals.
Taken together, the elevated muscle capillarity in the GA
of MM mice is most probably explained by elevated basal
VEGF. In the PLT, elevated muscle capillarity occurred
in the presence of decreased basal TSP-1 expression and
little or no increase in VEGF, suggesting that TSP-1 may
also be playing an important role, at least in the PLT
of MM mice. Despite the differences in these individual
muscles, there is growing evidence that physiological
regulation of angiogenesis is dependent on the balance
between positive and negative angiogenic proteins such
that the ratio of VEGF to TSP-1 expression may actually
be more important than their individual expression
levels per se (Olfert & Birot, 2011). The present results
support the notion of an altered balance leading to
capillary adaptation, with the notable exception of the
PLT muscle in Non-MM mice. One explanation for this
discrepancy may be that other angiogenic regulators (such
as endostatin, angiopoetins and their receptors, matrix
metalloproteinases) are also playing a role, but are not
accounted for in this study. Indeed, while we focused on
VEGF and TSP-1 because of their recognized prominence
in effecting changes in the skeletal muscle vascular bed, it
is entirely possible (and likely) that other regulators also
contribute to the basal angiogenic state (Olfert & Birot,
2011).
It is interesting to note that increased capillarity
occurred predominately in skeletal muscle composed of
glycolytic myofibres (i.e. GA and PLT) and not in muscle
composed of mostly oxidative myofibres (i.e. SOL). This
observation is consistent in both high aerobic selected lines
(i.e. MM and Non-MM), and might suggest that muscles
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with greater glycolytic metabolic profiles experienced the
greatest amount of evolutionary change in these selectively
bred lines of mice. This idea is consistent with the
observation that glycolytic myofibres may be principally
responsible for driving the angiogenic response to acute
exercise (Birot et al. 2003; Waters et al. 2004). It may also
be that muscles having a predominant role in locomotor
activity (i.e. GA and PLT) would be the most evolved in
these mice, whereas postural skeletal muscles (such as the
SOL) are less likely to have been influenced.
Exercise capacity, angiogenesis and VEGF

It remains clear that muscles found to have elevated
basal VEGF expression are also the muscles with elevated
capillarity (Fig. 4). In TSP-1 knockout mice, increases
in skeletal muscle capillarity (achieved without exercise
training) are also associated with greater exercise capacity
(Malek & Olfert, 2009), whereas losses in muscle capillarity
(due to deletion of VEGF in myocytes) are shown to
reduce exercise performance (Olfert et al. 2009). The
strong association between exercise capacity and muscle
capillarity is also supported in selectively bred rats with
high and low aerobic capacity (Howlett et al. 2003). Thus,
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the present findings are consistent with the evidence that
skeletal muscle capillarity and muscle O2 conductance
are critical determinants of aerobic exercise performance
(Howlett et al. 2003). It is interesting to note, however,
that V̇O2 max is not statistically different between MM mice
and any of the other high aerobic capacity mouse lines,
except during exercise in hypoxia (Rezende et al. 2006a,b).
If O2 transport in the mouse is principally limited at the
muscle–capillary interface, as implied by these and the
other aforementioned data, then the greater capillarity in
GA muscle of MM mice could help explain the advantage
in V̇O2 max seen during hypoxic exercise over Non-MM
mice (Rezende et al. 2006a). Although these data do
not establish a cause-and-effect relationship, they are in
harmony with the view that VEGF-mediated increases in
skeletal muscle capillarity contribute to the greater exercise
capabilities observed in mice with an innate high aerobic
capacity. Given the positive relationship noted for VEGF
and C:F (Fig. 4) and the notable absence of an inverse
relationship for TSP-1 and C:F (Fig. 4), it could be argued
that VEGF may be the most critical determinant for muscle
capillarity. More importantly, the fact that VEGF and TSP1 had different responses within the triceps surae muscles
between these two high aerobic capacity lines (i.e. MM

Figure 4. Correlation of muscle VEGF and TSP-1 levels to capillary-to-fibre ratio (C:F)
Least-squares linear regression of C:F on basal VEGF and TSP-1 levels in the GA and PLT muscles of the three
mouse lines. Large symbols indicate mean values for each line and small symbols are values for individual animals.
Squares indicate control mice, triangles MM mice and circles Non-MM mice.
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versus Non-MM) suggests that basal angiogenic protein
expression may be, at least in part, an inherited trait that
may also account for some of the biological variability in
exercise capacity.
Genetic background may influence angiogenic
responses to acute exercise

In the context of exercise training, it has been shown
in standard laboratory mice and rats that the VEGF
response to acute exercise is attenuated in skeletal muscle
post-training (Olfert et al. 2001; Malek & Olfert, 2009).
It has been postulated that this is a direct response to
training-induced angio-adaptation (i.e. increased muscle
capillarity, improved blood flow distribution to working
muscle, and increased O2 conductance into the myocyte)
that functions to relieve metabolic stress on the myocyte
that is imposed by exercise. Given that local tissue hypoxia
is thought to be among the key stimuli for the VEGF
response to exercise (Levy et al. 1995; Breen et al. 1996;
Richardson et al. 1999; Olfert et al. 2001), we have
previously speculated that the attenuated VEGF response
to an acute bout of exercise post-training is the result of
increased muscle capillarity and greater O2 conductance
during exercise (Olfert et al. 2001; Malek & Olfert, 2009).
The present data could be interpreted to suggest that a
mechanism other than local hypoxia may be involved
in the modulation of VEGF during acute responses to
exercise. Indeed, if increased capillarity reduces local tissue
hypoxia, and this is responsible for modulating the VEGF
response, then it would be expected that an attenuated
VEGF response to exercise would be seen in MM mice
(which inherently displayed a greater number of capillaries
in their muscle compared with normal mice). However, as
it has also previously been shown that MM mice have
increased aerobic metabolic enzyme activities in hindlimb
muscles (Guderley et al. 2008), it could also be that MM
mice simply have a much higher oxygen flux and thus
the level of O2 within the muscles is relatively unchanged
compared with Non-MM and control mice (despite the
greater number of muscle capillaries). We also cannot
exclude the possibility that other mechanisms, such as
shear stress, local drops in muscle pH, modulation of other
matrix regulators and/or other angiogenic factors, may
have indirect influences on the VEGF response to exercise.
Some support for modulation of other angiogenic
factors comes from the TSP-1 data in the present study.
Thrombospondin-1 is a potent inhibitor of angiogenesis
and of VEGF directly (Gupta et al. 1999; Greenaway et al.
2007). In the MM mice, we found that TSP-1 levels were
lower in the PLT in basal conditions and in the GA in
the acute exercise conditions (Fig. 3). In both of these
circumstances, VEGF is also increased. This supports the
notion of an altered balance between positive (e.g. VEGF)
and negative (e.g. TSP-1) angiogenic factors (Hanahan &
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Folkman, 1996; Olfert & Birot, 2011). This altered balance
would be another elegant way that the MM mice are
genetically more able to adapt to an exercise stimulus.
Another potential explanation for the greater VEGF
response to exercise in MM mice may be that the
VEGF response to exercise is also genetically influenced.
Although it is difficult to decipher the relative contribution
of genetic versus environmental influences in setting an
individual’s exercise capacity, evidence supporting the
genetic influences can be seen from a recent report
involving fine genotype mapping of MM mice (Hartmann
et al. 2008). Hartmann et al. (2008) localized the gene
responsible for the mini-muscle phenotype to a 2.6335 Mb
of MMU11, a region that harbours ∼100 expressed
or predicted genes, many with known roles in muscle
development and/or function. Upon examination of
the genes within this region, we have identified two
genes, Tnfsf12/TWEAK and Ephrin ligands/receptors,
both of which have been shown to have some regulatory
role in angiogenesis and/or endothelial cell proliferation
(Helbling et al. 2000; Cheng et al. 2002; Donohue et al.
2003). What role, if any, these factors may exert on skeletal
muscle VEGF remains to be determined, but it is tempting
to speculate that these (or other) genes may support and/or
enhance angiogenesis in MM mice.
It should be noted that our data are not the first
to suggest that the VEGF response to exercise may be
influenced by genetic background. Prior et al. (2006)
have shown that genetic variants in the promoter
region of the VEGF gene correlate with whole-body
V̇O2 max in humans. Similar results were also reported in
response to hypoxia-mediated increased in VEGF gene
expression in cultured myotubes (Prior et al. 2006).
Our data, combined with these previous studies, imply
that individual gene responses may influence exercise
performance, and suggest that the VEGF response to
exercise may, at least in part, be an inherited trait.
Comparison of muscle mass and fibre-type profile
among mouse lines

It has previously been shown that MM mice have a
significantly decreased triceps surae muscle mass (Syme
et al. 2005; Guderley et al. 2006, 2008; McGillivray et al.
2009). Likewise, the present study shows that GA and
PLT muscle mass was decreased in the MM mice when
compared with the control and Non-MM mice (Table 1).
Opposite to what is seen in the GA and PLT muscles, the
SOL of the MM mice was increased over 130% (on a body
mass-specific basis) when compared with both the control
mice and the Non-MM line (Table 1).
In mice, the GA has an aerobic profile that is mixed,
with superficial portions of the muscle containing mainly
type IIb/x fibres, whereas the deep portions contains many
type IIa and type I fibres (Guderley et al. 2008; Wong
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et al. 2009). In contrast, the SOL is comprised primarily
of type I or IIa fibres. Assessment of fibre type in these
mice reveals that MM mice have a greater proportion of
type I than type II myofibres compared with control and
Non-MM mice (Table 2). These findings are supported by
earlier observations that MM mice have increased type I
and type IIa fibres along with decreased type IIb fibres
in the medial GA muscle (Guderley et al. 2008). This
myofibre composition is consistent with the elevated C:F
ratio found in the GA of the MM mice in the present
study, further supporting the notion of a greater oxidative
muscle metabolic profile capable of supporting greater
aerobic capacity.
This also raises the issue of the influence of muscle
mass and/or fibre type/size on skeletal muscle aerobic
performance. It could be argued that greater cardiac
output (as indicated by larger cardiac mass in both
absolute terms and relative to body size) could itself
contribute to improved exercise capacity in MM mice
(Table 1). Perhaps the strongest argument against this
hypothesis is provided by the Non-MM mice, which
exhibit an equally high aerobic endurance capacity to
the MM mice but do not have greater cardiac mass
(in absolute or relative terms) compared with control
animals (Garland et al. 2002; Table 1). Moreover, we
would also contend (irrespective of any improvements in
central cardiac function) that blood flow to the working
muscle is also controlled by local metabolic demand. In
combination with the greater muscle metabolic potential
of MM mice, such as increased mitochondrial enzymatic
activity (Guderley et al. 2006), it is perhaps debatable
whether greater cardiac function in these MM mice might
be considered as improved or simply an attempt to
keep up with metabolic demand of the working muscle.
Nonetheless, there are presently no data which document
cardiac output or function in these mice, thus we do not
know if cardiac function is altered.
In summary, these data generally support the
notion that skeletal muscle angiogenesis in physiological
conditions is likely to be controlled by a balance between
pro- and anti-angiogenic factors, and also suggest that
the expression of VEGF versus TSP-1 may differ among
muscles. Moreover, the observation that basal VEGF and
TSP-1 expression, and the VEGF and TSP-1 response
to exercise, were different between the two high aerobic
capacity mouse lines seems to suggest first, that a
mechanism other than local hypoxia might be regulating
the VEGF response to exercise and second, that the
VEGF response to exercise may, in part, be genetically
determined.
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